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ABSTRACT 
Breast cancer is the most common malignancy in women worldwide. Five-year 
survival rates of breast cancer are high (91 %), but due to its high incidence, it is still 
the leading cause of cancer death in females. In 2017, breast cancer was diagnosed 
in 4974 patients, and 928 patients died of breast cancer, according to Finnish Cancer 
registry data.1 
The prognosis of metastatic breast cancer has only modestly improved during the 
last few decades. This improved survival is mostly due to the implementation of 
effective anti-HER2 therapy in standard clinical care of metastatic HER2-positive 
breast cancer. During this century, the advances in the treatment of the other 
metastatic breast cancer subtypes, hormone receptor positive and triple-negative, 
have been minimal in terms of improving patient survival. The most aggressive 
subtype with the greatest treatment challenges is the triple-negative breast cancer, in 
which all three clinically significant breast cancer receptors, i.e., estrogen, 
progesterone and HER2, are not expressed. The oncological treatment options for 
metastatic breast cancer depend on the receptor status, tumor burden, prior adjuvant 
therapies, patient performance status, other comorbidities and patient preferences. 
For hormone receptor-positive disease, endocrine therapy is recommended as a 
first-line treatment option. Chemotherapy should be considered as the first-line 
treatment only in cases of visceral crisis. In addition, all patients with advanced breast 
cancer can be treated with chemotherapy after disease progression on endocrine 
therapy. For triple-negative patients, endocrine therapy is not effective, so 
chemotherapy is the only valid option for these patients. The taxanes docetaxel and 
paclitaxel are the most common choices for the first-line chemotherapy treatment 
of metastatic breast cancer. 
Bevacizumab is a monoclonal antibody targeting vascular endothelial growth 
factor A. Angiogenesis is one of the hallmark processes of malignant tissue, needed 
for its proliferation, and bevacizumab aims to inhibit tumor neovascularization. 
Several phase III trials have evaluated bevacizumab as a treatment for metastatic 
breast cancer in combination with several chemotherapy agents. These studies with 
bevacizumab have resulted in a few months’ benefit in progression-free survival and 
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higher frequency of response rates. However, an overall survival benefit was not 
established in any of the studies. 
This study was designed to evaluate the feasibility of bevacizumab in combination 
with taxane chemotherapy as first-line chemotherapy treatment of metastatic HER2-
negative breast cancer, to evaluate biomarkers for their prognostic value in advanced 
breast cancer and to improve the sensitivity and specificity of the CA15-3 tumor 
marker in disease monitoring. The median progression-free survival, which was the 
primary endpoint in our trial, was 11.3 months. This is similar to other results from 
first-line bevacizumab combinations. The median overall survival of our patients 
reached almost three years, which can be considered a good outcome. The toxicity 
related to bevacizumab treatment was mostly manageable, although one patient died 
of treatment-related side effects. In the biomarker study, low plasma interleukin-8 
level was associated with excellent long-term survival. In addition, high plasma Tie1 
was found to be a novel factor for poor prognosis in metastatic breast cancer. In this 
study, patients with high levels of the extracellular fragment of the Tie1 receptor and 
angiopoietin-2 had the poorest survival. In the substudy aiming to improve CA15-3 
as a breast cancer tumor marker, the new nanoparticle-lectin immunoassay CA15-
3WGA was significantly more sensitive than the conventional CA15-3 assay. 
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TIIVISTELMÄ 
Rintasyöpä on naisten yleisin pahanlaatuinen sairaus. Rintasyövän viiden vuoden 
elossaoloennusteet ovat hyviä (91 %), mutta johtuen rintasyövän yleisyydestä se on 
silti naisten suurin syöpäkuolemien aiheuttaja. Suomen syöpärekisterin tilastojen 
mukaan vuonna 2017 rintasyöpä todettiin 4974 potilaalla ja 928 potilasta kuoli 
rintasyöpään.1 
Tällä vuosisadalla levinneen rintasyövän ennuste on parantunut vain 
vaatimattomasti. Tehokkaat HER2-vasta-ainehoidot ovat nykyään standardikäytössä 
levinneen HER2-positiivisen rintasyövän hoitona, ja levinneen rintasyövän 
ennusteen paraneminen johtuu suurimmalta osin ainoastaan HER2-positiivisesta 
alatyypistä. Edistysaskeleet hormonireseptoripositiivisen ja kolmoisnegatiivisen 
rintasyövän hoidossa ovat olleet vähäisiä potilaiden elinajan pidentymisen suhteen. 
Kolmoisnegatiivisessa rintasyövässä kaikki kolme rintasyöpäreseptoria ovat 
negatiivisia: estrogeeni, progesteroni ja HER2. Kolmoisnegatiivinen tauti on kaikkein 
aggressiivisin ja sen hoidossa on eniten haasteita. Levinneen rintasyövän 
hoitovaihtoehtoihin vaikuttavat syövän reseptoristatus, kasvainkuorma, mahdolliset 
aiemmat liitännäishoidot, potilaan toimintakyky, muut sairaudet ja potilaan oma 
mielipide annettavista hoidoista. 
Hormonireseptoripositiivisessa levinneessä taudissa endokriinista hoitoa 
suositellaan ensilinjan hoidoksi. Kemoterapiaa suositellaan ensilinjan hoidoksi vain 
tilanteissa, joissa potilaalla on uhkaavia sisäelinmetastaaseja. Muille potilaille 
kemoterapiaa harkitaan siinä vaiheessa, kun rintasyöpä on edennyt yhden tai 
useamman endokriinisen hoidon aikana. Kolmoisnegatiivisessa rintasyövässä 
hormonaaliset hoidot eivät ole tehokkaita ja siksi kemoterapia on ainoa 
hoitovaihtoehto tätä aggressiivista tautimuotoa sairastavilla potilailla. Taksaani, 
dosetakseli ja paklitakseli, on tavanomaisin valinta levinneen rintasyövän ensilinjan 
kemoterapiahoidoksi. 
Bevasitsumabi on verisuonen endoteelin kasvutekijä-A:ta kohtaan vaikuttava 
monoklonaalinen vasta-aine. Verisuonten muodostuminen on yksi pahanlaatuiden 
kudoksen tunnusomaisista piirteistä, jotta tuumorikudos pystyy lisääntymään. 
Bevasitsumabi pyrkii estämään kasvaimen uudisverisuonimuodostusta. Useat 
vaiheen III tutkimukset ovat arvioineet bevasitsumabin tehoa kemoterapiaan 
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yhdistettynä levinneen rintasyövän hoitona. Bevasitsumabitutkimuksissa taudin 
etenemisvapaassa ajassa ollaan saavutettu muutaman kuukauden hyöty ja 
hoitovasteet ovat olleet yleisempiä. Kuitenkaan hyötyä kokonaiselossa-ajassa ei ole 
pystytty osoittamaan missään näistä tutkimuksista. 
Tämän tutkimuksen tarkoituksena oli arvioida bevasitsumabihoidon 
soveltuvuutta levinneen HER2-negatiivisen rintasyövän ensilinjan 
kemoterapiahoidoksi yhdistettynä taksaanihoitoon, plasman biomerkkiaineita 
levinneen rintasyövän ennustetekijöinä sekä parantaa CA15-3 
kasvainmerkkiainemenetelmän herkkyyttä ja tarkkuuta rintasyövän hoidon 
seurannassa. Tutkimuksemme ensisijainen päätetapahtuma, mediaani taudin 
etenemisvapaa-aika, oli 11,3 kuukautta, mikä on samaa luokkaa kuin muissa 
ensilinjan bevasitsumabihoitotutkimuksissa. Tutkimuspotilaidemme mediaani 
kokonaiselossaolo-aika saavutti kuitenkin lähes kolmen vuoden rajapyykin, mitä 
voidaan pitää hyvänä tuloksena. Bevasitsumabihoitoon liittyvät haittavaikutukset 
olivat enimmäkseen hallittavissa huolimatta siitä, että yksi potilas menehtyi 
bevasitsumabihoidon haittavaikutuksiin. Ennustetekijätutkimuksessa plasman 
matala interleukiini-8-pitoisuus oli yhteydessä erinomaiseen 
pitkäaikaisselviytymiseen. Lisäksi korkea plasman Tie1-pitoisuus osoittautui 
levinneen rintasyövän uudeksi huonon ennusteen merkiksi. Tässä tutkimuksessa 
huonoin ennuste oli niillä potilailla, joilla todettiin sekä korkea Tie1-reseptorin 
solunulkoisen osan pitoisuus että plasman korkea angiopoietiini-2-pitoisuus. CA15-
3 määritysmenetelmän kehitystä selvittäneessä osatyössä uusi lektiinipohjainen 
CA15-3WGA menetelmä oli perinteistä CA15-3 määritysmenetelmää tilastollisesti 
merkitsevästi herkempi. 
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1 INTRODUCTION 
Breast cancer is the most common cancer in females worldwide, with 2.09 million 
breast cancers diagnosed in 2018, making up 24.2% of all new cancer cases in 
women2. However, the prognosis of primary breast cancer is mainly good: in 
Finland, the five-year net survival rate is one of the highest in the world, and 88.5% 
[95% confidence interval (CI) 87.7-89.3] of the patients are alive five years after the 
breast cancer diagnosis3. However, due to the high incidence of breast cancer, it is 
the leading cause of cancer death in females worldwide and in Finland1,4. 
Over the last few decades, the prognosis of breast cancer has improved mainly 
due to improved detection and earlier diagnosis4. Additionally, due to adjuvant and 
neoadjuvant therapies with long-term follow-up data, patient survival has 
improved5,6. The population-based mammography screening program was initiated 
in Finland in 1987, and since 1992, the program covered the entire country. This 
organized mammography screening program has decreased breast cancer mortality. 
However, the studies have yielded varying estimates of the survival benefit (0-43 %). 
Criticism of national screening programs has been raised since results with no 
survival benefit have also been published.7–10 Approximately 200 women need to be 
screened to avoid one breast cancer death, and all these screened women are 
predisposed to the fear of breast cancer and the possibility of overdiagnosis11. 
Although in general the prognosis of breast cancer is good, and most breast 
cancers will not recur, numerous women still face the diagnosis of incurable 
metastatic disease. In 2018, 626 679 women died of metastatic breast cancer (mBC)2. 
The prognosis of mBC has improved, but this is mainly limited to human epidermal 
growth factor receptor 2 (HER2)-positive breast cancer12–14. No significant 
improvement has been observed in the prognosis of other breast cancer subtypes, 
including hormone receptor-positive HER2-negative mBC and biologically 
aggressive triple-negative breast cancer (TNBC)12–14. 
Globally, remarkable regional variation exists in the prognosis of breast cancer. 
In low- and middle-income countries, breast cancer is more commonly diagnosed as 
metastatic stage IV disease, and these countries also have the highest mortality rates 
for breast cancer15. Up to 36.1% of newly diagnosed breast cancer cases were 
metastatic in black South African people compared to only 3.0% in Sweden15. There 
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is also considerable variation in the access of new treatment modalities and drugs. 
For example, trastuzumab, a monoclonal antibody targeting HER2, has been the 
standard treatment for HER2-positive breast cancer for almost two decades and has 
proven to improve patient survival13,16. However, in a web-based survey mapping 
the global use of HER2 testing and antiHER2 therapy, 20% of the Asian responders 
did not have HER2 testing routinely available, and 80-100% of Latin American, 
Asian and African responders had encountered a situation that due to treatment 
costs, patient did not receive recommended HER2-targeted adjuvant therapy17. 
Angiogenesis, the formation and maintenance of vascular structures, is essential 
for all human cells18. Angiogenesis is an essential process for tumor proliferation, 
progression and metastatic spread. Tumor vasculature is different from normal 
vasculature. Tumor blood vessels are disorganized and irregular19. In addition, the 
blood flow is mostly sporadic, resulting in a damaged capillary network20. Adipose 
tissue surrounding the malignant cells and the stromal cells are responsible for 
producing angiogenic growth factors, e.g., vascular endothelial growth factors A, B 
and C (VEGF-A, -B and -C), fibroblast growth factor, matrix metalloproteinases 
(MMPs) and interleukin-8 (IL-8)21,22. Vascular endothelial growth factors recruit 
vascular endothelial cells to propagate and form tube-like structures23. The precursor 
endothelial cells originate from bone marrow. They migrate through the circulation 
to a vascular niche and start to form new blood vessels in the presence of vascular 
growth factors: VEGFs, fibroblast growth factor and platelet-derived growth 
factor20,24. VEGF-A is the most highly expressed member of the VEGF family in 
many pathological processes25,26. The effect of VEGF-A on the target cells is 
mediated mainly by its membrane receptor, vascular endothelial growth factor 
receptor 2 (VEGFR-2), although it binds with higher affinity to vascular endothelial 
growth factor receptor-1 (VEGFR-1)25–28. VEGF-A binding to VEGFR-2 activates 
multiple intracellular signaling pathways that result in survival, proliferation, 
migration and remodeling of endothelial cells28. Both VEGF-A and VEFGR-2 are 
expressed in breast cancer tissue29. 
Bevacizumab is a monoclonal antibody to VEGF-A. Bevacizumab inhibits 
vascular endothelial cell proliferation and therefore tumor angiogenesis30. 
Bevacizumab is used in combination with chemotherapy regimens in various 
indications for malignant diseases, including metastatic colon cancer, ovarian cancer, 
non-small cell lung cancer and kidney cancer31. In the treatment of breast cancer, 
bevacizumab is indicated for the first-line treatment of metastatic disease in 
combination with either paclitaxel or capecitabine31. The combination with 
capecitabine can only be considered if the patient is not suitable for other 
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chemotherapy options, including taxanes or anthracyclines31. However, the Finnish 
national breast cancer guidelines do not recommend the use of bevacizumab as a 
treatment for mBC32. 
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2 REVIEW OF THE LITERATURE 
2.1 Treatment of early breast cancer 
2.1.1 Diagnostics of primary breast cancer 
Primary assessment of a breast tumor includes a trimodal approach: physical 
examination, imaging and a core-needle biopsy of the suspected lesion33. Imaging 
modalities include bilateral mammography and ultrasound of the breast and regional 
lymph nodes followed by magnetic resonance imaging (MRI) of the breast only in 
selected cases34. MRI can be considered in cases of a high risk of breast cancer, for 
example, breast cancer susceptibility gene (BRCA) gene mutation carriers, a lobular 
tumor histology or other reasons to suspect tumor multifocality, a discrepancy 
between mammography and ultrasound findings that might alter operative treatment 
decisions or a discrepancy between clinical and imaging findings35. Pathological 
assessment is based on a core-needle biopsy of the primary breast tumor to 
determine the histological type, grade and receptor status of the tumor. In addition, 
a fine-needle aspiration or a core biopsy must be performed on the suspected axillary 
lymph nodes33. 
2.1.2 Surgery 
A multidisciplinary team with a breast cancer-specialized medical and radiation 
oncologist, at least one surgeon, a pathologist and a radiologist should be consulted 
pre- and postoperatively for each patient before coming to a treatment decision36,37. 
Most patients with operable breast cancer are referred to surgery. In the case of a 
locally advanced setting, a large primary tumor or inflammatory breast cancer, 
neoadjuvant therapies are considered, especially in more aggressive tumor types: 
triple-negative or HER2-positive breast cancer38. Surgery options for the breast 
include breast-conserving surgery or mastectomy, depending on patient choice, 
comorbidities, tumor size, location, multicentricity, prior chest wall radiotherapy and 
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contraindications to radiotherapy33,38. The surgery is considered sufficient if the 
microscopic margins are free of the invasive cancer and at least 2 mm from ductal 
carcinoma in situ (DCIS)39,40. Obtaining wider negative margins than required by no 
ink on the tumor is not indicated in routine practice38,39,41. An axillary lymph node 
dissection is performed for patients with clinically detected lymph node metastases; 
otherwise, sentinel node biopsy is a sufficient procedure 33,38. Previously, the patients 
with positive sentinel lymph node metastases underwent an axillary lymph node 
dissection42. However, according to the results of the ACOSOG Z0011 trial, patients 
with 1-2 sentinel lymph node metastases did not benefit from axillary lymph node 
evacuation if they were treated with adjuvant radiotherapy and systemic therapy43. 
In 2019, new results were published from the AMAROS trial. According to the 
results, the patients with a tumor size smaller than 5 cm, no clinical signs of axillary 
lymph node metastases and a positive sentinel node diagnosed during breast cancer 
surgery did not benefit in terms of survival from a complete axillary lymph node 
dissection44. In this study, both the complete lymph node dissection group patients 
and the comparison group patients underwent radiotherapy according to standard 
clinical practice. The extensive axillary surgery group patients suffered more often 
from chronic lymph edema of the limb, as expected.44 
2.1.3 Pathology 
An accurate evaluation of the tumor by an experienced pathologist and a full 
pathology report are essential for further oncology treatment decisions on early 
breast cancer45. The pathological assessment should be made according to the 
tumor-node-metastasis (TNM) staging system (Supplementary Table 1) and to the 
World Health Organization (WHO) classification46,47. In addition to the TNM 
assessment, the report should include the histological type, grade(s) of the tumor(s), 
evaluation of the resection margins, vascular invasion, immunohistochemical (IHC) 
evaluation of estrogen and progesterone receptors and HER2 status48,49. Hormone 
receptor positivity is defined as estrogen and/or progesterone positivity ≥ 1%. 
HER2 may be determined from all invasive tumors by in situ hybridization or only 
for the tumors with an ambiguous IHC score of 2+49. The Finnish breast cancer 
group recommends verifying HER2 positivity with in situ hybridization for all tumors 
with IHC scores of 2+ or 3+32. Ki-67, a proliferation marker assessed by IHC, adds 
useful information about the aggressiveness of the tumor50,51. Additionally, for the 
treatment decision and for evaluation of the patient’s prognosis, tumors should be 
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grouped into intrinsic subtypes based on the histology and the receptor status data 
(Table 1)45. Furthermore, high-risk patients are screened by computed tomography 
(CT) and a bone scan for distant metastases. The high-risk features include clinically 
positive axillary lymph nodes, large tumors (≥ 5 cm), aggressive biology and clinical 
signs of metastases33. 
Table 1.  Intrinsic subtypes of breast cancer based on the St Gallen consensus 201545 
 Receptor status 
 ER PR HER2 Ki-67* 
Luminal A + ≥ 20% negative low 
Luminal B + + / - + / - high 
HER2 overexpression - - + any 
Basal-like - - - any 
* Ki-67 should be interpreted based upon local laboratory values; the cut-off value for low vs. high Ki-67 is 
approximately 20% 
Abbreviations: ER: estrogen receptor; PR: progesterone receptor; HER2: human epidermal growth factor 
 
2.1.4 Gene expression profiling for early breast cancer 
Several gene expression profiles were evaluated for their extra prognostic and 
predictive information and for the selection of patients who would more likely 
benefit from adjuvant chemotherapy. Most of the studies were done retrospectively, 
and only a few large prospective phase III trials were published: TAILORx, PlanB 
and MINDACT. 
Oncotype DX is a 21-gene recurrence score (RS) assay that has been validated 
most extensively in prospective studies41,52. It includes the following genes: Ki-67, 
STK15, Survivin, CCNB1, MYBL2, HER2, GRB7, MMP11, CTSL2, GSTM1, CD68, 
BAG1, ER, PGR, BCL2, SCUBE2, ACTB, GAPDH, RPLPO, GUS and TFRC. 
These genes are associated with tumor proliferation, invasion, HER2 expression and 
the estrogen pathway. The expression of these genes is normalized to the reference 
genes, which are the last five genes in the list above.53 In the TAILORx study 
evaluating the clinical utility of Oncotype DX, the aims of the study were to confirm 
that a low RS of 0 to 10 was associated with a low rate of distant recurrence even if 
patients were treated with endocrine therapy alone and whether patients with mid-
range RS of 11 to 25 would benefit from chemotherapy54. The study enrolled 
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patients with axillary node-negative, hormone receptor-positive, HER2-negative 
breast cancer. On the basis of Oncotype DX RS, the patients were assigned to four 
treatment groups. The women with low RS (≤ 10) received only endocrine therapy, 
and those with high RS (≥ 26) were treated with chemotherapy and endocrine 
therapy. The patients with mid-range RS (11-25) were randomized to either 
endocrine therapy alone or both chemo- and endocrine therapy54,55. The patients 
with RS ≤ 10 had a very good prognosis: 5-year disease-free survival (DFS) was 
94%55. After a 5-year follow-up, distant metastases were observed in 1% of the 
patients, and according to recent updated results after a 9-year follow-up, only 3% 
of the patients had a distant recurrence54. Only 8% of low-RS patients had tumors 
with size ≥ 3 cm, and only 7% were grade 3 tumors. For those reasons, according to 
the European breast cancer treatment guidelines, the vast majority of the low-RS 
patients would not be recommended chemotherapy anyway33. However, even in this 
low-RS patient population, 22% of the patients were categorized as clinically high-
risk patients, and for these patients, the RS score might be useful. After a 9-year 
follow-up, there was no difference between the mid-range RS patients randomized 
to the endocrine therapy alone group and the group treated with both chemotherapy 
and endocrine therapy [invasive disease-free survival (IDFS) 83.3% vs. 84.3%, 
respectively]. Therefore, endocrine therapy was noninferior to chemo- and 
endocrine therapy for patients with node-negative, HER2-negative, hormone 
receptor-positive patients with RS between 11 and 25. However, a subset of patients 
younger than 50 and with RS 16-25 had some benefit from chemotherapy (p=0.03)54. 
Prospective trials are focusing on the Oncotype DX 21-gene RS assay in patients 
with node-positive tumors but the results are not yet available. 
The MammaPrint gene profiling assay was created by analyzing genes related to 
disease recurrence in patients with lymph node-negative breast cancer. The 
researchers chose 70 genes that were most strongly associated with a short interval 
to distant metastasis, i.e., the poor-prognosis signature. The poor-prognosis 
signature included genes regulating invasion, cell cycle, metastasis and angiogenesis. 
56 This 70-gene MammaPrint signature was prospectively evaluated in the 
MINDACT study57. The MINDACT study patients had ≤ 5 cm primary tumors and 
≤ 3 axillary lymph node metastases. MammaPrint was applied to categorize the 
patients to either low or high genomic risk, and additionally, the patients were 
divided into low or high clinical risk. The patients with both low genomic and low 
clinical risk were omitted from chemotherapy, but they had an excellent 5-year 
distant metastasis-free survival rate of 94.7% (95% CI 92.5-96.2). The patients with 
discordant results of genomic and clinical risk assessment were randomized to either 
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chemotherapy or no-chemotherapy. The patients with high clinical risk and low 
genomic risk had an absolute benefit of 1.9% in distant metastasis-free survival 
[Hazard ratio (HR) 0.65, 95% CI 0.38-1.10, p=0.11] and a 3% benefit in DFS (HR 
0.64, 95% CI 0.43-0.95, p=0.03) if they had received chemotherapy compared to the 
patients with no chemotherapy after 5-year follow-up, but the study was not 
powered to assess the statistical significance of these differences. The patients with 
low clinical risk and high genomic risk had smaller differences in distant metastasis-
free survival depending on whether they had received chemotherapy or not (96.1% 
vs. 93.9%, respectively, HR 0.90, 95% CI 0.40-2.01, p=0.80).57 
The TAILORx and MINDACT studies only enrolled patients with node-negative 
breast cancer. The PlanB trial focused on a more high-risk patient population with 
node-positive patients included58. Chemotherapy was omitted for patients with 
Oncotype DX RS ≤ 11, and three-year DFS was excellent, at 98%, with endocrine 
therapy alone58. According to the PlanB trial, the RS score is an independent 
prognostic marker for early breast cancer, with the multivariate HR for DFS being 
at about same level as for tumor grade58. 
National Comprehensive Cancer Network (NCCN) clinical practice guidelines 
for breast cancer recommend the use of Oncotype DX for adjuvant chemotherapy 
considerations. Oncotype DX is both predictive and prognostic with category level 
1 evidence for node-negative patients according to the NCCN guidelines41. For 
node-positive patients, Oncotype DX adds only prognostic information, and its 
predictive value will be evaluated in the future RxPONDER study. Evidence for 
MammaPrint is also considered level 1 for breast cancer prognosis, but so far, its 
predictive value is undetermined.41 The St Gallen treatment consensus guidelines for 
early breast cancer considered that gene expression profiles might be most valuable 
for chemotherapy decision making in patients with tumors between 1 and 3 cm, 0-3 
positive axillary lymph nodes and intermediate tumor proliferation38. However, the 
Finnish breast cancer group does not yet recommend the use of the gene expression 
profiles for adjuvant chemotherapy treatment decisions32. 
2.1.5 Adjuvant chemotherapy treatment of luminal A, luminal B and triple-
negative breast cancer 
General recommendations for adjuvant systemic therapy for HER2-negative early 
breast cancer are presented in Table 2. For suitable patients, the adjuvant 
chemotherapy schedule should include an anthracycline, a taxane and an alkylating 
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agent59. Adjuvant capecitabine may be added to triple-negative patients based on the 
reduced recurrence rates in the triple-negative subgroup in the FinXX trial60. For 
patients with a high risk of cardiac complications who are not suitable for 
anthracycline therapy, docetaxel with cyclophosphamide can be considered61. 
Docetaxel-cyclophosphamide is also feasible for elderly patients and is superior to 
the doxorubicin-cyclophosphamide combination61. Adjuvant chemotherapy is 
usually administered for four to eight chemotherapy cycles33. 
Table 2.  Systemic treatment recommendations for HER2-negative breast cancer subtypes33,38 
 Recommended therapy Comments 
Luminal A Endocrine therapy Consider chemotherapy for patients with multiple lymph 
node metastases, high tumor grade or at least 2-5 cm 
tumors 
Luminal B Endocrine therapy + 
chemotherapy Chemotherapy can be omitted for stage ≤ T1bN0 
Triple-negative Chemotherapy Chemotherapy is recommended for patients with stage 
T1bN0 or higher 
Neoadjuvant chemotherapy is recommended for patients with locally advanced, 
inoperable breast cancer or inflammatory breast cancer33. Patients with a large 
primary tumor and a hope for breast conservation may also be considered for 
neoadjuvant systemic treatment depending on the tumor biology33,38. However, the 
neoadjuvant chemotherapy approach is the preferred choice for stage II to III 
TNBC38. Adding platinum salt to the standard anthracycline-taxane neoadjuvant 
treatment can be considered for triple-negative patients since pathological complete 
response (pCR) is more frequent62,63. Inconsistent results from the use of nab-
paclitaxel instead of standard paclitaxel as neoadjuvant treatment were published64,65. 
The GeparSepto trial reported a clinically significant difference in pCR in favor of 
nab-paclitaxel for triple-negative patients64. However, there was no significant 
difference in pCR in triple-negative patients between standard solvent-based 
paclitaxel and nab-paclitaxel in the ETNA trial65. TNBC patients who do not achieve 
pCR with neoadjuvant chemotherapy treatment may be further treated with 
capecitabine for eight cycles postoperatively66. Capecitabine, in this setting, reduced 
the risk of disease recurrence by 40% and the risk of death by approximately 50%66. 
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2.1.6 Adjuvant treatment of HER2-positive breast cancer 
For HER2-positive breast cancer, the backbone of the adjuvant treatment is HER2-
targeted antibody trastuzumab. HER2-positive breast cancer is always considered a 
disease with high risk for recurrence, with the exception of very small tumors (≤ 5 
mm); therefore, adjuvant chemotherapy with trastuzumab is recommended38. 
Trastuzumab reduces breast cancer recurrence or death by approximately 40% in 
patients with HER2-positive early breast cancer67–70. Trastuzumab is administered 
either sequentially or concurrently with standard chemotherapy therapy containing 
taxane and anthracycline38. After completion of the chemotherapy, trastuzumab is 
continued up to one year. A less toxic option for stage I HER2-positive disease with 
a shorter treatment duration is weekly paclitaxel and trastuzumab for 12 weeks 
followed by trastuzumab for up to one year. This treatment option results in an 
excellent IDFS rate of 98.7% at three years71. 
Neratinib is an irreversible tyrosine kinase inhibitor (TKI) targeting HER1, 
HER2 and HER4. In the ExteNET trial, neratinib was given for one year after 
standard trastuzumab-based adjuvant treatment. The five-year IDFS was 2.5% 
higher in the neratinib group compared to the placebo group (HR 0.73, 95% CI 0.57-
0.92, p=0.0083). Nevertheless, severe grade 3 diarrhea was common, although it was 
manageable with loperamid, in the patients receiving neratinib (40% of the 
patients).72 
The optimal duration of adjuvant trastuzumab therapy has been extensively 
studied, but no other duration has found to be superior compared to one year, 
although cardiac adverse events were less common with shorter treatment 
duration73–76. Additionally, extended trastuzumab treatment up to two years did not 
result in a survival benefit in the HERA trial77. 
Other anti-HER-2 therapies were also investigated in the neoadjuvant or adjuvant 
setting as a dual HER2 inhibition with trastuzumab. Pertuzumab, another HER2 
receptor-targeting antibody, is currently the standard first-line treatment of 
metastatic HER2-positive breast cancer in combination with trastuzumab and 
docetaxel, based on the CLEOPATRA trial78. Pertuzumab was also investigated in 
the treatment of early breast cancer. As a neoadjuvant treatment, pertuzumab 
increased the pCR rate up to 45.8% when combined with trastuzumab and 
docetaxel79. However, in the adjuvant setting, pertuzumab resulted in only a modest 
improvement in the survival of the HER2-positive patients, with an absolute 
increase in the IDFS of 0.9% at three years when combined with the standard 
trastuzumab-containing chemotherapy80. 
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Lapatinib, a TKI targeting HER1 and HER2, was also investigated in several trials 
in adjuvant and neoadjuvant settings81–87. As a neoadjuvant treatment, a dual 
blockade with lapatinib and trastuzumab increased the pCR rate, but no survival 
benefit was demonstrated with lapatinib-containing treatments81–87. Therefore, 
considering the extra toxicity and cost, lapatinib cannot be recommended as a 
neoadjuvant or adjuvant treatment. 
Patients who attain a pCR due to neoadjuvant treatment have improved 
survival88,89. For that reason, it is rational to focus research efforts on patients with 
residual disease after neoadjuvant therapy and therefore a higher risk of disease 
recurrence. Trastuzumab emtansine (T-DM1), an antibody-drug conjugate of 
trastuzumab and cytotoxic agent emtansine, was studied in HER2-positive patients 
with residual disease after neoadjuvant treatment, and the results of this study (the 
KATHERINE trial) were recently published. Patients who had received T-DM1 up 
to one year following trastuzumab-containing neoadjuvant treatment and standard 
breast cancer surgery had a 3-year IDFS of 88.3%, compared to 77.0% in the 
standard trastuzumab treatment arm (p<0.001)90. Additionally, T-DM1 as a single-
agent neoadjuvant treatment for HER2-positive breast cancer was less effective than 
dual blockade with trastuzumab and pertuzumab plus chemotherapy but was 
significantly less toxic91. 
2.1.7 Adjuvant endocrine treatment 
Adjuvant endocrine therapy is recommended for breast cancer patients with 
estrogen receptor-positive disease33,38. The available endocrine therapy options are 
the estrogen receptor modulator tamoxifen,  the nonsteroidal aromatase inhibitors 
(AIs) letrozole and anastrozole, the steroidal AI exemestane and the selective 
estrogen receptor downregulator fulvestrant92,93. Tamoxifen and AIs are taken orally 
once daily, and fulvestrant is injected subcutaneously on days 0, 14, and 28 and every 
28 days thereafter. The daily doses of tamoxifen and AIs are fixed (20 mg, 2.5 mg, 1 
mg and 25 mg, respectively). Adjuvant tamoxifen for five years reduced the risk of 
disease recurrence by approximately 40% and breast cancer mortality by 
approximately one-third in hormone receptor-positive patients5,94,95. Tamoxifen is 
the standard endocrine adjuvant treatment for premenopausal patients33,38. For 
postmenopausal breast cancer patients, five years of AI therapy is a more efficient 
endocrine therapy choice, since it reduced recurrence rates by approximately 30% 
compared to tamoxifen and reduced breast cancer mortality by approximately 15%96. 
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However, the absolute benefit of AI treatment compared to tamoxifen was modest 
(10-year gain 3.6% in breast cancer recurrence and 2.1% in breast cancer mortality)96. 
Therefore, tamoxifen is still an appropriate choice for some patients based on 
differences in side-effect profiles between tamoxifen and AIs and the breast cancer 
prognosis of the individual patient33,38. 
Ovarian function suppression (OFS) using luteinizing hormone-releasing-
hormone (LHRH) analogues may be considered for high-risk premenopausal 
patients33,38. The high-risk premenopausal patients who also received adjuvant 
chemotherapy had an increased 8-year DFS rate of 5.3% with the tamoxifen-OFS 
combination compared to tamoxifen alone (HR 0.76, 95% CI 0.60-0.97)97. Similarly, 
the 8-year DFS rate was increased by 9.0% with the exemestane-OFS combination 
compared to tamoxifen alone (HR 0.68, 95% CI 0.53-0.88)97. The St Gallen 2017 
early breast cancer treatment guidelines recommend pairing OFS with either 
tamoxifen or exemestane for premenopausal patients with at least N2 nodal 
involvement and/or for patients aged ≤ 35 years38. 
Five-year adjuvant endocrine treatment has been a standard for decades, but 
multiple phase III trials investigated the benefit of extended adjuvant endocrine 
therapy up to ten years98–108. For high-risk premenopausal patients, adjuvant 
tamoxifen can be continued up to ten years, based on the results of the ATLAS and 
aTTOM trials105,106. Both of these studies reported a significant decrease in disease 
recurrence, by approximately 15%, and the ATLAS trial also demonstrated an overall 
survival (OS) benefit (HR for OS 0.87, 95% CI 0.78-0.97, p=0.01)105,106. Treatment 
with an AI after five years of tamoxifen increased 5-year DFS by 34% (p=0.01) in 
the MA.17 trial98. The other studies (NSABP, IDEAL and DATA) investigating 
extended AI treatment (2-5 years after initial tamoxifen therapy) demonstrated a 
trend towards higher DFS99,102,103. According to a meta-analysis of these studies, a 
nonsignificantly greater DFS benefit was observed in patients with larger tumors (≥ 
2 cm, HR for DFS 0.77 vs. 0.88, p for difference = 0.44), nodal metastases (HR 0.72 
vs. 0.83, p for difference = 0.31) and both hormone receptors positive (HR 0.68 vs. 
1.01, p for difference = 0.31)109. Treatment guidelines for early breast cancer 
recommend considering extended endocrine therapy for patients with a high risk of 
relapse but also highlight the importance of taking into account the side effects and 
tolerability of endocrine therapy33,38,110. 
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2.1.8 Adjuvant radiotherapy 
Radiotherapy to the chest wall and regional lymph nodes after mastectomy reduced 
disease recurrence by 25% (p<0.00001) and breast cancer mortality by 16% 
(p=0.001) in the patients with axillary lymph node metastases111. In addition to lymph 
node-positive patients, post mastectomy radiation therapy is also recommended for 
patients with large (at least 5 cm) tumors independent of the nodal status and for 
patients with positive resection margins33. 
Adjuvant radiotherapy is recommended for all patients after breast-conserving 
surgery. After breast-conserving surgery, whole-breast irradiation (WBI) reduced the 
10-year risk of disease recurrence by 48% and the 15-year risk of breast cancer 
mortality by 18%112. Traditionally, radiotherapy for the breast is given in 2-gray (Gy) 
fractions five days a week for a total of 25 times. However, hypofractionated WBI is 
considered effective and safe for patients of all ages and tumor characteristics113–115. 
The American Society for Radiation Oncology (ASTRO) guidelines recommend the 
hypofractionation scheme of either 40 Gy in 15 fractions or 42.5 Gy in 16 
fractions113. Current hypofractionation schemes truncate the treatment duration to 
three weeks. Boost irradiation can be considered for patients with risk factors for 
local relapse: age < 50 years, grade 3 tumors, extensive DCIS or vascular 
invasion116,117. In a randomized phase III study, a 16 Gy boost was given to breast 
cancer patients who had undergone breast-conserving surgery. In the younger age 
groups, a clear reduction in ipsilateral local relapses was observed: 44% reduction in 
patients aged ≤ 40 years in the boost irradiation group compared to the no-boost 
group (p=0.003) and 34% reduction for patients aged 41-50 years (p=0.007). 
However, for patients older than 50 years, the reduction in local relapses was 
nonsignificant (for age 51-60 years p=0.02, for age >60 years p=0.019, statistical 
significance level in this study was 0.01)116. Without prolongation of the radiotherapy 
treatment duration, the boost can also be delivered concomitantly with the WBI, a 
technique called simultaneously integrated boost (SIB)118,119. 
Nodal irradiation is recommended for patients with lymph node 
metastases33,111,112. Recently, at the San Antonio Breast Cancer Symposium 2018, a 
new EBCTCG meta-analysis of 13 500 women was presented, focusing on regional 
node irradiation. In this meta-analysis, the patients treated with more contemporary 
radiotherapy techniques had better breast cancer survival and fewer recurrences than 
patients who had not received radiotherapy. The patients with at least four lymph 
node metastases were the group with the most pronounced radiotherapy benefit, 
with an 8% decrease in breast cancer mortality. In contrast, the patients with no 
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lymph node metastases did not gain a breast cancer survival benefit from 
radiotherapy.120 
Accelerated partial breast irradiation (APBI) can further shorten the radiotherapy 
period. It can be considered for breast cancer patients with a low risk of recurrence: 
age at least 50 years, unifocal tumor with a diameter ≤ 3 cm, no lymph node 
metastases, nonlobular histology, no extensive intraductal component or lympho-
vascular invasion and surgical margins ≥ 2 mm121,122. The update of an ASTRO 
Consensus statement considered low-risk DCIS patients also eligible for APBI: 
screen-detected, low or intermediate grade, size ≤ 2.5 cm and surgical margins ≥ 3 
mm122. Several trials have compared APBI to WBI123–130. The radiation treatment 
schemes in the studies varied from a one-dose 21 Gy intraoperative radiotherapy 
session directed to the tumor bed with electrons to an accelerated external-beam 
radiation dose delivered twice daily at 3.85 Gy for a week for a total dose of 38.5 
Gy125,128. No survival difference between APBI and WBI has been demonstrated, 
but the rates of local recurrence were variable between the studies125–130. In the 
RAPID trial, the cosmetic outcome of the breast was worse in the APBI group 
compared to the WBI group, but the cosmetic results in the Italian APBI trial were 
opposite124,125. In conclusion, APBI can be considered for patients with a low risk of 
local recurrence who prefer a shorter treatment duration over potentially worse 
cosmetic outcomes. 
Adjuvant radiotherapy, particularly left-sided, increases the incidence of cardiac 
morbidities in long-term follow-up131. Cardiac side effects can be decreased using 
modern three-dimensional treatment planning and techniques such as deep-
inspiration breast hold (DIBH)132. Cardiac toxicity can be further reduced by 
avoiding unnecessary concomitant use of adjuvant AI during adjuvant breast cancer 
radiotherapy133. In addition to the cardiac side effects of adjuvant radiotherapy, 
regional nodal irradiation increases the risk of peripheral lymphedema and 
pneumonitis134. 
2.1.9 Bevacizumab as a treatment of early breast cancer 
Bevacizumab was also studied in the treatment of early breast cancer. Most 
bevacizumab studies in early breast cancer focused on neoadjuvant treatment. All of 
these neoadjuvant studies demonstrated a significant increase in the proportion of 
patients achieving a pCR with bevacizumab combined with various chemotherapy 
options62,135–138. In most studies recruiting both hormone receptor-positive and -
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negative patients, the bevacizumab pCR benefit was more pronounced in triple-
negative patients135–137. However, the pCR rates were higher in hormone receptor-
positive patients than in triple-negative patients in the NSABP B-40 study138. In 
contrast to the other bevacizumab neoadjuvant studies, in the NSAB B-40 trial, the 
patients received adjuvant bevacizumab for 10 cycles in addition to the neoadjuvant 
bevacizumab. The chemotherapy backbone in the neoadjuvant treatment was either 
docetaxel alone, docetaxel + capecitabine or docetaxel + gemcitabine. This is the 
only bevacizumab neoadjuvant trial with significantly improved OS in patients 
treated with bevacizumab (HR 0.65, 95% CI 0.49-0.88, p=0.004). Interestingly, the 
OS improvement was more clear in hormone receptor-positive patients. However, 
the results of the study were somewhat conflicting since no DFS benefit was 
observed (HR 0.80, 95% CI 0.63-1.01, p=0.06)139. None of the other neoadjuvant 
trials reported was able to demonstrate a DFS or OS benefit135,140,141. 
The role of bevacizumab as an adjuvant therapy of HER2-negative breast cancer 
was evaluated in two large randomized phase III trials. Both studies reported no 
bevacizumab benefit. In the BEATRICE trial, only patients with triple-negative 
disease were included, and these 2591 patients with operable breast cancer received 
standard adjuvant chemotherapy with or without bevacizumab (10 mg/kg every two 
weeks or 15 mg/kg every three weeks) for one year. Adding bevacizumab to the 
adjuvant chemotherapy did not result in an IDFS (HR 0.87, 95% CI 0.73-1.03, 
p=0.11) or OS benefit (HR 0.93, 95% CI 0.74-1.17, p=0.52)142. Patients with high-
risk HER2-negative breast cancer were enrolled in another adjuvant trial, E5103143. 
In this study, most patients had ER-positive disease (64%). The study had three 
treatment arms. In arm A, patients were treated with placebo combined with 
doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel. In arm B, 
patients received bevacizumab only during AC and paclitaxel. In arm C, patients 
received bevacizumab during AC and paclitaxel and then bevacizumab monotherapy 
for 10 cycles. There were no significant differences in the primary endpoint IDFS 
between the treatment arms [Arm C vs. arm A: HR 0.87 (95% CI 0.71-1.06, p=0.17), 
arm B vs. arm A: HR 0.93 (95% CI 0.78-1.16, p=0.62)] or in the OS [Arm C vs. arm 
A: HR 0.89 (95% CI 0.68-1.17, p=0.41), arm B vs. arm A: HR 1.01 (95% CI 0.77-
1.33, p=0.92)].143 
Taking into account the above-mentioned bevacizumab trials in early breast 
cancer, the role of bevacizumab remains unclear, and therefore, it is not 
recommended to be used as neoadjuvant or adjuvant treatment outside clinical 
trials33,38. 
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2.2 Metastatic breast cancer (mBC) 
The median (m) OS of mBC is approximately two years, and only one quarter of the 
patients is still alive five years after the diagnosis of metastatic disease144. The 
prognosis varies depending on the breast cancer subtype. In a Dutch retrospective 
analysis of mBC patients diagnosed between 2007 and 2009, the patients with 
hormone receptor-positive, HER2-positive mBC had the longest survival (mOS 34.4 
months). In the same study, median survival for hormone receptor-positive, HER2-
negative breast cancer patients was 24.8 months, hormone receptor-negative, HER2-
positive patients 19.9 months, and triple-negative patients only 8.8 months 
(p<0.001).145 In addition, the localization of the metastases at the initial advanced 
disease diagnosis was associated with significant differences in patient survival. The 
patients with only lymph node metastases or bone metastases had the longest 
survival (47 months and 43 months, respectively)146. The patients with visceral 
metastases had a median survival reduced by almost half (26 months), and for 
patients with central nervous system (CNS) metastases, the median survival was only 
11 months (p<0.01)146. 
2.2.1 Diagnostics of advanced breast cancer 
The diagnostic work-up for mBC includes imaging of the chest, abdomen and bone; 
medical history documentation; physical examination; and laboratory assesment16. A 
core biopsy should be performed, if accessible, of a metastatic lesion, especially in 
the de novo metastasis situation16,147. For patients with a history of early breast 
cancer, a biopsy should nevertheless be performed since the hormone and HER2 
receptor status of the breast cancer may change over time. In a meta-analysis of 39 
studies accessing receptor conversion and paired samples of primary tumors and 
metastatic lesions, ER receptor conversion was observed in 19% of patients, PR 
conversion in 31% of patients and HER2 conversion in 10% of patients148. 
However, since no prospective studies have been conducted on discordant receptor 
status patients, endocrine therapy and/or antiHER2 therapy should be considered 
when receptor status has been positive in at least one biopsy16. 
Metastatic TNBC is an aggressive subtype with the most treatment challenges in 
the field of breast cancer, since there are not yet any targeted therapy options 
available. TNBC has the highest risk of metastatic disease of the breast cancer 
subtypes and the poorest survival149. The risk of TNBC recurrence is high during 
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the first five years after primary breast cancer diagnosis, and after that, recurrences 
of TNBC are rare150. TNBC metastasizes more often to the visceral organs and the 
CNS than other breast cancer subtypes, while bone metastases are less frequently 
observed151. 
2.2.2 Circulating tumor markers for detection of breast cancer recurrence 
CA15-3 and carcinoembryonic antigen (CEA) have been investigated and used as 
circulating tumor markers in breast cancer for decades. CA15-3 assays detect the 
shed or soluble form of the transmembrane protein Mucin-1 (MUC-1). Altered 
MUC-1 expression is associated with cancer pathogenesis and metastasis152. MUC-1 
expression is observed at some levels in all invasive breast carcinomas153. CA27.29 
is another MUC-1-associated antigen with comparable results to those of CA15-
3154,155. 
CEA is a group of glycoproteins involved in cell adhesion. During fetal 
development, CEA is produced in the gastrointestinal tract, but the production ends 
before birth. However, elevated CEA levels are frequently observed in multiple 
malignancies, especially adenocarcinomas153,156–159.  
In a large retrospective patient cohort of over 1000 patients with local breast 
cancer diagnosis, an elevated preoperative level of CA15-3 or CEA was associated 
with breast cancer death (p=0.0001), and additionally, elevated CA15-3 was 
associated with breast cancer recurrence (p=0.0003)160. Monitoring serum CA15-3 
and CEA at six-week intervals after primary breast cancer treatment, a 100% increase 
in the individual baseline value in each patient resulted in 38.3% sensitivity for CA15-
3 to detect disease recurrence, 21.3% sensitivity for CEA and 55.3% sensitivity for 
the combination of both markers161. Another study retrospectively analyzed CA15-
3 and CEA levels in the follow-up of breast cancer patients and demonstrated a 
specificity for both tumor markers >98% using an increase of 100% in the marker 
level as a cut-off. The sensitivity using the same cut-off levels was 55.6% for CA15-
3, 40.6% for CEA and 66.3% for the combination of both markers162. The sensitivity 
for CA15-3 was even lower for detecting local recurrences163,164. However, another 
study found CEA monitoring to provide no additional value to CA15-3 
monitoring165. In a prospective study of 1023 patients, CA15-3 and CEA were 
analyzed every 3-6 months during breast cancer surveillance. CA15-3 and CEA levels 
were elevated prior to the diagnosis of mBC in 41% and 40% of the patients, 
respectively, with a lead time of 4-5 months.166 Retrospective analysis of a French 
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breast cancer patient cohort reported that half of the breast cancer relapses were 
diagnosed due to the symptoms of the patients, but 19% of the relapses were found 
due to elevated CA15-3 levels167. Monitoring the CA15-3 or CEA level has not 
demonstrated any survival benefit; therefore, routine monitoring of these markers 
during breast cancer follow-up is not currently recommended33,168,169. 
Other circulating markers have also been evaluated for prognosis or recurrence 
of breast cancer (Table 3). MicroRNAs are a class of small, single-stranded, 
noncoding RNA molecules that can be detected in liquid biopsies170. MicroRNAs 
21, 23b, 126, 155, 190, 200b and 200c have all been associated with carcinogenesis 
and were therefore investigated as markers for breast cancer recurrence and 
prognosis (Table 3)170,171. Increased levels of alkaline phosphatase (ALP) were 
observed in 4% of breast cancer patients during follow-up, and elevated ALP level 
alone was not associated with a significantly higher risk of breast cancer recurrence 
(Table 3)172. Tissue polypeptide antigen (TPA), a marker for proliferation, had a 
sensitivity comparable to CA15-3, but lower specificity for breast cancer173. Using a 
combined analysis of CA15-3, CEA and TPA levels increased the sensitivity of these 
tumor markers during breast cancer follow-up174. Tissue polypeptide-specific antigen 
(TPS) detects cytokeratins 18 and 19, which are highly expressed in breast 
carcinomas175. TPS alone had lower sensitivity in detecting breast cancer recurrence, 
but combined with CA15-3, the sensitivity increased to 88%176. In another study, 
TPS was less sensitive than CA15-3 to detect breast cancer relapses, and the 
combination of CA15-3, CEA and/or TPS did not increase the sensitivity compared 
to CA15-3 alone for visceral recurrences. In addition, false-positive elevations were 
more common with the TPS assay (12%).177 
NCCN guidelines do not recommend screening for metastases with laboratory 
markers in the absence of clinical signs of recurrent disease41. Similarly, the European 
guidelines state that monitoring tumor markers, such as CA15-3 and CEA, does not 
produce survival benefit and is therefore not recommended33. 
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Table 3.  Prognostic and predictive tumor markers investigated for breast cancer recurrence or 
diagnosis 
Author, year Circulating 
marker 
Study design Result 
Swellam et al. 
2019170 
CEA 
CA15-3 
miRNA-21 
miRNA-126 
miRNA-155 
n=96 stage I-III BC 
patients 
n=47 patients with BBL 
 
CEA: ≥ 5 ng/ml: BC 49%, BBL 19%, p<0.0001 
CA15-3, ≥ 30 ng/ml: BC 52%, BBL 23%, p<0.0001 
miRNA-21, ≥228.6-fold change: BC 64%, BBL 13%, p<0.0001 
miRNA-126, ≤40-fold change: BC 89%, BBL 0%, p<0.0001 
miRNA-155, ≥124-fold change: BC 96%, BBL 6%, p<0.0001 
Papadaki et 
al. 2018171 
miRNA-21 
miRNA-23b 
miRNA 190 
miRNA-200b 
miRNA-200c 
n=155 consecutive 
patients with early breast 
cancer, treated with 
surgery and chemotherapy 
miRNA-21, miRNA-23b, miRNA-200c higher in patients with BC 
relapse (p<0.001, p=0.028, p<0.001, respectively) 
miRNA-190 lower in patients with BC relapse (p=0.013) 
High miRNA-21 expression related to shorter DFS (p<0.001) 
High miRNA-200c expression related to shorted DFS (p=0.005) 
Keshaviah et 
al. 2007172 
CA15-3 
ALP 
Combined analysis of 7 
trials 
n=3953 
Elevated CA15-3: risk of recurrence HR 1.30, p=0.0005 
 Elevated ALP: risk of recurrence HR 1.04, p=0.82 
Elevated CA15-3 and ALP: risk of recurrence HR 4.69, 
p<0.0001 
Vizcarra et al. 
1996173 
CA15-3 
CEA 
TPA 
n=80 healthy controls 
n=421 local BC 
n=117 mBC 
Specificities: CA15-3 95.7%, CEA 95.5%, TPA 81.9% 
Sensitivities: CA15-3 64.1%, CEA 44.4%, TPA 67.5% 
Soletormos et 
al. 1993178 
CA15-3 
CEA 
TPA 
n=90 
TM monitoring during BC 
follow-up 
Sensitivity for mBC diagnosis:  
CA15-3 48%, CEA 10%, TPA 19% 
Negative predictive value for CA15-3 86% 
Nicolini et al. 
1991174 
CA15-3 
CEA 
TPA 
n=285 
TM monitoring during BC 
follow-up 
Sensitivity for mBC diagnosis: 
CA15-3 46%, CEA 7%, TPA 63% 
 CA15-3+CEA+TPA 87% 
CA15-3+TPA 83%, CEA+TPA 70% 
D’Alessandro 
et al. 2001176 
CA15-3 
TPS 
n=349 
TM monitoring during BC 
follow-up for 5 years 
Sensitivity for mBC diagnosis: 
CA15-3 72%, TPS 66% 
CA15-3+TPS 88% 
Given et al. 
2000177 
CA15-3 
CEA 
TPS 
n=1082 
TM monitoring during BC 
follow-up 
Sensitivity for mBC diagnosis: 
CA15-3: 68% for visceral, 69% for bone recurrence 
CEA 27% and 47%, respectively 
TPS 64% and 51%%, respectively 
n: number of patients; miRNA: microRNA; BC: breast cancer; BBL: benign breast lesion; DFS: disease-free 
survival; ALP: alkaline phosphatase; mBC: metastatic breast cancer; TM: tumor marker 
The presence of circulating tumor cells (CTCs) in the peripheral blood was 
associated with a higher risk of breast cancer recurrence. The CTC count was 
analyzed in 547 patients who participated in the E5103 phase III adjuvant trial179. 
The CTCs were positive in 26 patients (5%). The recurrence rates per person-year 
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of follow-up were 21% in the CTC-positive group and 2% in the CTC-negative 
group179. HER2 status may also be analyzed using immunofluorescence from CTCs. 
In a meta-analysis including approximately 3000 patients with early breast cancer, 
the presence of CTCs was associated with increased risk for breast cancer recurrence 
(HR 2.86, 95% CI 2.19-3.75, p<0.01) and worse OS (HR 2.78, 95% CI 2.22-3.48, 
p<0.01)180. In a retrospective analysis of 107 patients, 37 patients had HER2-positive 
CTCs. Of these 37 patients, only 10 patients (27%) had HER2-positivity in primary 
breast cancer tissue specimen, as determined by immunohistochemistry.181 However, 
the development of other liquid biopsy methods to analyze circulating tumor DNA 
(ctDNA) will presumably lessen the use of CTCs in the future. 
Liquid biopsies are a promising method for detecting early tumor relapses and 
have been evaluated in several trials. Fragmented DNA is released into the 
circulation by apoptotic and necrotic cancer cells, and ctDNA can be detected in 
peripheral blood by using polymerase chain reaction (PCR) or genome sequencing 
techniques182. In a study of 640 patients with various malignant diseases, ctDNA was 
detectable in 50% of patients with localized breast cancer and in > 80% of patients 
with mBC183. A meta-analysis of 69 trials and 5700 patients with breast cancer was 
published in 2018. In this pooled analysis, only 3 studies evaluated the association 
between breast cancer recurrence and ctDNA mutations. CtDNA mutations 
detected in peripheral blood were significantly associated with breast cancer 
recurrence (OR 3.79, 95% CI 1.80-8.00, p<0.001)184. A very recent paper was 
published in April 2019 focusing on prospective ctDNA surveillance of 49 breast 
cancer patients after adjuvant therapy. Plasma samples were collected every 6 
months for up to 4 years. Plasma was analyzed for 16 gene variants selected from 
primary tumors. During follow-up, 18 patients faced breast cancer recurrence, and 
16 of these relapses were predicted by ctDNA up to 2 years before clinical 
manifestation of the metastatic cancer (median time 9 months, range 0.5-24 months). 
Therefore, the sensitivity of the patient-specific ctDNA assay to detect relapses was 
89%. CtDNA positivity was not observed in any of the 31 nonrelapsing patients.185 
2.3 Treatment of metastatic breast cancer 
The treatment recommendations for mBC patients depend on the hormone receptor 
status, HER2 status, prior (neo)adjuvant treatment, performance status of the 
patient, comorbidities, patient preference and presence of visceral crisis16. The age 
of the patient should not be a reason to withhold effective therapy, and careful 
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assessment for patient performance status and comorbidities should be done, 
preferably with the help of comprehensive geriatric assessment16,186 . 
For several decades, mBC was treated with either endocrine therapy or 
chemotherapy. HER2-targeted therapy has also been used for the treatment of 
advanced disease for patients with HER2-positive breast cancer. The efficacy of 
bevacizumab was investigated as a treatment of mBC in combination with either 
chemotherapy or endocrine therapy. Additionally, several new treatment options 
have emerged during the last decade: the mammalian target of rapamycin (mTOR) 
inhibitor everolimus, cyclin-dependent kinase 4 and -6 (CDK4/6) inhibitors, poly 
ADP ribose polymerase (PARP) inhibitors, and phosphatidylinositol 3-kinase 
(PI3K) inhibitors187. The estrogen receptor signaling pathway interacts with the 
signaling pathways related to mTOR inhibitors, PI3K inhibitors and CDK4/6 
inhibitors, and the mechanisms of action of these compounds in the treatment of 
hormone receptor-positive mBC are presented in Figure 1. 
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Figure 1.  Nonchemotherapeutic treatment options for metastatic hormone receptor-positive breast 
cancer. Mechanisms of actions of endocrine therapies: aromatase inhibitors, tamoxifen and 
fulvestrant; mTOR inhibitor everolimus; PI3K inhibitors; and CDK4/6 inhibitors in cancer 
cells. Each of these is discussed in detail in the following chapters. AKT: protein kinase B; 
CDK: cyclin-dependent kinase; ER: estrogen receptor; ERK/MAPK: extracellular signal-
regulated kinase/mitogen-activated protein kinase; MEK: mitogen-activated protein kinase; 
MTORC1: mammalian target of rapamycin complex 1; MTORC2: mammalian target of 
rapamycin complex 2; P: phosphorylation; PIP2: phosphatidylinositol 3,4-bisphosphinate; 
PIP3: phosphatidylinositol 3,4,5-bisphosphinate; PI3K: phosphatidylinositol 3-kinase; RAF: 
rapidly accelerated fibrosarcoma kinase; RAS: rat sarcoma kinase; S6: S6 kinase; TSC: 
tuberous sclerosis protein. Figure from O'Shaughnessy et al. 2018187. 
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2.3.1 Endocrine therapy for hormone receptor-positive mBC 
Endocrine therapy is recommended as the first-line treatment of advanced hormone 
receptor-positive disease in the absence of visceral crisis16,41,147. A meta-analysis of 4 
phase III trials of first-line endocrine therapy and in 1400 patients revealed that 
response rates were higher in nonvisceral mBC than in visceral mBC (34% vs. 30%, 
respectively, p=0.038), but the duration of responses was equal in patients with vs. 
without visceral involvement188. Endocrine therapy trials in mBC have mainly 
enrolled postmenopausal patients. However, consensus guidelines recommend 
premenopausal patients be treated under the same principles as postmenopausal 
patients, but they should be offered OFS or ovarian ablation in combination with 
endocrine therapy16,147. 
The first trial of the antitumor activity of tamoxifen as a treatment of mBC was 
published in 1971189. It was followed two years later by another trial focusing on 
different dosage levels of tamoxifen, 10 and 20 mg, and 20 mg was found to be more 
effective190. The pharmaceutical company that ran the trial, ICI Pharmaceutical 
Division, abandoned further investigation of tamoxifen for financial reasons. 
Therefore, the next trial had to wait until the 1980’s and showed improved survival 
with tamoxifen for patients with early breast cancer191. Since the 1970’s tamoxifen 
has been the gold standard treatment for the first-line endocrine therapy of mBC192. 
AIs were compared to tamoxifen as a treatment of mBC. Letrozole was superior 
to tamoxifen in terms of response rates (32% vs. 21%, p=0.0002) and median 
progression-free survival (mPFS 9 vs. 6 months, p<0.0001)193. Two phase III trials 
compared the efficacy of anastrozole to tamoxifen as a first-line treatment in 
postmenopausal women194,195. The first one demonstrated similar efficacy results for 
anastrozole and tamoxifen, and in the second trial, anastrozole was superior to 
tamoxifen (median time to progression, mTTP, 11 months vs. 6 months, 
respectively, p=0.005)194,195. EORTC conducted a phase III study comparing the 
efficacy of exemestane and tamoxifen as first-line endocrine therapies in 
postmenopausal women. PFS was longer in the exemestane-treated patients than in 
the tamoxifen-treated patients (mPFS 10 months vs. 6 months, p=0.03)196. However, 
after longer follow-up, the difference in PFS between exemestane- and tamoxifen-
treated patients disappeared (HR 0.87, 95% CI 0.70-1.08, p=0.121)196. 
Fulvestrant was compared to AIs and tamoxifen for the treatment of mBC 
cancer. The recommended dose for fulvestrant is currently 500 mg per injection, 
which was found to be superior to the dose of 250 mg per injection in the 
CONFIRM trial197–199. Initially, fulvestrant 250 mg was found to be noninferior to 
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tamoxifen, anastrozole and exemestane200–202. The phase II FIRST trial compared 
fulvestrant 500 mg to anastrozole as a first-line treatment for advanced breast cancer. 
The study failed to demonstrate a significant improvement in its primary end-point, 
clinical benefit rate (73% vs. 67%, respectively, p=0.386). However, the secondary 
end-points, OS and TTP, were superior with fulvestrant compared to anastrozole 
(HR for OS 0.70, p=0.04, 6-month improvement in mOS, HR for TTP 0.66, p=0.01, 
10-month improvement in TTP)203,204. A larger phase III trial, FALCON, was 
conducted to confirm the findings of the FIRST trial205. Postmenopausal patients 
with metastatic hormone receptor-positive mBC were randomly assigned to receive 
either fulvestrant 500 mg or anastrozole as a first-line treatment. There were no 
differences in response rate (p=0.73) or clinical benefit rate (p=0.30) between the 
treatment arms. However, patients treated with fulvestrant had significantly longer 
mPFS compared to patients treated with anastrozole (mPFS 17 vs. 14 months, HR 
0.80, p=0.049)205. OS results have not yet been published. 
Fulvestrant was also investigated in combination with an AI, but the results of 
the three phase III studies were conflicting206–208. All three studies enrolled patients 
with hormone receptor-positive breast cancer with no previous therapy for advanced 
disease. The patients in the S0226 and FACT trials were randomized to receive 
anastrozole with or without fulvestrant. The SoFEA trial had 3 randomized 
treatment arms: fulvestrant + anastrozole, fulvestrant + anastrozole-placebo and 
exemestane. The S0226 and SoFEA trials enrolled only postmenopausal patients, 
but the FACT trial also enrolled premenopausal patients with the requirement to use 
LHRH analogue. In the FACT and SoFEA trials, no improvement was observed in 
PFS (FACT: HR 0.99, p=0.91, SoFEA: HR 1.0, p=0.98) or in OS (FACT: HR 1.0, 
p=1.00, SoFEA: HR 0.95, p=0.61) for the patients treated with the combination of 
fulvestrant and anastrozole compared to single-endocrine agent treatment. However, 
the S0226 trial, with a similar study design, reported a significant improvement in 
PFS and OS in fulvestrant plus anastrozole-treated patients compared to anastrozole 
alone (HR for PFS 0.68, p=0.007, HR for OS 0.82, p=0.03)206,209. The subgroup 
analysis of this study suggested that patients with no prior adjuvant endocrine 
therapy and a disease-free interval of more than 10 years had the greatest benefit 
from dual endocrine therapy206. The mOS for patients with no prior adjuvant 
endocrine therapy was 52 months with the anastrozole-fulvestrant combination 
compared to 40 months for patients treated with anastrozole alone209. Most of the 
patients enrolled in the FACT and SoFEA trials had a disease relapse during adjuvant 
endocrine therapy and therefore had more endocrine-resistant disease, which may 
explain the lack of survival benefit207,208. However, due to conflicting results, the use 
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of combination endocrine therapy for postmenopausal patients is not strongly 
recommended in the treatment guidelines of mBC16,41. 
2.3.2 mTOR inhibitors in mBC 
Hormone receptor-positive mBC may be treated with a combination of the mTOR 
inhibitor everolimus and an AI. The PI3K/AKT/mTOR pathway becomes 
activated during secondary endocrine resistance, providing the rationale for 
combining mTOR inhibitors with endocrine therapy210. The everolimus and 
exemestane combination was studied in postmenopausal patients who had 
experienced disease progression during or shortly after treatment with a nonsteroidal 
AI, letrozole or anastrozole. Everolimus in combination with exemestane improved 
mPFS by 4 months compared to placebo plus exemestane (mPFS 7 months vs. 3 
months, p<0.001)211. However, the response to everolimus plus exemestane was rare 
(9.5% vs. 0.4%, respectively, p<0.001). In addition, everolimus added treatment 
toxicity: 55% of study patients in the BOLERO-2 trial experienced ≥ grade 3 adverse 
events, e.g., stomatitis (8%), anemia (5%), hyperglycemia (4%) and pneumonitis 
(3%)211,212. Moreover, no OS benefit was observed with this combination 
(everolimus+exemestane: mOS 31 months; placebo+exemestane: mOS 27 months; 
HR 0.89, 95% CI 0.73-1.10, p=0.14)212. 
mTOR inhibitors were investigated as a first-line treatment for mBC. Phase II 
BOLERO-4 trial enrolled postmenopausal patients with no prior treatment for 
metastatic disease, and they were all treated with the combination of everolimus and 
letrozole213. The mPFS for the first-line treatment with everolimus and letrozole was 
22 months (95% CI 18-25 months), and mOS was not yet reached213. The phase III 
HORIZON trial compared the efficacy of another mTOR inhibitor, temsirolimus, 
combined with letrozole vs. placebo combined with letrozole as a first-line treatment 
of advanced breast cancer214. No improvement in the primary end point PFS was 
reported (HR for PFS 0.90, 95% CI 0.76-1.07, p=0.25)214.  
Since everolimus and exemestane are both orally available and their toxicity is 
mostly manageable, the combination is considered a treatment option for 
postmenopausal patients with secondary endocrine-resistant mBC, according to the 
positive results of the BOLERO-2 trial16,211,212. 
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2.3.3 CDK4/6-inhibitors in mBC 
Recently, three CDK4/6-inhibitors, palbociclib, ribociclib and abemaciclib, 
demonstrated substantial PFS benefit in combination with endocrine therapy as a 
treatment of advanced hormone receptor-positive breast cancer. These compounds 
prevent the cell cycle from progressing from G1 to S phase215. As a first-line 
treatment for postmenopausal patients, palbociclib, ribociclib or abemaciclib 
combined with an AI provided a significant improvement in mPFS by 9.3-13.4 
months compared to a placebo with an AI (palbociclib: HR 0.58, 95% CI 0.46-0.72, 
p<0.001; ribociclib: HR 0.57, 95% CI 0.46-0.70, p<0.001; abemaciclib: HR 0.54, 95% 
CI 0.42-0.70, p<0.001)216–218. CDK4/6 inhibitors were also investigated for the 
treatment of more hormone-resistant advanced breast cancer either with disease that 
had progressed on adjuvant endocrine therapy or while receiving first-line endocrine 
therapy for metastatic disease. In this setting, palbociclib, ribociclib or abemaciclib 
combined with fulvestrant demonstrated a mPFS benefit of 4.9-7.7 months 
compared to placebo with fulvestrant (palbociclib: HR 0.46, 95% CI 0.36-0.59, 
p>0.001; ribociclib: HR 0.59, 95% CI 0.48-0.73, p<0.001; abemaciclib: HR 0.55, 95% 
CI 0.45-0.68, p<0.001)219–221. Of the above-mentioned trials, PALOMA-3 
(palbociclib) and MONARCH-2 (abemaciclib) also enrolled premenopausal patients 
with the requirement that they use a LHRH analogue alongside the study 
treatment219,221. For ribociclib, a separate phase III first-line endocrine therapy study 
for premenopausal patients was conducted222. In this trial (MONALEESA-7), the 
premenopausal patients received either ribociclib or a placebo with tamoxifen or 
nonsteroidal AI plus a LHRH analogue. The mPFS benefit (10.8 months) in the 
ribociclib treatment arm was similar to the benefit in studies focusing on 
postmenopausal patients (HR 0.55, 95% CI 0.44-0.69, p<0.001)222. 
CDK4/6 inhibitors were quite well tolerated. The most common side effect from 
these treatments was neutropenia, which was the most pronounced with 
palbociclib216,217,223. The specific side effects from ribociclib were the elevation of 
liver enzymes and the prolongation of the QTc interval, which results in a need of 
ECG monitoring217. Finally, abemaciclib caused less neutropenia, but diarrhea was 
common, although it was manageable with lopestrogenamid223. 
The PALOMA-3 and MONALEESA-7 trials are the only CDK4/6 trials with 
OS results already published224,225. PALOMA-3 compared palbociclib and 
fulvestrant to placebo and fulvestrant, but the study was not powered to demonstrate 
significant OS differences between the treatment groups. The numerical gain in mOS 
with the palbociclib vs. placebo remained the same as the previously reported mPFS 
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difference (34.9 months vs. 28.0 months, HR 0.81, 95% CI 0.64-1.03, p=0.09)224. 
The OS results of premenopausal patients in the MONALEESA-7 trial were recently 
reported in ASCO 2019, and it is the first CDK4/6 inhibitor study with OS results 
for a treatment-naïve patient population in advanced breast cancer. The OS was 
significantly longer in patients treated with ribociclib and endocrine therapy 
compared to placebo and endocrine therapy, although the mOS was not yet reached 
(HR 0.71, 95% CI 0.54-0.95, p=0.0098)225. 
The OS results of the other first-line CDK4/6 trials for postmenopausal patients 
are eagerly awaited. However, based on the PFS and preliminary OS results, 
CDK4/6 inhibitors are recommended for the treatment of hormone receptor-
positive mBC for either first-line treatment in combination with an AI or for a later 
line combined with fulvestrant if the patient has already been treated with another 
endocrine therapy16. 
2.3.4 Chemotherapy of mBC 
Chemotherapy is recommended for mBC patients with either triple-negative disease, 
HER2-positive disease (see section 2.4.1), hormone receptor-positive disease with 
visceral crisis or endocrine-resistant disease16. The ESO-ESMO Advanced Breast 
Cancer consensus guideline defined visceral crisis as severe organ dysfunction, as 
assessed by signs and symptoms, laboratory studies and rapid progression of 
disease16. 
The era of more modern chemotherapy regimens began in 1976 when an Italian 
oncologist, Gianni Bonadonna, published his results on the efficacy of the 
chemotherapy regimen of cyclophosphamide, methotrexate and fluorouracil (CMF) 
as a treatment of early breast cancer226. The same Italian group was the first to 
describe the use of anthracyclines in mBC in 1969227. However, it was not until the 
1990’s that the first anthracycline-containing regimen of doxorubicin combined with 
cyclophosphamide (AC) became the gold-standard adjuvant treatment of early breast 
cancer228. Epirubicin was later introduced as a less cardiotoxic anthracycline than 
doxorubicin229. Paclitaxel’s antitumor activity was described in 1971, and it was the 
first taxane to be introduced230. Paclitaxel was originally isolated from the bark of 
the Pacific yew tree Taxus brevifolia, and like other taxane-group compounds, it binds 
to microtubules and induces their stabilization by inhibiting their depolymerization, 
thereby leading to apoptosis231. However, the development of paclitaxel was slow 
due to poor availability of raw material and poor solubility, and only in 1995 did the 
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United States Food and Drug Administration (FDA) approve paclitaxel for the 
treatment of mBC. Paclitaxel was compared to doxorubicin and to their combination 
as first-line chemotherapy of mBC in a phase III trial published in 2003232. Response 
rate, median time to treatment failure (TTF) and OS were equivalent between 
paclitaxel and doxorubicin monotherapies. However, the combination of 
doxorubicin and paclitaxel had a higher response rate and longer mTTF than the 
monotherapies, but no survival benefit was observed232. Docetaxel is a semisynthetic 
taxane compound derived from needles of the European yew tree Taxus baccata, with 
a similar mechanism of action to paclitaxel233. Phase III trial results demonstrated 
improved survival and TTP with docetaxel compared to paclitaxel for treatment of 
mBC that had progressed after anthracycline-containing chemotherapy (mOS 15 vs. 
13 months, p=0.03)234. However, hematologic and nonhematologic toxicities were 
more common for docetaxel 100 mg/m2 every 3 weeks compared to paclitaxel 175 
mg/m2 every 3 weeks234. 
2.3.4.1 Taxanes as the treatment of mBC 
Taxanes were explored under different dosages and treatment cycles for their 
efficacy and tolerability as treatment of mBC. Weekly paclitaxel 80 mg/m2 was 
compared with paclitaxel 175 mg/m2 every three weeks in a phase III trial235. This 
study also enrolled HER2-positive patients, and they were all treated with 
trastuzumab. Weekly paclitaxel was superior to every three weeks, with response 
rates of 42% and 29%, respectively (p=0.004). Additionally, TTP and OS were also 
longer for weekly paclitaxel compared to paclitaxel every three weeks (mTTP 9 vs 5 
months, p<0.001, mOS 24 vs 12 months, p=0.0092, respectively)235. In a meta-
analysis of approximately 1500 mBC patients, weekly paclitaxel administration 
resulted in lower response rates [risk ratio (RR) 1.20, p<0.001], similar PFS (HR 1.02, 
p=0.860) and longer OS (HR 0.78, p=0.001) compared to paclitaxel administration 
every three weeks236. Additionally, the incidence of severe neutropenia, febrile 
neutropenia and peripheral neuropathy were lower with weekly paclitaxel 
administration compared to paclitaxel every three weeks236. Higher doses (210 
mg/m2 or 250 mg/m2) of paclitaxel every three weeks did not improve patient 
survival or response rates and caused more neurotoxicity and hematologic toxicity 
compared to the standard paclitaxel dose of 175 mg/m2 every 3 weeks237. Weekly 
docetaxel administration has been less extensively investigated than the 
administration of paclitaxel. One phase III trial randomized 118 patients patients to 
receive either docetaxel 35 mg/m2 weekly for 3 consecutive weeks followed by one 
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week of rest or docetaxel 75 mg/m2 every 3 weeks238. The response rates were higher 
with the 3-weekly regimen than with weekly docetaxel (36% vs 20%, respectively, p-
value was not reported), but no difference was observed in PFS or OS between the 
groups (p=0.46 or p=0.34, respectively)238. In addition, the weekly docetaxel regimen 
was better tolerated238.  
Both weekly paclitaxel and weekly docetaxel are also treatment options for elderly 
or frail patients with mBC. They were effective for these patients, and the toxicity 
was mostly manageable239. The toxicity profiles of these compounds differed in that 
anorexia, stomatitis and edema were more common with docetaxel and neurotoxicity 
and myalgia with paclitaxel239. 
Nab-paclitaxel was also studied for the treatment of mBC, but its position in the 
treatment of mBC is still uncertain16. Nab-paclitaxel is an albumin-bound paclitaxel 
administered as a colloidal suspension of 130 nm particles. This formula allows the 
infusion of significantly higher doses of paclitaxel than the standard solvent-based 
paclitaxel, shorter infusion schedule and no need for premedication240. In a phase III 
trial with mostly chemotherapy-pretreated mBC patients, response rates were higher 
and mTTP longer with nab-paclitaxel compared to standard paclitaxel (response 
rates 33% vs. 19%, p=0.001; mTTP 23 vs 17 weeks, p=0.006)241. The incidence of 
grade 4 neutropenia was significantly lower with nab-paclitaxel than with standard 
paclitaxel (9% vs 22%, p<0.001), but grade 3 neuropathy was more common with 
nab-paclitaxel (10% vs 2%, respectively, p<0.001)241. The same study group 
consequently conducted a trial with nab-paclitaxel compared to docetaxel as a first-
line treatment of mBC. The study patients were randomized to receive either nab-
paclitaxel 300 mg/m2 every 3 weeks, nab-paclitaxel 100 mg/m2 weekly, nab-
paclitaxel 150 mg/m2 weekly or docetaxel 100 mg/m2 every 3 weeks. The group with 
the highest nab-paclitaxel dose of 150 mg/m2 had significantly longer PFS than the 
docetaxel-treated patients (15 vs 8 months, p=0.012). However, no significant 
differences between response rates or the PFSs of other nab-paclitaxel dosages and 
docetaxel were observed.242 Another phase III trial compared weekly nab-paclitaxel 
150 mg/m2 to weekly paclitaxel or ixabepilone as first-line treatment of mBC, and 
additionally, all study patients received bevacizumab. Ixabepilone was inferior to 
weekly paclitaxel, and this treatment arm was closed for futility at the first interim 
analysis. No significant efficacy differences were observed between weekly paclitaxel 
and weekly nab-paclitaxel, with a trend favoring weekly paclitaxel (HR for PFS 1.20, 
p=0.054). Additionally, weekly paclitaxel was better tolerated than nab-paclitaxel, 
with a hematologic toxicity grade ≥3 in 22% of patients compared to 55% in the 
nab-paclitaxel group.243 
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2.3.4.2 Second or later line chemotherapy for mBC 
Patients with disease progression after taxane and anthracycline-containing cytotoxic 
therapy can be considered for additional chemotherapy, and multiple regimens exist 
for later-line chemotherapy options of mBC. Capecitabine, vinorelbine, gemcitabine, 
and platinum salts, either alone or in multiple combinations, demonstrated efficacy 
for mBC patients with prior taxane and anthracycline treatment16,41. With single 
capecitabine, the response rate ranged from 14 to 29% and PFS from 3 to 6 months 
in phase II-III studies in the anthracycline- and taxane-pretreated mBC 
population244. The efficacy of vinorelbine as a monotherapy was quite similar to that 
of capecitabine, with response rate ranging between 12 and 26% and PFS between 
3 and 4 months in the pretreated mBC population244. Additionally, vinorelbine with 
capecitabine enabled an all-oral combination with neutropenia as the dose-limiting 
toxicity and similar efficacy to intravenous vinorelbine with capecitabine245,246. 
Furthermore, alopecia was not a side effect for capecitabine or vinorelbine, which 
might be particularly important to some patients244.  
Eribulin, an inhibitor of microtubule dynamics, also offers a valid treatment 
option for mBC patients247. Eribulin-treated patients had significantly longer OS 
than the patients who were treated with chemotherapy by the investigator’s choice 
in a heavily pretreated mBC population (mOS 13 vs 10 months, p=0.041). In this 
phase III trial (EMBRACE), all study patients were previously treated with taxane 
and anthracycline, and 70% of the patients were previously treated with 
capecitabine247. In a subsequent phase III trial, patients with prior taxane and 
anthracycline therapy were randomized to receive either eribulin or capecitabine, but 
no significant OS or PFS benefit was observed with eribulin (mOS 16 vs 15 months, 
p=0.056, mPFS 4 vs 4 months, p=0.30, respectively)248. 
Gemcitabine was studied in combination with variable chemotherapeutic 
regimens and in a meta-analysis of more than 8000 mBC patients. Adding 
gemcitabine to various chemotherapy options improved the response rate, PFS and 
OS at the price of mainly increased hematologic toxicity249. However, the 
improvement in survival was limited to first-line combinations, and no PFS or OS 
improvement was observed with later-line gemcitabine-containing regimens249. 
Ixabepilone is an FDA-approved antineoplastic agent that stabilizes microtubule 
dynamics, leading to cell apoptosis250. Ixabepilone in combination with capecitabine 
had superior efficacy compared to capecitabine alone in the treatment of mBC 
patients with prior taxane and anthracycline therapy (RR for OS 0.91, 95% CI 0.84-
0.99, p=0.03; RR for PFS 0.79, 95% CI 0.74-0.85, p<0.001)251. However, as first-line 
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therapy, ixabepilone was less effective than paclitaxel, and as later-line treatment, no 
significant efficacy differences between ixabepilone and eribulin were observed251. 
2.3.4.3 Special considerations for the chemotherapy treatment of triple-negative mBC 
Chemotherapy for TNBC is recommended by the same principles as for other 
subtypes of mBC16,41. However, platinum salts, cisplatin and carboplatin can offer 
additional efficacy for patients with TNBC. BRCA1 mutation causes impairment in 
DNA double-strand repair, and DNA repair may be altered through other 
mechanisms, e.g., somatic or germline mutations in other genes, DNA methylation 
or attenuated mRNA expression252. Platinum compounds cause the formation of 
DNA-platinum adducts and intra- and interstrand DNA crosslinks; therefore, the 
cells with underlying deficiencies in the DNA repair system may be exceptionally 
sensitive to platinum salts253. 
As first-line therapy for metastatic TNBC, cisplatin combined with gemcitabine 
was superior to paclitaxel combined with gemcitabine in a phase III trial (HR for 
PFS 0.69, 95% CI 0.52-0.92, p=0.009). However, the difference between their 
mPFSs was minimal and not clinically significant (mPFS 7.7 vs. 6.5 months)254. 
Carboplatin area under curve (AUC) 6 every 3 weeks as a single agent was also 
compared to docetaxel 100 mg/m2 every 3 weeks in a first-line phase III trial (TNT) 
for mBC enrolling mainly TNBC patients. The overall response rates (ORRs) 
between carboplatin- and docetaxel-treated patients were similar (31% vs 34%, 
p=0.66), as were the PFSs and OSs (mPFS 3 vs 4 months, p=0.40, mOS 13 vs. 12 
months, p=0.96, respectively)255. The TNT trial also enrolled 43 patients with 
germline BRCA1/2 mutations. The BRCA-mutated patients had significantly higher 
response rates with carboplatin compared to docetaxel (68% vs. 33%, p=0.03) and 
longer PFS (mPFS 6.8 vs 4.4 months, p=0.002), but no OS benefit could be 
demonstrated with this small patient population255. The efficacy of platinum salts as 
a treatment for mBC has been recently explored in a meta-analysis, which suggested 
a significant PFS benefit with platinum-containing regimens for patients with 
metastatic TNBC256. However, the meta-analysis also reported a significant 
improvement in the frequency of response and in OS with cisplatin or carboplatin, 
but this result was not related to the hormone receptor status256. 
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2.3.5 PARP inhibitors for mBC patients with germline BRCA1/2-mutation 
Investigation of PARP inhibitors for the treatment of mBC has focused on 
BRCA1/2-mutated patients. PARP is a nuclear enzyme that regulates cell survival 
through DNA repair (Figure 2)257. The PARP inhibitors olaparib, veliparib and 
talazoparib trap PARP proteins on damaged DNA, resulting in cytotoxic PARP-
DNA complexes258.  
 
Figure 2.  Mechanism of action of PARP inhibitors in patients with BRCA-mutated tumors. Tumors with 
BRCA mutations have deficient homologous recombination repair pathways. HR: 
homologous recombination. Figure modified from Sonnenblick et al. 2015259 
The phase III OlympiAD trial randomized mBC patients with germline BRCA 
mutations to receive either oral olaparib 300 mg twice daily or single-agent 
chemotherapy (capecitabine, vinorelbine or eribulin). PFS was significantly longer 
(mPFS 7 vs 4 months, p<0.001) and the response rate higher (60% vs. 29%) in 
patients treated with olaparib compared to chemotherapy260. In the entire patient 
population, no significant OS benefit was observed in olaparib-treated patients 
compared to patients treated with single-agent chemotherapy (HR for OS 0.90, 
p=0.513). However, the patients treated with olaparib as a first-line treatment had a 
significant 8-month improvement in mOS (23 vs 15 months, HR 0.51, p=0.02, 
respectively)261. 
The phase III EMBRACA trial had a similar treatment design as the OlympiAD 
trial. The patients with mBC and a germline BRCA1/2 mutation were randomized 
to receive talazoparib 1 mg orally once daily or single-agent chemotherapy 
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(capecitabine, eribulin, gemcitabine or vinorelbine). PFS was longer in patients 
treated with talazoparib compared to chemotherapy (9 vs 6 months, HR 0.54, 
p<0.001), and the response rate was higher (63% vs. 27%), but no OS benefit was 
demonstrated (HR 0.76, 95% CI 0.55-1.06, p=0.11)262. 
Veliparib was investigated for BRCA germline-mutated mBC patients in a phase 
II trial with three randomized treatment arms: veliparib + carboplatin/paclitaxel, 
veliparib + temozolomide, placebo + carboplatin/paclitaxel. No significant PFS or 
OS benefit was demonstrated (p-value for PFS 0.2, p-value for OS 0.16). However, 
the ORR was higher for patients treated with veliparib+carboplatin/paclitaxel (78%) 
compared to patients treated with placebo+carboplatin/paclitaxel (61%, p=0.03)263. 
PARP inhibitors were generally well tolerated, with grade 3-4 toxicity rates 
ranging from 26 to 37%, and treatment was discontinued less often than single-agent 
chemotherapy (5-6% vs. 8-9%, respectively)260,262. The most common grade ≥3 
adverse events were hematologic: anemia, neutropenia and leukocytopenia. 
Additional side effects of all grades included nausea, diarrhea, vomiting, fatigue and 
headache.260,262 In conclusion, taking into account the oral availability, good 
tolerability and the efficacy observed in phase III trials, olaparib and talazoparib are 
compelling treatment options for mBC patients with a germline BRCA1/2 mutation 
once reimbursed. 
2.3.6 PI3K inhibitors 
Phase III trial results of the efficacy of PI3K inhibitors were recently published. 
Approximately 40% of mBC patients with hormone receptor-positive and HER2-
negative disease have activating PIK3CA mutations 252,264. One of the mechanisms 
of resistance to endocrine therapy is the aberrant activation of PI3K signaling210. 
SOLAR-1 was a phase III study of the efficacy of an oral PI3K inhibitor, alpelisib, 
in hormone receptor-positive mBC patients with prior AI treatment265. The study 
patients were randomized to receive either alpelisib 300 mg daily with fulvestrant or 
placebo with fulvestrant. The primary end-point, PFS, in the cohort of PIK3CA-
mutated cancer was significantly improved in patients treated with the combination 
of alpelisib and fulvestrant compared to placebo with fulvestrant (mPFS 11 vs. 6 
months, HR 0.65, 95% CI 0.50-0.85, p<0.001). The most common adverse events 
related to alpelisib were hyperglycemia, gastrointestinal side effects and rash.265 
Buparlisib is another oral PI3K inhibitor that was evaluated in the phase III 
BELLE-2 and BELLE-3 trials. BELLE-2 enrolled hormone receptor-positive mBC 
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patients with prior AI therapy, and the patients were randomized to receive 
fulvestrant with either buparlisib 100 mg daily or placebo. In the entire study 
population, mPFS was significantly longer in buparlisib-treated patients than in the 
placebo group (mPFS 7 vs 5 months, HR 0.80, 95% CI 0.68-0.94, p=0.0033). In the 
ctDNA PIK3CA mutant cohort, mPFS was also significantly longer in the buparlisib 
group than in the placebo group (mPFS 7 vs. 3 months, HR 0.58, 95% CI 0.41-0.82, 
p=0.001). However, 23% of the patients treated with buparlisib combined with 
fulvestrant had serious adverse events: increased liver enzymes, hyperglycemia and 
rash. The high toxicity rates led to the decision for no further studies to be continued 
with this combination.266 On the other hand, BELLE-3 enrolled hormone receptor-
positive, HER2-negative mBC patients with disease progression and who were 
treated or had been treated with an mTOR inhibitor. The mPFS improvement in 
patients treated with buparlisib and fulvestrant was modest compared to the mPFS 
in patients treated with placebo and fulvestrant (mPFS 4 vs. 2 months, HR 0.69, 95% 
CI 0.53-0.84, p=0.00030). Similarly, in the BELLE-3 trial, the frequency of serious 
adverse events was high (22%), and the most common grade ≥3 side-effects were 
increased liver enzymes (19%) and hyperglycemia (12%).267 
The phase III SANDPIPER trial enrolled patients with hormone receptor-
positive, HER2-negative advanced breast cancer and a PIK3CA mutation. The study 
patients were all previously treated with an AI. Patients were randomized to receive 
fulvestrant with the PI3K inhibitor taselisib 4 mg orally per day or with a placebo. 
The mPFS was longer in the taselisib group than in the placebo group (mPFS 7 vs. 
5 months, HR 0.70, p=0.0037). The most common ≥ grade 3 adverse events were 
gastrointestinal toxicities and hyperglycemia. Dose discontinuations and reductions 
were more common in patients treated with taselisib and fulvestrant than placebo 
and fulvestrant (17% vs 2% and 37% vs 2%, respectively)268. 
Although alpelisib, buparlisib and taselisib are all PI3K inhibitors, their specificity 
to target receptors varies. PI3Kα, PI3Kβ and PI3Kγ are enzyme isoforms of PI3K269. 
Buparlisib is a pan-PI3K inhibitor, taselisib is a β-sparing PI3K inhibitor, and 
alpelisib targets specifically PI3Kα265–268. The specificity differences between the 
agents may explain the differences in the adverse events (grade 3 hyperglycemia: 
alpelisib 37%, buparlisib 15% and taselisib 10%). In addition, the numerical PFS 
improvement was longer with alpelisib (+5 months) than with buparlisib and 
taselisib (+2 months)265–268. Therefore, alpelisib is the most promising PI3K 
inhibitor for the future treatment of secondary hormone-resistant mBC with a 
PIK3CA mutation. 
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2.3.7 Immunotherapeutic treatment options for mBC 
As for many other malignancies, immunotherapy has also been investigated for the 
treatment of mBC. Tasuku Honjo’s group at Kyoto University identified and cloned 
the programmed death-1 (PD-1) receptor in the 1990’s, and for this discovery, the 
Nobel prize in physiology and medicine was awarded to Tasuku Honjo in 2018270,271. 
Since the discovery of the PD-1 receptor, multiple PD-1 receptor- and programmed 
death ligand-1 (PD-L1) receptor-targeting antibodies have been investigated, e.g., for 
the treatment of melanoma, non-small cell lung cancer and renal cell carcinoma272–
274. The interaction of PD-1 receptor with its ligand PD-L1 inhibits T-cell activation. 
This tumor-related immune suppression can be prevented by using PD-1 or PD-L1 
inhibitors.270,275–277  
 Atezolizumab is a PD-L1 inhibitor that was investigated in the phase III 
IMpassion130 trial in combination with nab-paclitaxel as a treatment for advanced 
treatment naïve TNBC. The trial was randomized and placebo-controlled. The most 
significant result of the IMpassion130 trial was the long OS improvement in patients 
with PD-L1-positive tumors treated with the combination of atezolizumab and nab-
paclitaxel (mPFS 25 vs 15.5 months, HR 0.62, 95% CI 0.45-0.86). Additionally, PFS 
was longer in patients treated with the combination of atezolizumab and nab-
paclitaxel compared to patients treated with placebo and nab-paclitaxel (mPFS 7.2 
vs 5.5 months, HR 0.80, 95% CI 0.69-0.92, p=0.002; PD-L1-positive patients: mPFS 
7.5 vs. 5.0 months, respectively, HR 0.62, 95% CI 0.49-0.78, p<0.001).278 The OS 
improvement by 9.5 months led to the FDA approval of atezolizumab for the 
treatment of advanced TNBC with tumor tissue PD-L1 expression ≥ 1%279. 
IMpassion130 is the only phase III immunotherapy trial on mBC with published 
results. Otherwise, only phase I-II data exist from PD-1/PD-L1 inhibitors for mBC 
treatment. Pembrolizumab, avelumab and atezolizumab were all investigated as 
single-agents for mBC treatment. In the Keynote-086 trial, 170 patients with 
advanced TNBC and prior taxane and anthracycline treatment were enrolled in the 
study. The ORR was only 5.3%, and the mOS was 9 months. However, the 
responses to pembrolizumab were durable: the median duration of response was not 
reached, and 63% of responses continued ≥ 12 months.280 Atezolizumab as a single 
agent for advanced TNBC patients demonstrated similarly long responses to 
immunotherapy: the median duration of response was 21 months in the 10% of the 
study patients who responded to atezolizumab281. The phase Ib JAVELIN study 
enrolled heavily pretreated HER2-negative patients regardless of the hormone 
receptor status and evaluated the single-agent activity of the PD-L1 antibody 
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avelumab. The ORR in the triple-negative subgroup was 5.2%. However, only 2 
responses (2%) were observed in 110 hormone receptor-positive patients in the 
study.282 
2.3.8 HER2-positive mBC 
2.3.8.1 First-line treatment of HER2-positive advanced breast cancer 
HER2-targeted therapy is recommended for patients with HER2-positive mBC16. 
The CLEOPATRA trial demonstrated a substantial OS benefit with the 
pertuzumab-trastuzumab-docetaxel combination as first-line therapy compared to 
the previous standard therapy, trastuzumab-docetaxel (mOS 56.5 months vs. 40.8 
months, HR 0.68; 95% CI 0.56 to 0.84, p<0.001)283. This has become the new 
standard first-line therapy for patients able to tolerate taxane16,41. The ORR was 80% 
and the mPFS 19 months in patients who received pertuzumab-trastuzumab-
docetaxel combination therapy in the CLEOPATRA trial. Pertuzumab did not 
increase cardiac toxicity compared with trastuzumab-docetaxel. However, diarrhea 
and rash were more common in pertuzumab-treated patients compared to the 
control group.283  
Other chemotherapy regimens were also investigated as first-line therapies in 
combination with pertuzumab and trastuzumab. Phase II studies with weekly 
paclitaxel combined with pertuzumab and trastuzumab and vinorelbine 
intravenously (i.v.) combined with pertuzumab and trastuzumab resulted in ORRs 
of 59% and 74%, respectively284,285. The mPFS of the weekly paclitaxel triplet 
combination was 19.5 months (95% CI 14-26 months) and the vinorelbine triplet 
combination 14.3 months (95% CI 11.2-17.5 months)284,285. These combinations 
may be an option for patients unable to tolerate docetaxel, since the side effects were 
more tolerable with weekly paclitaxel and vinorelbine triplet therapies284,285.  
The results of the phase IIIb PERUSE trial focusing on the safety of the 
pertuzumab-trastuzumab-taxane combination were published in February 2019286. 
Altogether, 1436 study patients received pertuzumab and trastuzumab at standard 
doses with either docetaxel (n=775), paclitaxel (n=589) or nab-paclitaxel (n=65) by 
the investigator’s choice. The adverse events were consistent with the results of the 
CLEOPATRA trial. Some differences in the incidence of specific adverse events 
existed, according to the taxane compound: all-grade neuropathy was more common 
with paclitaxel than with docetaxel (31% vs 16%), febrile neutropenia and mucositis 
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were less common with paclitaxel compared to docetaxel (1% vs. 11% and 14% vs. 
25%, respectively). The ORRs for different taxanes were similar: 79% for 
pertuzumab-trastuzumab-docetaxel, 83% for pertuzumab-trastuzumab-paclitaxel 
and 77% for pertuzumab-trastuzumab-nab-paclitaxel. The same was true of the 
mPFSs (20 months, 23 months and 18 months, respectively).286 
T-DM1 was also investigated as first-line therapy of HER2-positive mBC. The 
phase III MARIANNE randomized patients to receive either the trastuzumab-
taxane combination, T-DM1 or pertuzumab combined with T-DM1287. There were 
no statistically significant differences in ORR or PFS between the three treatment 
groups, although T-DM1 was better tolerated287. 
2.3.8.2 Endocrine therapy for HER2-positive mBC 
Endocrine therapies can be used in combination with HER2-targeted therapies in 
patients with hormone receptor-positive and HER2-positive breast cancer. In the 
subgroup analysis of the CLEOPATRA trial, the patients with nonvisceral disease 
did not have a statistically significant improvement in PFS or OS283. According to 
the treatment guidelines of breast cancer, patients with hormone receptor-positive 
HER2-positive mBC can be considered for first-line endocrine therapy with HER2-
targeted therapy if the tumor burden is minimal and there are no signs of rapid 
disease progression16,41. 
The PERTAIN trial randomized postmenopausal patients to trastuzumab and an 
AI with or without pertuzumab as first-line treatment of hormone receptor- and 
HER2-positive mBC. The mPFS was longer in patients treated with the triplet 
combination compared to the duplet combination (mPFS 18.9 months vs. 15.8 
months, p=0.007)288. However, half of the PERTAIN study patients had received 
induction chemotherapy with a taxane for 18 to 24 weeks before the initiation of 
endocrine therapy288. The PERTAIN study reinforces the current practice of adding 
endocrine therapy to pertuzumab and trastuzumab maintenance therapy after 
discontinuation of the first-line taxane treatment16. 
2.3.8.3 Second and later-line treatment options for HER2-positive mBC 
The phase III EMILIA trial enrolled patients who had previously received 
trastuzumab and a taxane. Patients were randomized to either T-DM1 or lapatinib-
capecitabine. The ORR was 10% higher in the T-DM1 group than in the lapatinib-
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capecitabine group (44% vs. 31%, respectively). The mPFS was 9.6 months in T-
DM1-treated patients compared to 6.4 months in patients treated with lapatinib and 
capecitabine. The mOS was approximately five months longer in the T-DM1 group 
(HR 0.68, 95% CI 0.55-0.85, p<0.001)289. EMILIA also enrolled patients with brain 
metastases, and survival data for these patients were retrospectively analyzed290. The 
mPFS was quite similar between the T-DM1 and lapatinib-capecitabine groups (5.9 
months vs. 5.7 months). However, the T-DM1-treated patients had a significantly 
longer mOS of 26.8 compared to 12.9 months in lapatinib-capecitabine-treated 
patients (HR 0.38, 95% CI 0.18-0.80, p=0.0081)290. More heavily pretreated patients 
were enrolled in the TH3RESA trial: they had at least two previous HER2-targeted 
treatment lines, including trastuzumab, lapatinib and taxane291. In this pretreated 
patient population, T-DM1-treated patients had a 7-month-longer mOS compared 
to the physician’s choice chemotherapy group (HR 0.68, 95% CI 0.54-0.85, 
p=0.0007). No T-DM1 trials have been conducted in pertuzumab-trastuzumab dual 
blockade-treated patients. However, since the OS benefit with T-DM1 in second- 
and later-line trials is clear, T-DM1 is considered a standard second-line treatment 
for metastatic HER2-positive breast cancer16,41. 
Lapatinib was also investigated as a treatment of metastatic HER2-positive breast 
cancer. As first-line therapy, mPFS was shorter with the lapatinib-taxane 
combination than with the trastuzumab-taxane combination (mPFS 9.1 months vs. 
13.6 months, p<0.001)292. For patients previously treated with anthracycline, taxane 
and trastuzumab, adding lapatinib to capecitabine resulted in a modest two-month 
improvement in mPFS compared to capecitabine alone (mPFS 6.2 months vs. 4.3 
months, p<0.001), and no OS benefit was observed293. However, the ORR for 
patients with brain metastases was 29.2% with the lapatinib-capecitabine 
combination according to a meta-analysis of 800 patients, suggesting that patients 
with CNS involvement might benefit from this combination294. Dual blockade with 
trastuzumab and lapatinib for patients previously treated with a trastuzumab-
containing regimen resulted in modest but statistically significant improvement in 
PFS (by three weeks) compared to lapatinib alone (mPFS 11.1 weeks vs. 8.1 weeks, 
p=0.011). However, the combination of the two HER2-targeted therapies 
demonstrated a survival benefit (mOS 14 months vs. 9.5 months, HR 0.74, 95% CI 
0.57-0.97, p=0.026)295. The combination of trastuzumab and lapatinib was also 
studied in the phase III ALTERNATIVE trial combined with an AI in 
postmenopausal patients previously treated with endocrine therapy, trastuzumab and 
a chemotherapy296. The mPFS was superior with the trastuzumab-lapatinib-AI 
combination compared to trastuzumab-AI (mPFS 11 months vs. 5.7 months, 
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p=0.0064). Additionally, patients treated with the lapatinib-AI combination had a 
longer mPFS than patients treated with the trastuzumab-AI combination (mPFS 8.3 
months vs. 5.7 months, p=0.0361)296. To conclude, lapatinib can be used as a 
treatment of mBC in combination with capecitabine or trastuzumab. However, the 
improvement in patient survival with T-DM1 has moved lapatinib combinations to 
the role of later-line treatments of advanced HER2-positive breast cancer16.  
2.3.9 Bevacizumab as a treatment of advanced breast cancer 
2.3.9.1 First-line treatment of mBC with bevacizumab 
Several phase III first-line trials were conducted for bevacizumab-chemotherapy 
combinations as treatments of mBC (Table 4). The E2100, AVADO, RIBBON-1 
and TURANDOT trials evaluated the efficacy of bevacizumab-taxane combinations. 
In the E2100 trial, the patients treated with the bevacizumab-paclitaxel combination 
had a higher ORR and longer mPFS than the patients treated with paclitaxel alone297. 
In the AVADO trial, the patients treated with a higher bevacizumab dose had a 
significantly longer mPFS than the patients treated with the placebo-docetaxel 
combination. However, there were no statistically significant differences in PFS 
between bevacizumab 7.5 mg/kg combined with docetaxel and placebo-docetaxel.298 
The ORR were higher in bevacizumab-containing treatment arms. The RIBBON-1 
trial randomized patients to either placebo with chemotherapy or bevacizumab with 
chemotherapy. The chemotherapy was chosen by the investigator, and the available 
options were capecitabine, a taxane or an anthracycline. As above, bevacizumab-
containing treatment arms had a longer mPFS than the placebo groups.299 The 
TURANDOT trial compared two bevacizumab-containing treatment arms: 
bevacizumab-paclitaxel and bevacizumab-capecitabine. The objective of the study 
was to demonstrate noninferior OS with the bevacizumab-capecitabine combination 
versus the bevacizumab-paclitaxel combination. The bevacizumab-capecitabine-
treated patients had a noninferior mOS compared to bevacizumab-paclitaxel-treated 
patients. However, the mPFS was significantly shorter in bevacizumab-capecitabine-
treated patients than in bevacizumab-paclitaxel-treated patients.300 
No OS benefit was demonstrated in any of these phase III first-line bevacizumab 
trials (Table 4)297–301. The first-line bevacizumab treatment improved the mPFS by 
2-6 months, and response to treatment was 11-18% more frequent297–299. However, 
because of the lack of OS benefit, bevacizumab plus chemotherapy is recommended 
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only for the treatment of selected patients with high tumor burden and therefore a 
higher need for tumor response16,41. 
Table 4.  Phase III trials with bevacizumab as first-line treatment of HER2-negative metastatic 
breast cancer 
Trial 
Author, year 
n Treatment arms RR  Median PFS  Median OS 
E2100 
Miller et al. 
2007297 
722 BEV 10 mg/kg d1, d15 + PAC90 Q4W 
PAC90 Q4W 
37% 
21% 
11.8 months 
5.9 months 
p<0.001 
26.7 months 
25.2 months 
p=0.16 
AVADO 
Miles et al. 2010298 
736 BEV 7.5 mg/kg + DOC100 Q3W 
BEV 15 mg/kg + DOC100 Q3W 
Placebo + DOC100 Q3W 
55% 
64% 
46% 
9.0 months 
10.1 months 
8.2 months 
p1=0.12, p2=0.006 
30.8 months 
30.2 months 
31.9 months 
p1=0.72, p2=0.85 
RIBBON-1 
Robert el al. 
2011299 
1237 BEV 15 mg/kg Q3W + CAP 
Placebo + CAP 
BEV 15 mg/kg Q3W + TX/ANT 
Placebo + TX/ANT 
35% 
24% 
51% 
38% 
8.6 months 
5.7 months 
9.2 months 
8.0 months 
p3<0.001, p4<0.001 
NR 
NR 
NR 
NR 
p3=0.27, p4=0.83 
TURANDOT 
Zielinski et al. 
2016300 
564 BEV 10 mg/kg d1, d15 + PAC90 Q4W 
BEV 15 mg/kg + CAP Q3W 
44% 
27% 
10.9 months 
8.1 months 
p=0.0066 
30.2 months 
26.1 months 
p=0.007 
MERiDiAN 
Miles et al. 
2017301,302 
481 BEV 10 mg/kg d1, d15 + PAC90 Q4W 
Placebo + PAC 90 Q4W 
54% 
33% 
11.0 months 
8.8 months 
p=0.0007 
28.8 months 
25.8 months 
p=0.59 
n: number of patients; BEV10: bevacizumab 10 mg/kg; d: day; PAC90: paclitaxel 90 mg/m2 on days 1,8 and 15; 
Q2W: every two weeks; Q3W: every three weeks; Q4W: every 4 weeks; m: months; HR: hazard ratio; DOC100: 
docetaxel 100 mg/m2; CAP: capecitabine; TX: taxane; ANT: Anthracycline; RR: response rate; PFS: progression-
free survival; p1: BEV7.5 vs. placebo; p2: BEV15 vs. placebo; p3: BEV+CAP vs. placebo+CAP; p4: BEV+TX/ANT 
vs. placebo+TX/ANT; OS: overall survival; NR: not reported 
MERiDiAN had a similar study design as E2100 trial, and the efficacy results were 
similar (Table 4)302. One objective of the MERiDiAN trial was to evaluate baseline 
plasma VEGF-A level as a predictive biomarker. However, the baseline plasma 
VEGF-A level did not identify the patients with the most benefit from bevacizumab 
(plasma VEGF-A high vs. low, interaction p-value 0.46)302. 
The ATHENA trial was an open-label single-arm study that evaluated the efficacy 
and tolerability of bevacizumab-based regimens as first-line treatments of mBC. 
Altogether, 2251 patients were enrolled in the study, and most study patients were 
treated with a bevacizumab-taxane combination. The mTTP in the ATHENA trial 
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was 9.5 months, which was quite similar to those of phase III trials with 
bevacizumab, and no new toxicity concerns were raised303. 
Taxanes and capecitabine were the most extensively investigated cytotoxic 
regimens in combination with bevacizumab, but other chemotherapy combinations 
were also studied. Nab-paclitaxel was not superior to bevacizumab-paclitaxel, with 
mPFSs of 9.3 months and 11 months, respectively (HR 1.20, 95% CI 1.00-1.45, 
p=0.054)243. Adding intravenous vinorelbine to bevacizumab-capecitabine did not 
prolong PFS compared to the bevacizumab-capecitabine combination (HR for PFS 
0.84, 95% CI 0.70-1.01, p=0.058)304. 
Bevacizumab for the treatment of HER2-positive mBC was studied in the 
randomized phase III AVEREL trial305. The study patients were treated with 
trastuzumab-docetaxel with or without bevacizumab as first-line therapy305. 
Bevacizumab did not improve patient survival (mPFS 17 months in the bevacizumab 
group and 14 months in the non-bevacizumab group, HR 0.82, 95% CI 0.65-1.02, 
p=0.775) or response rate (74% vs. 70%, respectively, p=0.35)305. 
2.3.9.2 Bevacizumab as second-line therapy for mBC 
Bevacizumab was also studied as a second- or later-line therapy. RIBBON-2 
included patients with one previous cytotoxic treatment for mBC. Patients received 
chemotherapy with capecitabine, gemcitabine, vinorelbine or a taxane and were 
randomized to receive either bevacizumab or placebo. Median PFS improvement by 
two months was observed in patients in the bevacizumab-chemotherapy arm (HR 
0.78. 95% CI 0.64-0.93, p=0.007).306 RIBBON-2 included 112 patients with TNBC, 
and the efficacy data for these patients were retrospectively analyzed. In this triple-
negative subgroup, the PFS improvement was more pronounced with bevacizumab 
(mPFS 6 months vs. 3 months, HR 0.50, p=0.0006).307 
Another phase III trial (AVG2119g) evaluated capecitabine with or without 
bevacizumab in mBC patients previously treated with 1-2 chemotherapy regimens 
for metastatic disease. The ORR for patients treated with the bevacizumab-
capecitabine combination was 20%, and the ORR for the capecitabine group was 
9% (p=0.001). However, no significant differences in PFS or OS were observed.308 
The phase III TANIA trial enrolled patients previously already treated with first-line 
bevacizumab-containing chemotherapy. The study patients were randomized to 
either continue bevacizumab with second-line chemotherapy or receive 
chemotherapy treatment alone. Continuing bevacizumab resulted in a statistically 
significant but modest PFS improvement (mPFS 6.3 months vs. 4.2 months, HR 
 62 
0.75, 95% CI 0.61-0.93, p=0.007).309 Additionally, the continuation of bevacizumab 
was possible with third-line chemotherapy, but this did not improve survival310. As 
in other later-than-first-line studies, no OS benefit was demonstrated310. 
2.3.9.3 Maintenance therapy with bevacizumab 
Bevacizumab as a maintenance therapy after first-line chemotherapy was also 
studied311,312. The HER2-negative hormone receptor-positive patients in the phase 
III randomized AROBASE trial were previously treated with first-line bevacizumab-
taxane for 16-24 weeks. The patients with nonprogressive disease were randomized 
to either continuation with bevacizumab-taxane or maintenance bevacizumab with 
exemestane. The Independent Data and Monitoring Committee recommended 
terminating the patient enrollment because the probability of reaching a statistically 
significant improvement in PFS by the end of the study was only 7% at that point311. 
The HR for PFS was 1.0 for bevacizumab-taxane compared to bevacizumab-
exemestane (95% CI 0.7-1.5, p=0.998).311 Maintenance bevacizumab was compared 
to bevacizumab-capecitabine for nonprogressive patients previously treated with 
first-line bevacizumab-docetaxel for 3-6 cycles in the phase III IMELDA trial. 
Bevacizumab-capecitabine improved PFS and OS compared to bevacizumab alone 
(mPFS 12 months vs. 4 months, HR 0.38, 95% CI 0.27-0.55, p<0.001, mOS 39 
months vs. 24 months, HR 0.43, 95% CI 0.26-0.69, p=0.003).312 In conclusion, the 
IMELDA trial suggested that bevacizumab maintenance therapy without endocrine 
therapy or chemotherapy was not considered as an effective therapy choice. 
2.3.9.4 Bevacizumab combined with endocrine therapy 
Postmenopausal patients with hormone receptor-positive advanced breast cancer 
were enrolled in two phase III studies focusing on first-line endocrine therapy with 
bevacizumab. The LEA trial evaluated endocrine therapy (letrozole or fulvestrant) 
with or without bevacizumab as first-line treatment of hormone receptor-positive 
mBC. Neither mPFS nor mOS was superior in the bevacizumab-containing 
treatment arm.313 Similarly, the CALGB 40503 trial enrolled postmenopausal 
patients with hormone receptor-positive advanced breast cancer, and they were 
treated with letrozole with or without bevacizumab. Bevacizumab with letrozole 
prolonged PFS compared to letrozole alone (mPFS 20 months vs. 16 months, HR 
0.75, 95% CI 0.59-0.96, p=0.016). No significant OS difference was observed.314 
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2.3.9.5 Adverse events related to bevacizumab 
Bevacizumab increases treatment toxicity, but adverse events are mostly grade 1-2 
and are manageable. The specific adverse events related to bevacizumab include 
hypertension, proteinuria, bleeding and thromboembolic events297–299,306. 
Hypertension of at least grade 3 was observed in 4-15% of the mBC patients 
treated with bevacizumab, and it was the most common bevacizumab-related 
toxicity297–299,306,315. Early hypertension during bevacizumab treatment was also 
linked to longer PFS in some studies, but overall, it did not predict clinical 
benefit316,317. 
Proteinuria was also quite common, but grade ≥3 proteinuria was reported in 
only 2.0-3.6% of the patients in the phase III trials focusing on the treatment of 
mBC297–299,306. Bleeding, primarily epistaxis, of all grades was observed in up to half 
of the bevacizumab-treated patients, but severe bleeding was rare297–299,306. Febrile 
neutropenia and sensory neuropathy were also more common in bevacizumab-
treated patients318. However, thromboembolic events and gastrointestinal 
perforations were not significantly more common in phase III breast cancer trials319. 
Additionally, grade 3-4 cardiovascular side effects, mainly left ventricular systolic 
function, were reported more often in bevacizumab-treated patients, with a 
frequency of 1-6% of the bevacizumab-treated patients297–299,306,319. 
A meta-analysis of 20 000 patients treated with bevacizumab focusing on 
cardiovascular toxicities demonstrated an increased risk for cerebral ischemia (RR 
3.11, p=0.003), arterial adverse events (e.g., myocardial ischemia, RR 1.37, p=0.004) 
and venous adverse events (e.g., venous thromboembolism, RR 1.29, p<0.001)320. 
Fatal adverse events related to bevacizumab were also reported. However, fatal 
events were not more common for mBC patients treated with bevacizumab than for 
patients treated with chemotherapy alone321. Hypertension and proteinuria were 
more commonly reported in older breast cancer patients ≥ 70 years old treated with 
bevacizumab-chemotherapy combination than in younger patients322. For patients 
treated with bevacizumab plus endocrine therapy, the treatment toxicity was more 
common in older patients (> 65 years) and in patients with other comorbidities: 
impaired vision or lower physical function323.  
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2.4 Prognostic circulating markers for advanced breast cancer 
2.4.1 VEGF-system and biomarkers for bevacizumab 
Oxygen supply to the tumor is essential for the malignant tissue to proliferate. 
Therefore, angiogenesis plays a key role in tumorigenesis. A schematic illustration of 
the tumor angiogenesis pathways under hypoxemic conditions is presented in Figure 
3. Under hypoxemic conditions in the tumor tissue, hypoxia-inducible factor-1 alpha 
(HIF-1α) is upregulated, leading to an increase in the transcription of numerous 
genes involved in angiogenic processes, e.g., VEGFs, fibroblast growth factor 1 
(FGF-1), platelet-derived growth factor (PDGF), MMPs, angiopoietins 1 and 2 
(Ang1 and Ang2) and Tie2324,325. HIF-1α translocates to the nucleus from the 
cytoplasm during hypoxia and forms a complex with HIF-1β. The complex binds to 
hypoxia-response elements (HREs), which are located in regulatory sites of HIF 
target genes326. Overexpression of HIF-1α is common in primary tumors and in 
metastases, and it is associated with poor patient outcome in multiple 
malignancies326,327. As hypoxia is the inducer of tumor angiogenesis, hypoxic or 
anoxic conditions are noted in 50-60% of solid tumors328. 
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Figure 3.  Angiogenic signaling in the hypoxemic tumor environment. Tumor cells react to tissue 
hypoxia and secrete angiogenetic growth factors and cytokines to promote blood vessel 
sprouting. ECM: Extracellular matrix; FGF: Fibroblast growth factor; FGFR: Fibroblast 
growth factor receptor; HIF-1: Hypoxia-inducible factor-1; HRE: Hypoxia-response element; 
MMPs: Matrix metalloproteinases; PDGF: Platelet-derived growth factor; PDGFR: Platelet-
derived growth factor receptor; VEGF-A: Vascular endothelial growth factor; VEGFR2: 
Vascular endothelial growth factor receptor 2. Figure created by Jukka Lehtiniemi, Tampere 
University 
As a consequence of the release of proangiogenic growth factors, a process known 
as ‘angiogenic switch’ is triggered20. Growth factors induce chemotaxis of endothelial 
cells and vessel sprouting towards the hypoxemic tumor, resulting in an atypical 
morphology and poor functioning of the vasculature20,329. During tumor 
angiogenesis, proangiogenic pathways are upregulated compared to physiological 
conditions330. Tip cells are the cells that lead the sprouting vessels, and they do not 
proliferate themselves. Tip cells direct the migration and form the connections 
between the sprouting vessels. Proliferating endothelial stalk cells are the adjacent 
cells behind the tip cells.331 
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The VEGF family has a key role in tumor angiogenesis. The family consists of 
five growth factors (VEGF-A, VEGF-B, VEGF-C, VEGF-D and placental growth 
factor (PlGF)) and their receptors (VEGFR-1, VEGFR-2, VEGFR-3, neuropilin-1 
and neuropilin-2)332. VEGFs differ in their physiological functions due to differences 
in the binding specificities to VEGF receptors333. VEGF-A is the most widely 
investigated and best-characterized member of the VEGF family. High intratumoral 
VEGF-A expression is observed in many tumor types, including breast cancer, 
gastrointestinal tract malignancies, kidney cancer, ovarian cancer and lung cancer, 
among others334. In response to hypoxia via HIF-1 signaling, VEGF-A is synthetized 
and secreted by multiple cells in the tumor microenvironment: fibroblasts, 
inflammatory cells including tumor associated macrophages (TAMs). It is also 
secreted by autocrine secretion by tumor cells themselves328,335. The main biological 
functions of VEGF-A include vascular endothelial cell proliferation and survival, 
activation of enzymes that are involved in extracellular matrix degradation, increased 
vascular permeability, chemotaxis for macrophages and mobilization of endothelial 
precursor cells from bone marrow336. VEGF-A binds with higher affinity to the 
tyrosine kinase receptor VEGFR-1 than to VEGFR-2. However, the kinase activity 
of VEGFR-1 is less than that of VEGFR-2, and therefore, the biological effects of 
VEGF-A are mediated mainly by VEGR-2332. On some cell types, VEGF-A also 
interacts with neuropilin-1, which can enhance the interaction of VEGF-A and 
VEGFR-2332,337. 
Other pathways significantly influence tumor angiogenesis. The delta-like 4 (Dll-
4)-Notch pathway regulates tumor angiogenesis and is upregulated in tumor 
vasculature338. Additionally, hypoxia can cause MET receptor overexpression. The 
MET pathway can increase tumor proliferation through multiple pathways, including 
RAS, PI3K, and STAT3. VEGF-A stimulation through VEGFR-2 regulates MET 
signaling. Additionally, the interaction of neuropilin-1 and the MET receptor 
increases the proliferation and survival of tumor cells. 326 
Multiple prognostic and predictive circulating markers were evaluated with the 
aim of identifying the patients who would most benefit from bevacizumab (Table 
5). In the AVADO trial, high VEGF-A was associated with shorter PFS among 
patients given bevacizumab 7.5 mg/kg (p=0.01)339. Therefore, the phase III 
MERiDiAN trial was conducted to evaluate high VEGF-A level as a prospective 
biomarker for bevacizumab benefit. However, MERiDiAN failed to prove a high 
baseline plasma VEGF-A level was applicable in selecting patients who would 
benefit most from bevacizumab (Table 5).301,302 CTCs ≥ 3/7.5 ml were prognostic 
for shorter TTP (p<0.05). However, the study group explored different cut-off levels 
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for CTCs, and none of the other thresholds was predictive of TTP. Circulating 
endothelial cells (CECs) were also evaluated as prognostic markers, but CECs were 
not prognostic for a bevacizumab benefit at any threshold.340 VEGF-A gene 
polymorphisms were analyzed from a baseline blood sample by PCR in the 
MO19391 trial. Of the several polymorphisms tested, only 926 C > T was associated 
with shorter TTP (p=0.02, Table 5).341 
Extensive effort has been devoted to the search for tissue and genetic biomarkers 
for bevacizumab-treated patients, but none of these demonstrated its potential as a 
predictive biomarker for clinical use342. High expression of VEGFR-3 was associated 
with more frequent responses (p=0.038), and high expression of VEGFR-1 was 
associated with poor survival (p=0.025) in mBC patients treated with bevacizumab-
containing chemotherapy in a small retrospective analysis343. However, the above-
mentioned results were not validated in a larger patient cohort. VEGF-A single-
nucleotide polymorphisms (SNPs) as prognostic markers were evaluated in 363 
tumor blocks of patients who participated in the E2100 trial344. The VEGF-2578 AA 
and VEGF-1154 A genotype were associated with improved OS compared with the 
alternate genotype combination (p=0.023 and p=0.001, respectively)344. The same 
study group also reported that VEGF-A amplification was associated with worse OS 
(p=0.08). 
From the extensive retrospective biomarker evaluation, plasma VEGF-A levels 
were considered the most promising prognostic marker for bevacizumab efficacy. 
This hypothesis was tested prospectively in the MERiDiAN trial as reported above 
(Table 5)302. As baseline plasma VEGF-A level did not help identify the patients with 
the most benefit from bevacizumab according to the MERiDiAN trial, no suitable 
prognostic marker for clinical use currently exists. 
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Table 5.  Circulating prognostic and predictive markers for bevacizumab benefit in breast cancer 
patients 
Marker Author, year Study design n Result 
VEGF-A high 
 
Miles 2013339 AVADO, phase III, mBC 
BEV + DOC 
396 BEV 7.5 mg/kg:  
HR for PFS 0.52 (95% CI 0.33-0.81) 
Interaction p=0.01 
BEV 15 mg/kg: 
HR for PFS 0.49 (95% CI 0.31-0.76) 
Interaction p=0.08 
 Gianni 2013305 AVEREL, phase III, mBC 
BEV + DOC + trastuzumab 
162 HR for PFS 0.70 (95% CI 0.43-1.14) 
Interaction p=0.80 
 Cameron 2013345 BEATRICE, phase III 
Stage I-III TNBC 
Adjuvant BEV 
1178 Third quartile cut-off: 
HR for DFS 0.64 (0.35-1.16) 
Interaction p=0.36 
 Miles 2017302 
Miles 2018301 
MERiDiAN, phase III, mBC 
BEV + PAC 
481 HR for PFS 0.64 (95% CI 0.47-0.88) 
Interaction p=0.46 
HR for OS 0.85 (95% CI 0.63-1.14), p=0.27 
VEGFR-2 high Miles 2013339 AVADO, phase III, mBC 
BEV + DOC 
396 BEV 7.5 mg/kg:  
HR for PFS 0.46 (95% CI 0.28-0.74) 
Interaction p=0.03 
BEV 15 mg/kg: 
HR for PFS 0.54 (95% CI 0.35-0.85) 
Interaction p=0.25 
 Cameron 2013345 BEATRICE, phase III 
Stage I-III TNBC 
Adjuvant BEV 
1178 HR for DFS 0.61 (0.39-0.97) 
Interaction p=0.03 
CTCs Bidard 2010340 MO19391, mBC 
BEV + taxane 
67 Baseline CTC ≥ 3/7.5 ml: 
shorter TTP (p<0.05) 
VEGF-A 
polymorphism 
Etienne-Grimaldi 
2011341 
MO19391, mBC 
BEV + taxane 
137  936CT or 936TT: median TTP 11.5 months 
(95% CI 10.2-25.8) 
936CC: median TTP 9.7 months (95% CI 
7.8-12), p=0.02 
n: number of patients; VEGF-A: vascular endothelial growth factor-A; mBC: metastatic breast cancer; BEV: 
bevacizumab; DOC: docetaxel; HR: Hazard ratio; PFS: progression-free survival; TNBC: triple-negative breast 
cancer; DFS: disease-free survival; PAC: paclitaxel; VEGFR-2: vascular endothelial growth factor receptor-2; 
CTC: circulating tumor cells 
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2.4.2 Angiopoietin-Tie pathway 
The endothelial angiopoietin/Tie (Ang/Tie) system is a second receptor tyrosine 
kinase signaling pathway in addition to VEGF and its receptors. The Ang/Tie system 
is important during fetal angiogenesis, lymphatic vessel development and 
homeostasis of the mature vasculature346,347, as well as in tumor angiogenesis 348,349. 
The Ang/Tie system includes human angiopoietin growth factors 1, 2 and 4 (Ang1, 
Ang2, Ang4), which are ligands for Tie2 receptor350–352. In contrast, Tie1 is an orphan 
receptor with no known ligand.  
Significant interest has emerged in targeting the Ang/Tie system for the treatment 
of malignant diseases. Ang1 and Ang2 have opposing actions on the Tie2 receptor. 
Ang1 stabilizes the vasculature and activates Tie2 more strongly than Ang2. On the 
other hand, Ang2 can act as an agonist or antagonist to the Tie2 receptor depending 
on the autocrine circumstances.350 In normal homeostasis, the Ang2 level is low, but 
the Ang2/Ang1 ratio is increased in diseases with inflammation, such as sepsis and 
malignancies including breast cancer353,354. HIF-1-mediated signaling in hypoxic 
malignant tissues also induces the secretion of angiopoietins355. High Ang2 level 
correlates with poor patient survival in multiple malignancies356–358. Trebananib, a 
peptibody that inhibits the binding of Ang1 and Ang2 to Tie2, was already 
investigated in a phase III trial for the treatment of ovarian cancer, and other 
Ang/Tie system-targeting antibodies or TKIs are currently being evaluated in clinical 
trials359–361. 
The significance of the Tie1 receptor in the tumor environment is less well 
understood. All angiopoietins bind to Tie2, and the Tie1 receptor has no known 
ligands346,362. However, Tie1 participates in the Ang-Tie2 signal transduction 
complex346,362–364. Additionally, Tie1 expression in tumor vessel endothelium is 
increased during tumor angiogenesis365. Tie1 deletion in mice led to a decrease in 
microvessel density, intratumoral necrosis and growth delay in tumors at late 
stages366. Additionally, Tie1 loss in mice reduced the extravasation of tumor cells and 
decreased metastases366. In another preclinical study, Tie1 deletion reduced tumor 
growth and angiogenesis348. Increased concentrations of Tie1 were observed in 
association with acute or chronic inflammation due to ectodomain cleavage of 
Tie1367,368. However, circulating Tie1 levels in breast cancer have not been explored. 
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2.4.3 Cytokines and other circulating proteins 
Inflammatory processes are heavily involved in tumorigenesis, angiogenesis and 
metastasis. Lifestyle-related cancer risk factors, such as tobacco smoking, sun 
exposure and obesity, are linked to cancer through chronic inflammation369. 
Similarly, some chronic viral and bacterial infections also increase cancer risk via 
inflammation370. Additionally, in malignant diseases, the tumor itself triggers 
inflammatory mechanisms that will engender a protumorigenic 
microenvironment371. Infiltrating immune cells and fibroblasts secrete cytokines, 
chemokines and growth factors that mediate inflammatory signals and promote 
tumor growth372,373. Chemokines are a group of cytokines that promote chemotaxis 
of leukocytes at the source of chemokine secretion374. Chemokines are further 
classified into four subfamilies depending on whether there are cysteines at the 
amino terminus: CXC, CC, CX3X and C375. Only selected cytokines, chemokines 
and growth factors relevant to this thesis are discussed in more detail below. 
2.4.3.1 Interleukins 8, 6 and 18 
IL-8 (also known as CXCL8) is a proinflammatory cytokine376,377. Other chemokines 
in the same CXC subfamily are epithelial neutrophil-activating protein (CXCL5), 
granulocyte chemotactic peptide-2 (CXCL6), neutrophil-activating protein (CXCL7 
and melanoma growth stimulatory activity proteins (CXCL1, CXCL2 and 
CXCL3)375. A common feature of CXC chemokines is their role in neutrophil 
migration. These chemokines can be secreted by both immune cells and non-
leukocytes, e.g., epithelial, endothelial and tumor cells378. IL-8 signaling is mediated 
by the G-protein-coupled receptors cysteine-X-cysteine chemokine receptor 1 
(CXCR1) and CXCR2379. These receptors have different chemokine-binding 
specificity: IL-8 and CXCL6 are ligands for CXCR1, whereas CXCR2 has multiple 
ligands: IL-8, CXCL1-3, CXCL5 and CXCL7380. The effects of IL-8 secretion in a 
tissue are complex. It recruits and activates neutrophils and attracts macrophages, 
dendritic cells, mast cells and myeloid-derived suppressor cells381–385. Cancer stem 
cell survival and migration are potentiated by IL-8 action via CXCR1386. IL-8 itself 
promotes further IL-8 production and release in macrophages, mast cells and 
keratinocytes387–389. IL-8 also stimulates the invasiveness of tumor cells390,391. 
IL-8 also plays a role in angiogenesis, increasing the proliferation and survival of 
endothelial cells392. IL-8 induces endothelial cell VEGF-A production, and by an 
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autocrine mechanism, it increases the expression of VEGFR2393. Indeed, two studies 
reported IL-8 mediated resistance to antiangiogenic therapies394,395.  
High circulating IL-8 level and tumor expression are associated with poor 
prognosis in cancer patients396–398. Even in local breast cancer, a high serum IL-8 
concentration is associated with a shorter DFS399,400. IL-8 level correlates with the 
tumor burden in many malignant diseases401. Additionally, high IL-8 level is 
associated with chemoresistance in malignant diseases402,403. Interestingly, changes in 
circulating IL-8 level reflected and predicted the response to the PD-1 inhibitor 
nivolumab or pembrolizumab in non-small cell lung cancer or melanoma patients404. 
Multiple IL-8-targeting antibodies or CXCR1/2 inhibitors have been evaluated 
in clinical trials for the treatment of inflammatory and infectious diseases and for the 
treatment of cancer405,406. Reparixin, an inhibitor of CXCR1 and CXCR2, was already 
evaluated for the treatment of HER2-negative mBC in a phase Ib study. Serious 
toxicities related to reparixin in combination with paclitaxel were rare (3%), and no 
dose-limiting toxicities were observed.407 A phase II trial investigating the efficacy of 
reparixin with paclitaxel for the treatment of metastatic TNBC is underway 
(clinicaltrials.gov, NCT02370238). An anti-IL-8 antibody, HuMax-IL-8, 
demonstrated promising in vitro activity for TNBC408. 
Interleukin-6 (IL-6) is another proinflammatory cytokine in the tumor 
microenvironment that is present with increased levels in the serum and at the tumor 
site in breast cancer patients409. IL-6 participates in the proliferation and 
differentiation of malignant cells410,411. IL-6 signaling is mediated through the 
interleukin-6 receptor (IL-6R)-glycoprotein 130 (gp130) complex. Binding of IL-6 
with its receptor can activate multiple proliferation pathways in cancer cells, 
including JAK/STAT3, PI3K/AKT and Ras/MAPK.412 Increased serum IL-6 is 
associated with poor survival in breast cancer413–415. IL-6, IL-6R and gp130 are also 
targeted by multiple monoclonal antibodies and antagonists in anticancer drug 
development efforts412. 
The importance of interleukin-18 (IL-18) in malignancies is less well understood 
than the roles of IL-8 and IL-6. IL-18 increases the expression of adhesion 
molecules, nitric oxide synthesis and chemokine production416. IL-18 expression was 
significantly higher in breast cancer tissue compared to the surrounding tissue of the 
same patient. However, IL-18 expression was similar in breast cancer tissue 
compared to IL-18 expression in benign breast diseases.417 High serum IL-18 level 
correlated with poor prognosis in patients with early TNBC418. Accordingly, high IL-
18 expression in tumor stroma is associated with better clinical responses to 
neoadjuvant chemotherapy in locally advanced or inflammatory breast cancer419. In 
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vitro, high expression of IL-18 was noted in doxorubicin-resistant cell lines420. 
Interestingly, in the era of immuno-oncologic therapies, IL-18 was found to increase 
immunosuppression by upregulating PD-1 expression421. IL-18 was also investigated 
in combination with PD-1 and CTLA-4 inhibitors for augmenting immunotherapy 
activity422. In addition, dose-escalation studies were conducted with recombinant 
human IL-18 as a part of a combination treatment of lymphoma423,424. 
2.4.3.2 Matrix metalloproteinases 
MMPs are a family of membrane-bound and secreted proteinases that take part in 
intravasation and extravasation processes in the extracellular matrix425. In addition, 
MMPs have a role in multiple functions that modify the tumor microenvironment: 
proliferation, invasion of tumor cells, cell survival, angiogenesis, adipogenesis and 
inflammatory processes426. During angiogenesis, MMPs degrade extracellular matrix 
to facilitate endothelial cell invasion for sprouting blood vessels427. MMPs also target 
tumor cell receptors and thereby activate proliferation pathways and inhibit 
apoptosis428. The secretion of MMPs, including MMP-9 and MMP-2, is induced by 
the HIF-1 pathway426. MMP-9 has an essential role in tumor angiogenesis by 
triggering the angiogenic switch20,429. TAMs are the major source of MMP-9, and 
once it is released into the tumor microenvironment, VEGF-A and fibroblast growth 
factor-2 (FGF-2) are secreted430,431. MMP-9 is also expressed in multiple 
inflammatory cells, mesenchymal cells, endothelial cells and pericytes, but to a lesser 
extent in tumor cells432. MMP-2 also contributes to tumor growth since tumor 
angiogenesis and proliferation are downregulated in MMP-2 knockout mice, and 
stromal MMP-2 and MMP-9 may act synergistically427,433. 
Studies of MMP-9 as a prognostic marker in breast cancer have yielded 
conflicting results. Most studies have reported that high MMP-9 expression in tumor 
tissue or in plasma/serum was associated with a higher risk of breast cancer relapse 
and/or shorter OS434–439. However, opposite results have also been published, with 
high MMP-9 tissue expression being a potential indicator for favorable 
prognosis440,441. In meta-analyses, MMP-9 and MMP-2 expression were both 
associated with poor prognosis in localized breast cancer442–444. However, the 
prognostic role of MMP-9 and MMP-2 has been investigated mostly in localized 
breast cancer and, its prognostic value in mBC is still unexplored. 
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2.4.3.3 YKL-40 
YKL-40 (also known as chitinase-3-like protein 1) plays a role in the proliferation of 
fibroblasts and chondrocytes, differentiation of macrophages, inflammation, 
remodeling of extracellular matrix and organization and migration of endothelial 
cells445–447. Patients with malignant pleural effusions had higher levels of YKL-40 in 
serum and pleural fluid than patients with nonmalignant pleural effusions448. High 
circulating YKL-40 level was associated with poor survival in patients with renal cell 
carcinoma, lung cancer, gastric cancer and hepatocellular cancer patients449–453. In 
addition, higher serum YKL-40 level was observed in melanoma patients compared 
to healthy controls454. The clinical significance of YKL-40 has also been investigated 
in breast cancer patients, but the results of these studies have been inconsistent455–
462. According to a meta-analysis, high YKL-40 was associated with unfavorable OS 
(HR 1.48, 95% CI 1.11-1.97) and shorter DFS (HR 1.51, 95% CI 1.10-2.07) in breast 
cancer patients463. 
2.4.3.4 Resistin 
Obesity is a risk factor for breast cancer in postmenopausal women464,465. Therefore, 
adipocytokines, including resistin, among others, may be related to breast cancer 
development and prognosis. Resistin is involved in the regulation of insulin 
resistance466. In malignancies, resistin may promote the metastatic potential of breast 
cancer cells by inducing epithelial-to-mesenchymal transition467. The expression of 
resistin receptor CAP1 was associated with more unfavorable breast tumor 
characteristics – estrogen receptor negativity and higher tumor grade468. Circulating 
resistin level was also elevated in breast cancer patients compared to healthy 
controls469–471. Additionally, compared with low resistin expression, high resistin 
expression in the primary breast cancer tissue was associated with poorer patient 
survival and more unfavorable clinicopathological features of the primary cancer472. 
Interestingly, resistin attenuated doxorubicin-induced apoptosis in a preclinical 
breast cancer cell line study. Therefore, the researchers suggested resistin antagonism 
should be investigated to overcome chemotherapy resistance in mBC patients.473 
In premenopausal breast cancer patients, however, high serum resistin was 
associated with longer DFS and was correlated with node-negativity474. Similarly, in 
another study of premenopausal breast cancer patients, patients with invasive ductal 
breast carcinoma had lower serum resistin than the patients with DCIS or healthy 
controls475.  
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2.4.3.5 HMGB1 
High-mobility group box 1 (HMGB1) is a ubiquitous nuclear protein that 
participates in DNA repair, transcription, replication and the stabilization of nuclear 
homeostasis476–478. HMGB1 can also translocate from the nucleus into the cytoplasm 
and may be secreted from the cell, where it can trigger inflammatory responses and 
autophagy processes479,480. HMGB1 is expressed at higher levels in many tumor types 
compared with healthy tissue, and its expression is associated with many diseases, 
including cancer481,482. In a meta-analysis on multiple tumor types, high HMGB1 
expression was associated with shorter OS and PFS [HR 1.99 (95% CI 1.71-2.31) 
and HR 2.26 (95% CI 1.65-3.10), respectively].483 HMGB1 was considered a 
promising biomarker for breast cancer since circulating HMGB1 level increased 
significantly in responding breast cancer patients after a single dose of neoadjuvant 
chemotherapy, whereas no significant change was observed in nonresponders 
(p=0.002 and p=0.17, respectively)484. In TNBC patients, cytoplasmic expression of 
HMGB1 was significantly associated with higher tumor-infiltrating lymphocyte 
(TIL) levels and higher nuclear grade485. Furthermore, HMGB1 was investigated as 
a drug target in multiple trials, and recently, a metabolite of acetylsalicylic acid was 
also found to inhibit HMGB1486. 
2.5 Circulating tumor markers for disease monitoring 
Liquid biopsies are considered a promising method for monitoring mBC and for 
detecting resistance mutations. In a series of 30 women undergoing therapy for 
mBC, ctDNA, CA15-3 and CTCs were compared to standard imaging for 
monitoring metastatic cancer. In this comparison, ctDNA was more strongly 
correlated with changes in tumor burden than CA15-3 or CTCs487. At disease 
progression, the ctDNA level increased in 17 of the 19 women (89%) with confirmed 
progression on CT. CTCs increased in 7 of 19 progressing patients (37%) and CA15-
3 level in 9 of 18 progressing women (50%).487 
Estrogen receptor ESR1 mutations are a common mechanism of secondary 
endocrine resistance488–491. In a secondary analysis of the BOLERO-2 trial, ESR1 
mutations (Y537S and D538G) were analyzed from cell-free DNA (cfDNA) in 
baseline plasma samples. ESR1 mutations were detected in 41% of the study 
patients, and OS in these patients was significantly shorter than for patients without 
ESR1 mutation (mOS 20.7 vs 32.1 months, p<0.001).492 Therefore, the presence of 
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ESR1 mutations is associated with poor prognosis, but its predictive value remains 
unexplored. 
A potential resistance mechanism to CDK4/6 inhibitors was also identified by 
ctDNA analysis. Next-generation sequencing (NGS) of ctDNA was performed for 
the samples of 34 mBC patients with disease progression during CDK4/6 inhibitor 
treatment. FGFR-1/2 amplification or an activating mutation was observed in 14/34 
patients (41%). Moreover, baseline samples of MONALEESA-2 patients were 
analyzed for FGFR1 mutation status, and the patients with FGFR-1 amplification 
had shorter PFS compared to wild-type FGFR-1 patients. In the same study, FGFR-
1 TKI erdafitinib demonstrated promising activity in combination with palbociclib 
and fulvestrant in FGFR-1-amplified xenografts.493 
PI3K inhibitors are promising new agents for the treatment of hormone receptor-
positive HER2-negative mBC with prior AI therapy. The SOLAR-1 trial reported 
positive PFS results for alpelisib in the mBC patients with a PIK3CA-mutation as 
described in section 2.3.6265. The PIK3CA-mutation could be reliably analyzed in 
ctDNA: the patients with plasma PIK3CA-mutation positivity had a mPFS of 10.9 
months, and the patients with tissue PIK3CA positivity had a similar mPFS, 11.0 
months.494 Therefore, the possibility of analyzing PIK3CA mutations by liquid 
biopsies facilitates the introduction of PI3K inhibitors to the clinic. 
HER2 resistance mechanisms can be detected by ctDNA. A study of 18 HER2-
positive patients included 6 patients with progression of mBC. Analysis of ctDNA 
detected resistance mechanisms to anti-HER therapy: HER2 amplification (3/6), 
mutations in the gene TP53 (3/6) and mutations in genes related to mTOR/PI3K 
pathway (3/6).495 
A high CTC count in patients with mBC is associated with an unfavorable 
prognosis. The mCTC count in patients with mBC was 3/7.5 ml of blood (IQR 0-
25) in a retrospective analysis including 20 studies and 1944 patients496. A high CTC 
count (≥5 CTC/7.5 ml) was observed in 47% of the mBC patients. The patients 
with high CTC counts had significantly shorter PFS and OS (HR for PFS 1.92, 95% 
CI 1.73-2.14; HR for OS 2.78, 95% CI 2.42-3.19).496 In another study, mBC patients 
with detected CTCs ≥ 1 per 7.5 ml had significantly shorter mOS compared to the 
patients with no detectable CTCs (mOS 0.7 vs 1.8 years, p<0.001)497. CTCs were 
prospectively evaluated in one trial that aimed to evaluate CTCs for predicting 
response, PFS and OS in mBC patients498. A high CTC count (≥ 5 per 7.5 ml of 
whole blood) predicted poor survival (mPFS 2.7 months for CTC count ≥ 5 vs. 7.0 
months for CTC count < 5, p<0.001). However, the usefulness of CTCs for disease 
monitoring was limited because many patients had very low CTC counts or no 
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detectable CTCs (< 2 CTCs/7.5 ml in 66% of the mBC study patients).498 The 
SWOG S0500 trial randomly assigned patients with rising CTC counts after 21 days 
of chemotherapy to either continue initial therapy or to change to another 
chemotherapy. The patients had similar survival in both treatment arms. Thus, 
changing the chemotherapy regimen due to rising CTC count after one cycle of 
chemotherapy did not improve either OS or PFS. However, the patients with rising 
CTC counts after 21 days of chemotherapy had significantly shorter OS than the 
patients with decreasing CTCs after 21 days of chemotherapy or no CTCs at baseline 
(mOS 13 vs 23 vs 35 months, respectively, p<0.001).499 In conclusion, a high CTC 
count is strongly associated with poor prognosis, but no data support its use as a 
predictive marker for therapy response. 
2.5.1 CA15-3 
CA15-3 monitoring in mBC patients is recommended only for patients with 
nonmeasurable metastatic disease16,41. Approximately 80% of mBC patients have 
elevated CA15-3 levels500. Tampellini et al. conducted a trial with 790 mBC patients 
with the aim of studying whether serial CA15-3 measurements would provide 
additional prognostic information in addition to standard clinicopathological factors. 
The changes in CA15-3 level were mostly related to tumor responses, but individual 
discrepancies existed.501 Therefore, serial CA15-3 level measurements cannot be 
used alone for monitoring responses in mBC. 
One clinical problem associated with CA15-3 monitoring is the possibility of a 
spiking phenomenon. In a study of approximately 600 patients, spikes in CA15-3 
level were observed in 5% of the mBC patients, but the survival of these patients 
was similar to that in patients without CA15-3 spikes at the beginning of the 
treatment. The peak of the spike occurred at a median of 6 weeks, with decreasing 
CA15-3 levels thereafter.502 The spike in the beginning of the treatment might have 
been due to necrosis and apoptosis of tumor cells. In another study, CA15-3 levels 
at 8 and 12 weeks of therapy correlated with the treatment response, but not the 
marker level at 4 weeks, a time frame matching the spike phenomenon503. 
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3 AIMS OF THE STUDY 
This study was designed to evaluate the benefit from adding bevacizumab to 
standard first-line taxane chemotherapy in patients with advanced or metastatic 
breast cancer. Another aim was to evaluate the feasibility of the bevacizumab-taxane 
combination considering the known additional toxicity related to bevacizumab. In 
our study, bevacizumab was also continued after taxane discontinuation as a 
maintenance therapy. For hormone receptor-positive patients, endocrine therapy 
was administered with bevacizumab maintenance treatment. Therefore, an 
additional goal was to evaluate whether endocrine treatment and bevacizumab would 
have a synergistic benefit. The primary end-point of the study was progression-free 
survival. The secondary end-points included safety, response rate and overall 
survival. 
The aim of the exploratory biomarker study was to evaluate the prognostic value 
of plasma cytokines and other circulating proteins. The specific markers explored 
were Tie1, Ang2, IL-8, IL-6, IL-18, MMP-2, MMP-9, YKL-40, resistin and HMGB1. 
An additional aim was to evaluate if the new lectin-based CA15-3 assays would 
be more specific than conventional, widely used CA15-3 for monitoring the response 
by patients with mBC. 
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4 PATIENTS AND METHODS 
4.1 Patients 
Altogether, 65 patients were enrolled in this academic, prospective, nonrandomized 
phase II study in three Finnish University hospitals: Tampere, Turku and Oulu. 
Enrollment took place between May 2009 and October 2013. The data collection 
was closed in April 2015 after all the primary and secondary end-points of the study 
were met. The median follow-up time was 24.1 months (range 1.6-66.3 months). 
The study patients were diagnosed with histologically or cytologically confirmed 
HER2-negative mBC and had not received previous chemotherapy for the 
metastatic disease. Previous endocrine treatment was also allowed for advanced 
disease. Both pre- and postmenopausal hormonal status and measurable and 
nonmeasurable disease were allowed. The additional inclusion criteria included good 
performance status [Eastern Cooperative Oncology Group (ECOG) performance 
status 0-2] and adequate hematological, renal and hepatic function. The patients were 
suitable for taxane chemotherapy treatment, and they were allowed to have received 
chemotherapy as neoadjuvant or adjuvant treatment. The disease-free interval had 
to be at least 6 months after the completion of taxane-containing (neo)adjuvant 
chemotherapy. The patients were excluded in the case of CNS metastases, pre-
existing peripheral neuropathy of at least grade 2 by the National Cancer Institute 
Common Toxicity Criteria (NCI-CTC), version 3.0504. Additionally, patients with 
recent surgeries, a need for anticoagulants or thrombolytic agents, a history of 
coagulopathies, uncontrolled hypertension or clinically significant cardiovascular 
disease were excluded. Patients with a history of abdominal fistula, abscess or 
gastrointestinal perforation were not allowed to enter the study. Finally, the study 
patients were not allowed to have a history of other malignancies. 
4.2 Treatment 
In part I of the study, the patients received taxane chemotherapy combined with the 
VEGF-A antibody bevacizumab. Both regimens were administered intravenously. 
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Either paclitaxel or docetaxel was used as the taxane. The simplified study scheme is 
presented in Figure 4. Chemotherapy treatment was continued until maximal 
response, disease progression, unacceptable toxicity or patient refusal. Maximal 
response was defined as an achieved response with no change between two 
consecutive response evaluations. The study was initiated with docetaxel combined 
with bevacizumab, and this combination was continued until the AVADO trial 
results were published in 2010 showing negative results from the docetaxel-
bevacizumab combination298. Therefore, an amendment was made, and the study 
was continued with paclitaxel-bevacizumab. 
If docetaxel or paclitaxel was discontinued for reasons other than disease 
progression, the patients continued to receive bevacizumab every three weeks in part 
II of the study (Figure 4). In addition, the patients with hormone receptor-positive 
breast cancer received endocrine therapy according to the investigator’s choice. The 
part II treatment was continued until disease progression, unacceptable toxicity or 
withdrawal of patient consent. After disease progression, the continuation of 
bevacizumab was optional, and the second-line chemotherapy was the investigator’s 
choice. The recommended chemotherapy option for the second-line treatment was 
capecitabine. 
 
 
Figure 4.  Study scheme. The patients without disease progression entered study part II, when the 
taxane (docetaxel or paclitaxel) was discontinued. In part II, only hormone receptor-positive 
patients received endocrine therapy in combination with bevacizumab. d: day; Q4W: every 
4 weeks; HR: hormone receptor; PD: progressive disease; Q3W: every 3 weeks 
4.3 Toxicity and response evaluation 
Toxic side effects were monitored and graded according to the NCI-CTCAE, 
version 3.0504. Tumor evaluations by CT were performed every 12 weeks until 
disease progression according to the Response Evaluation Criteria in Solid Tumors 
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(RECIST), version 1.1505. After trial discontinuation, study patients were followed 
up every 6 months for their survival by patient records. OS was estimated from the 
date of randomization to the death of the patient, patient refusal or the last follow-
up date. 
4.4 Plasma samples 
Plasma samples were gathered for investigational purposes. The samples were 
obtained at study baseline, every sixth week during study part I and at taxane 
discontinuation. During study part II, the plasma samples were obtained every three 
weeks during the first two months and thereafter every 12 weeks and at the final 
study visit. 
Additionally, plasma samples were analyzed from women who participated in a 
breast cancer primary prevention study currently in progress at Tampere University. 
These women served as healthy control samples. 
4.5 Measurement of Tie1, Ang2, IL-8, IL-6, IL-18, MMP-2, 
MMP-9, YKL-40, resistin and HMGB1 
The plasma analyses were performed on the samples gathered at baseline, after six 
weeks of treatment, after six months of treatment and at the final study visit. 
Additionally, Tie1 was measured in 10 female breast cancer prevention study 
participants as healthy controls. Tie1 and Ang2 levels were measured in patient 
plasma samples using a modified hTie1 and hAng2 enzyme-linked immunosorbent 
assay (ELISA) protocol. Plasma IL-8, IL-6, IL-18, MMP-2, MMP-9, YKL-40, 
resistin and HMGB1 concentrations were measured by ELISAs. ELISAs were 
carried out according to a standard protocol. The detailed laboratory protocols can 
be found in the original publications (publications II-III).  
4.6 Measurement of CA15-3 and the glycovariant forms of 
CA15-3 
CA15-3 analyses were performed using three different assays: conventional CA15-3 
and two glycovariant forms, CA15-3MGL and CA15-3WGA. They were analyzed at 
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baseline, at week six of treatment, at month six of treatment and at final study visit. 
In addition, samples were analyzed from 20 healthy control subjects who 
participated in the breast cancer primary prevention study. In addition, the 
conventional CA15-3 concentrations were analyzed with a CA15-3 enzyme 
immunoassay (Fujirebio Diagnostics Inc., Malvern, PA, USA) according to the 
manufacturer’s instructions. The glycovariant forms of CA15-3 were analyzed using 
an in-house protocol described in original publication IV. 
4.7 Statistical analysis 
The median PFSs and OSs were calculated according to the Kaplan-Meier method. 
Adverse events and treatment responses were displayed in standard frequency tables. 
The statistical plan for the biomarker analysis was exploratory. Tie1, Ang2, IL-8, IL-
6, IL-18, MMP-9, MMP-2, YKL-40, resistin and HMGB1 were dichotomized as low 
or high for each patient using the median value as the cutoff. In addition, IL-8, IL-
6, IL-18, MMP-9, MMP-2, YKL-40, resistin and HMGB1 levels were divided into 
four groups using the baseline quartile ranges as the cutoff values. The Mann-
Whitney U test was used to compare differences in the baseline Tie1, Ang2 and IL-
8 levels between groups with different baseline characteristics and between IL-8 
trajectory groups. The Wilcoxon signed rank test was used to compare Tie1, Ang2 
and IL-8 levels at different time points. The Wilcoxon signed rank test was also used 
to compare baseline and week-six CA15-3 levels in relation to the treatment 
response. Spearman’s correlation was used to analyze the correlation between the 
conventional CA15-3 level and CA15-3MGL or CA15-3WGA level. Hazard ratios (HRs) 
with 95% CIs were calculated using Cox proportional hazard regression analysis. 
Multivariable analyses were adjusted for age (continuous), menopausal status 
(premenopausal/postmenopausal), hormone receptor status (negative/positive), the 
presence of visceral metastasis (yes/no), the number of metastatic lesions (cutoff of 
three metastatic lesions) and the extent of the disease (cutoff of three metastatic 
sites). Interleukin-8 values were clustered using trajectory analysis506. Trajectory 
analysis divided patients into groups with similar change patterns of interleukin-8 
level during chemotherapy treatment. P-values under 0.05 were considered 
statistically significant. Statistical analyses were performed using SPSS version 23 
(SPSS Inc., Chicago, IL, USA) and IL-8 trajectory analysis by R version 3.3.0. 
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4.8 Ethics 
The study protocol was approved by the Ethics Committee of Tampere University 
Hospital (R08142M). The trial was also registered at clinicaltrials.gov with trial 
identifier NCT00979641. Written informed consent was obtained from all patients 
enrolled in the study. 
Additionally, plasma samples were analyzed from women who participated in a 
breast cancer primary prevention study currently in progress at Tampere University. 
All participants in this breast cancer prevention study gave their written informed 
consent, and the Ethics Committee of Tampere University Hospital approved the 
study (R15023). 
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5 SUMMARY OF RESULTS 
5.1 Patient characteristics 
All 65 patients enrolled in the study were included in the survival analysis. The 
baseline characteristics of the patients are presented in Table 6. Plasma samples for 
the biomarker analysis were available from 58 patients, and the characteristics of 
these patients can also be found in Table 6. Baseline plasma samples were available 
from 53 patients. 
Table 6.  The baseline characteristics of patients 
 Overall study population (n=65) 
Plasma biomarker 
population (n=58) 
Median age (range), years 57 (32-75) 58 (32-75) 
Menopausal status, n (%) 
   Premenopausal 
   Postmenopausal 
 
10 (15.4) 
55 (84.6) 
 
9 (15.5) 
49 (84.5) 
History of early stage disease, n (%) 57 (87.7) 52 (89.7) 
Disease free interval, n (%) 
   ≤ 24 months 
   > 24 months 
 
11 (19.3) 
46 (80.7) 
 
10 (19.2) 
42 (80.8) 
Hormone receptor status, n (%) 
   ER+ and/or PR+ 
   ER- and PR- 
 
53 (81.5) 
12 (18.5) 
 
47 (81.0) 
11 (19.0) 
Prior endocrine therapy for metastatic disease, n (%) 18 (27.7) 15 (25.9) 
Number of metastatic lesions, n (%) 
   ≤ 3 
   > 3 
 
14 (21.5) 
51 (78.5) 
 
11 (19.0) 
47 (81.0) 
Extent of disease 
   < 3 sites  
   ≥ 3 sites 
 
39 (60.0) 
26 (40.0) 
 
36 (62.1) 
22 (37.9) 
Site of metastatic disease, n (%) 
   Visceral disease 
   Nonvisceral disease 
 
53 (81.5) 
12 (18.5) 
 
46 (79.3) 
12 (20.7) 
Abbreviations: n: number of patients; ER: estrogen receptor; PR: progesterone receptor 
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5.2 Clinical efficacy results (Publications I-III) 
In treatment part I, 32 patients were treated with the docetaxel-bevacizumab 
combination and 33 patients with the paclitaxel-bevacizumab combination. The 
patients with no disease progression at taxane discontinuation entered treatment part 
II. Of the 38 patients in part II, the majority had hormone receptor-positive disease 
(87%), and only five patients (13%) had hormone receptor-negative breast cancer. 
In part II, the hormone receptor-positive patients also received endocrine therapy 
with maintenance bevacizumab. Letrozole was the most common drug choice for 
these patients (n=19). Other endocrine therapy choices included anastrozole (n=4), 
exemestane (n=4), tamoxifen (n=3) and fulvestrant (n=3). 
The mPFS of all study patients was 11.3 months (95% CI 9.7-16.0), and the mOS 
was 35.1 months (95% CI 22.2-50.3). The ORR was 61.5% (n=40), with one 
complete response included. Stable disease was observed in 15 patients (23.1%). 
Only three patients (4.6%) did not respond to the treatment, and the best response 
for these three patients was a progressive disease. The mOS for patients with 
hormone receptor-positive disease was 45.0 months (95% CI 30.2-51.3). The mOS 
for the patients with triple-negative mBC was significantly shorter, as expected, at 
17.9 months (95% CI 8.5-26.9, p=0.011). 
The plasma biomarker population had similar efficacy results as the entire study 
population. The mPFS for the plasma biomarker population was 11.3 months (95% 
CI 8.3-14.4), and the OS was 37.5 months (95% CI 25.4-49.6). The ORR for the 
plasma biomarker population was 71.7%. 
After disease progression, the study patients were allowed to receive bevacizumab 
in combination with second-line chemotherapy, and 17 study patients were treated 
in this setting. The investigator’s choice as the chemotherapy regimen was 
capecitabine for 15 patients. One patient each received paclitaxel and vinorelbine. 
The mPFS for second-line therapy was 5.1 months (95% CI 4.4-16.1 months), and 
the OS was 33.8 months (95% CI 24.7-not reached). The ORR for the second-line 
treatment was 41%. 
5.3 Toxicity (Publication I) 
In treatment part I, the bevacizumab-taxane combination was generally well 
tolerated, and the reported toxicities were mostly grade 1-2. The grade 3-4 toxicities 
of the chemotherapy in part I are reported in Table 7. One patient died from 
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gastrointestinal perforation during the part I treatment. This patient had pre-existing 
diverticulosis and developed diverticulitis early during bevacizumab-taxane 
combination treatment. This resulted in gastrointestinal perforation and peritonitis.  
Table 7.  Grade 3-4 adverse events during treatment part I 
 Patients (n=65) 
Adverse events Grade 3-4 
Neutropenia 25 (38%) 
Leukocytopenia 13 (20%) 
Infection 9 (14%) 
Neutropenic infection 4 (6%) 
Pain 1 (2%) 
Fatigue 2 (3%) 
Diarrhea 1 (2%) 
Elevated lives enzymes 2 (3%) 
Nausea 1 (2%) 
Peripheral neuropathy 1 (2%) 
Cardiac disorders 1 (2%) 
Osteonecrosis of the jaw 1 (2%) 
Drug hypersensitivity 1 (2%) 
Gastrointestinal perforation 1* (2%) 
*Patient died, grade 5 adverse event 
 
Similarly, the toxicities were mostly grade 1-2 in treatment part II. Grade 3-4 adverse 
events during part II included two infections, two elevated liver enzymes, two 
hyponatremia and one each of leukocytopenia, peripheral neuropathy, anorexia, 
congestive heart failure and coronary artery thrombosis. 
Bevacizumab-related toxicities were monitored closely. One patient died during 
treatment part I, as mentioned above. This patient with pre-existing diverticulosis 
had diverticulitis and consequently a gastrointestinal perforation. The grade 5 
adverse event was suspected to be related to bevacizumab. Additionally, one patient 
had grade 4 proteinuria. Otherwise, bevacizumab-related toxicities were grade 1-2, 
including hypertension, proteinuria, hemorrhage, epistaxis and gastrointestinal 
fistula or abscess. 
During second-line bevacizumab-chemotherapy treatment, the side effects were 
mostly related to capecitabine. The reported grade 3-4 side effects were three cases 
of hand-and-foot syndrome and a single case of grade 4 diarrhea. 
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5.4 Results of the circulating prognostic markers 
5.4.1 IL-8 (Publication II) 
The patients were dichotomized into two groups using the median baseline IL-8 
level of 9.4 pg/ml as the cut-off value. The high-IL-8 group had significantly shorter 
OS by age-adjusted Cox regression (HR 2.14, 95% CI 1.10-4.12, p=0.023). However, 
in multivariate analysis, the difference between the low- and high-level groups was 
no longer statistically significant (p=0.159). 
Trajectory analysis resulted in three trajectory groups (Figure 5). The patients in 
trajectory group 1 had a significantly lower circulating IL-8 concentration than the 
patients in groups 2 and 3 at baseline (p<0.001 and p=0.002, respectively), at week 
six (p<0.001, p=0.002), at month six (p=0.006, p<0.001) and at the final visit 
(p=0.001, p<0.001). The OS was significantly shorter for the trajectory group 2 and 
3 patients compared to trajectory group 1 (Figure 5, p=0.004 and p=0.001, 
respectively).  
 
 
Figure 5.  a. The trajectory groups. The trajectory group 1 patients had a significantly lower plasma IL-
8 level than the patients in trajectory groups 2 and 3 during the entire first-line treatment 
period. b. Overall survival of the three trajectory groups. Patients with constantly low plasma 
IL-8 during the entire treatment period in trajectory group 1 had an exceptionally long median 
OS. * p-value group 2 vs. group 1, ** p-value group 3 vs. group 1 
 87 
For identifying patients with a favorable prognosis, a cut-off value of 16.6 pg/ml 
was found to be useful. All plasma IL-8 levels in trajectory group 1 patients remained 
below 16.6 pg/ml before and during the entire chemotherapy treatment period. The 
OS was significantly shorter for patients with plasma IL-8 levels higher than 16.6 
pg/ml before or during the treatment (multivariate HR 3.90, 95% CI 1.88-8.12, 
p<0.001). 
Additionally, the patients with baseline plasma IL-8 levels in the highest quartile 
(> 18.8 pg/ml) had poor survival regardless of the IL-8 levels during the treatment. 
The multivariate HR for PFS was 6.52 (95% CI 2.60-27.0, p<0.001) for the highest 
IL-8 quartile, and the multivariate HR for OS was 8.38 (95% CI 2.60-26.9, p=0.010). 
5.4.2 IL-6, IL-18, MMP-2, MMP-9, YKL-40 and HMGB1 (Publication II) 
Cox regression analyses were also performed for plasma IL-6, IL-18, MMP-2, MMP-
9, YKL-40 and HMGB1 concentrations. Using the median as the cut-off value, a 
baseline plasma MMP-9 level >76.4 ng/ml was borderline significant for longer OS 
(multivariate HR 0.52, 95% CI 0.26-1.03, p=0.063). In addition, the highest baseline 
plasma quartile level of YKL-40 was a sign of poor prognosis in age-adjusted Cox 
regression (HR 3.08, 95% CI 1.10-8.61, p=0.031). However, the highest YKL-40 
plasma quartile level was no longer significant in multivariate analysis (p=0.211). The 
median and quartile levels were used as cut-off values, and no significant differences 
were observed in terms of PFS. For IL-6, IL-18, MMP-2, resistin and HMGB1, there 
were no significant OS differences, either. 
5.4.3 Tie1 and Ang2 (Publication III) 
The median plasma Tie1 concentration at baseline was 21.0 ng/ml (95% CI 17.8-
23.3), and the median Ang2 concentration at baseline was 1.29 ng/ml (95% CI 1.03-
1.52). The Tie1 concentration of the healthy controls was significantly lower than 
the baseline plasma level of the mBC patients (p<0.001). The median concentrations 
were used as cut-off levels for the high- and low-Tie1 and -Ang2 groups. 
The mPFS and mOS were significantly longer in the low-baseline-Tie1 group 
compared to the high-Tie1 group (Figure 6). The multivariate HR for OS for the 
high-Tie1 group was 3.07 (95% CI 1.39-6.79, p=0.005). In contrast, the baseline 
Ang2 level was not prognostic for PFS or OS in multivariate Cox regression analysis. 
However, the longest mOS was observed in patients with both Tie1 and Ang2 levels 
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low at baseline. The multivariate HR for the patients with both Tie1 and Ang2 high 
at baseline was 4.32 (95% CI 1.44-12.94, p=0.009). The mOS for patients with low 
baseline levels of both Tie1 and Ang2 was 46.8 months (95% CI 23.8-79.8). 
However, the mOS for patients with high baseline levels of both Tie1 and Ang2 was 
only 21.5 months (95% CI 8.8.-34.7).  
 
 
Figure 6.  a. Progression-free survival and b. Overall survival of the plasma biomarker population 
grouped by baseline plasma Tie1 level. Cut-off value 21.0 ng/ml507. 
5.5 Glycovariant CA15-3 assays compared to the conventional 
CA15-3 (Publication IV) 
CA15-3MGL and CA15-3WGA lectin-based assays were compared to the conventional 
CA15-3 assay on the baseline plasma samples of 53 mBC patients. Receiver 
operating characteristic (ROC) curves were plotted, and AUCs were calculated. The 
clinical sensitivities were 81.1% for CA15-3WGA, 67.9% for CA15-3MGL and 66.0% 
for conventional CA15-3 at 90% specificity. The difference in the AUC was 
significant for CA15-3WGA (p=0.007) but not for CA15-3MGL (p=0.655) compared to 
the conventional CA15-3. The mBC patients had a significantly higher pretreatment 
CA15-3 concentration than the healthy controls by all three CA15-3 assays: 
conventional CA15-3 (p<0.001), CA15-3MGL (p=0.013) and CA15-3WGA (p<0.001). 
A strong correlation was observed between the baseline conventional CA15-3 
and CA15-3WGA concentrations (r=0.90, p<0.001). The correlation between baseline 
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conventional CA15-3 and CA15-3MGL levels was weaker (r=0.68, p<0.001). 
Additionally, we studied plasma samples from 19 patients who had confirmed 
disease progression at the final study visit. A clinically meaningful 30% increase in 
CA15-3 concentration was observed in 8 patients (42%) with conventional CA15-3, 
9 patients (47%) with CA15-3MGL and 5 patients (26%) with CA15-3WGA. The 
patients with rising CA15-3 levels were not all the same individuals by the different 
CA15-3 assays. 
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6 DISCUSSION 
In this study, we conducted a prospective, nonrandomized study to evaluate the 
feasibility of bevacizumab treatment in combination with the standard taxane 
regimen as a first-line chemotherapy treatment of mBC. We explored the prognostic 
value of several plasma proteins, including Tie1, Ang2, IL-8, IL-6, IL-18, MMP-2, 
MMP-9, YKL-40, resistin and HMGB1. Furthermore, we studied whether lectin-
based CA15-3MGL and CA15-3WGA assays would be more sensitive than the 
conventional CA15-3 assay in monitoring the responses to treatment in patients with 
mBC. 
6.1 Patients 
All 65 patients who entered the study were included in the efficacy and toxicity 
results. The median age of our study patients was 57 (range 32-75). The median age 
of study patients in other studies with first-line bevacizumab-taxane treatment ranges 
between 54-59297–299,315. Therefore, in this respect, our study population matches 
those of other studies. However, in a real-life setting, patients with mBC are older at 
the time of metastatic cancer diagnosis, with a median age ranging from 61 to 6412,508. 
This suggests that patients entering our and other clinical trials are younger and 
therefore more fit than the general mBC population.  
Most of our study patients had hormone receptor-positive disease (82%). In 
phase III first-line trials of bevacizumab for mBC, hormone receptor-positive 
tumors were observed in 60-84% of the patients, which is about the same level as in 
our study297–299,302. 
Many of our study patients had poor prognostic features of mBC at study 
initiation. Visceral disease was common (82%), and 80% of the patients had more 
than 3 metastatic lesions. In the phase III trials with bevacizumab, visceral disease 
was as common as in our study (68-87%)297,299. However, 40% of our patients had 
already received taxane as adjuvant therapy. This was more common than in the 
E2100 and AVADO trials (15-17%) and might be related to a more chemoresistant 
study population297,298.  
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We had plasma samples from only 58 patients and baseline samples from 53 
patients. However, the patients with plasma samples available were representative of 
the entire study population. The baseline characteristics of the plasma biomarker 
population were similar to those in the entire study population. Additionally, the PFS 
and OS were similar for these two patient populations. 
6.2 Bevacizumab as a treatment for metastatic breast cancer 
The mOS in our study reached almost three years (35.1 months), which can be 
considered an excellent result in mBC patients. The mOS ranged between 27 and 31 
months in the first-line phase III mBC trials with bevacizumab treatment297,298,300,302. 
The PFS of our study (11.3 months) was similar to those in first-line phase III trials 
(8.6-11.8 months)297–300,302. 
There are several possible reasons for the long OS in our study. In contrast to 
phase III first-line mBC studies of bevacizumab, we continued bevacizumab as a 
maintenance therapy after discontinuation. In addition, patients with hormone 
receptor-positive disease received endocrine therapy with bevacizumab 
maintenance. Maintenance treatment was given in 58% of our study patients, and 
most of these patients (87%) had hormone receptor-positive disease. VEGF and 
estrogen signaling pathways have several interaction points, and synergistic effects 
might be possible509–512. Additionally, 17 patients (26% of our study patients) 
received bevacizumab with second-line chemotherapy. In the treatment of colorectal 
carcinoma, continuation of bevacizumab with second-line chemotherapy has 
resulted in OS improvement513. On the other hand, accelerated tumor progression 
has been reported after short-term angiogenesis inhibition514. Therefore, prolonged 
VEGF inhibition might be a reason for the long OS in our study. Hypothetically, 
the accelerated tumor progression after discontinuation of bevacizumab might be 
the reason several phase III studies with bevacizumab were unable to demonstrate 
an OS benefit despite a statistically significant PFS improvement297–299. 
6.2.1 The clinical benefit for adding bevacizumab to standard 
chemotherapy treatment 
As discussed above, all of the phase III trials evaluating bevacizumab for the 
treatment of mBC have been unable to demonstrate an OS benefit297–299,301,306. 
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However, consistently higher response rates are reported with bevacizumab 
compared to standard chemotherapy297–299,302,306. The PFS improvement with 
bevacizumab is rather modest, 2-6 months, but there is a subset of patients who 
would benefit from bevacizumab297–299,302. Extensive biomarker research has been 
carried out with the aim of recognizing these patients, but no means exist to select 
these individuals in standard clinical care. Thus, the treatment decisions will be based 
on the clinical features of mBC. Current guidelines recommend the use of 
bevacizumab only in selected cases16. Similarly, in the NCCN breast cancer 
guidelines, bevacizumab-paclitaxel is categorized as a useful combination in certain 
circumstances and not as a preferred regimen41. Based on the clinical trial results, the 
most suitable mBC patient for bevacizumab treatment would be the one with a high 
need for tumor response. The need for the response would be related to high tumor 
burden and visceral disease. Therefore, the high frequency of responses achieved 
with bevacizumab-chemotherapy combinations would be a strong argument for the 
use of this combination for these few patients. 
6.3 Methodological considerations and study limitations 
Our study was a prospective, nonrandomized, academic phase II study with one 
treatment arm, and we treated 65 patients. Because the study had no comparator 
arm, it is difficult to draw strong conclusions from the results. For example, the 
reasons for the long OS that we found in our patients are partially speculative. The 
prospective, academic study design can definitely be considered a strength of the 
study. 
In 2017, breast cancer was the cause of death for 923 women and 5 men in 
Finland. Between 2012 and 2016, 54% of all the patients who died of breast cancer 
were over 70 years old in Finland.1 Finland is a sparsely populated country with long 
distances between cities, and malignant diseases are treated in five university 
hospitals and in several central hospitals515. Due to the limited number of women 
suffering from mBC and the scattered health care system, enrolling a large number 
of patients in a mBC clinical trial is challenging in Finland. Additionally, many 
patients with mBC might have impaired treatment-limiting performance status 
related to age, other comorbidities and metastatic disease itself, which is another 
limitation for enrolling patients in clinical studies. We succeeded in enrolling 65 
patients with mBC in an academic prospective trial in Tampere, Turku and Oulu 
University Hospitals. For the above-mentioned enrollment challenges, the number 
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of patients recruited to the mBC trial in Finland is significant. Furthermore, our study 
met its primary enrollment goal, which is another strength of our trial. 
The adverse events were monitored prospectively according to the study protocol 
and were graded by CTCAE terminology; therefore, the toxicity in our study can be 
compared to toxicity of other clinical trials. The responses were evaluated using 
RECIST criteria. The above- mentioned study protocols are strengths of our study. 
Plasma samples were not available from all study patients, although obtaining 
plasma samples was designed in the study protocol. The reasons for missing plasma 
samples are not known. Additionally, the reasons for the long OS of our study 
patients remain partly speculative since our study did not include a comparator arm.  
6.4 Circulating IL-8 levels during chemotherapy of advanced 
disease 
Low plasma IL-8 levels before and during first-line bevacizumab-taxane treatment 
are associated with excellent long-term prognosis. The mOS of our trajectory group 
1 patients, with constantly low IL-8 levels, was 50 months. The majority of our 
patients (60%) belonged to trajectory group 1. 
High IL-8 levels can be a sign of a chemoresistant form of breast cancer402,403. 
The trajectory group 3 patients, with the highest IL-8 levels in our study, had 
extremely poor survival, although only 6 patients belonged to this subgroup (mOS 
8 months). The patients with intermediate IL-8 levels, in trajectory group 2, also had 
significantly worse OS than the trajectory group 1 patients (mOS 24 months vs. 50 
months, respectively, p=0.004). In addition, the hypothesis of chemoresistance is 
supported by our finding of poor survival of the patients with the highest quartile of 
IL-8 level before initiation of first-line chemotherapy (HR 8.38, p>0.001). Therefore, 
IL-8 levels should be prospectively analyzed in clinical trials in the future to confirm 
our hypothesis of chemoresistance and possibly to guide treatment decisions for 
these poor-prognosis patients. Interestingly, an association of IL-8 level with 
treatment response was demonstrated in melanoma and non-small cell lung cancer 
patients receiving anti-PD-1 treatment, and this treatment approach could be 
worthwhile to evaluate in mBC patients with high IL-8 levels404. 
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6.5 Plasma IL-6, IL-18, MMP-2, MMP-9, YKL-40 and HMGB1 
levels as prognostic markers 
We explored additional cytokines and circulating markers with the aim of evaluating 
their prognostic significance. IL-6, IL-18, MMP-2, MMP-9, YKL-40 and HMGB1 
were not significantly prognostic in our patient population. The median IL-6 
concentration was 4 pg/ml in one study that reported high IL-6 was associated with 
poor prognosis414. In our study, the highest quartile cut-off level for plasma IL-6 was 
3.8 pg/ml. Therefore, we had very few patients with high IL-6 levels and presumably 
a poor prognosis on this basis. Additionally, the limited number of patients in our 
study was possibly one explanation for the other markers not demonstrating their 
weaker prognostic value. 
6.6 Tie1 and Ang2 as prognostic markers for metastatic breast 
cancer 
In our study, a baseline plasma Tie1 concentration higher than the baseline cut-off 
level of 21.0 ng/ml was strongly associated with both OS and PFS (HR 3.07, p=0.005 
and HR 3.78, p=0.003, respectively). High Tie1 expression was demonstrated in 
malignant tissue in previous studies365,516–518. However, our finding of the prognostic 
role of circulating Tie1 level in mBC patients is a novel and interesting result. The 
role of plasma Tie1 level as a prognostic marker should be validated prospectively in 
a larger mBC patient cohort. Furthermore, plasma samples as liquid biopsies are 
easily accessible compared to tissue samples, considering the possible need for 
surgical procedures for their acquisition. 
Plasma Tie1 in mBC patients was significantly higher than in healthy controls 
(p<0.001). This finding suggests Tie1 also plays a role in malignant processes. In a 
preclinical study, additive tumor growth inhibition was observed in Tie1-deficient 
mice, caused by the blockage of angiopoietin activity348. Ang2 impacts tumor growth 
at a different phase than Tie1, and this might be the reason for the possible 
synergism366. TKIs and antibodies targeting the Ang2/Tie system are being 
investigated in clinical trials, and in the future, tyrosine kinase receptors targeting the 
intracellular part of Tie1 would be worthwhile to explore360. 
The patients with high circulating levels of both Tie1 and Ang2 had a mOS of 47 
months, compared to the mOS of 22 months in patients with low plasma 
concentrations of both Tie1 and Ang2 (p=0.009). Circulating Ang2 level was 
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associated with poor prognosis in cancer patients in previous studies, but the 
combination of Tie1 and Ang2 levels was not previously explored357,358,519,520. The 
possible synergism of Tie1 and Ang2 might explain the combined effect on patient 
prognosis in our study366. 
6.7 Lectin glycovariants of CA15-3 for monitoring advanced 
breast cancer 
The aim of this study was to increase the sensitivity and specificity of CA15-3 in 
breast cancer monitoring by using new lectin-based glycovariants in the CA15-3 
assay. The use of a nanoparticle-lectin immunoassay was successful in the improving 
the CA12-5 assay521. In our study, the clinical sensitivity was significantly higher for 
the lectin-based CA15-3WGA assay (81%) than for the conventional CA15-3 assay 
(66%) at 90% specificity (p=0.007). In addition, the baseline CA15-3WGA level 
correlated with baseline CA15-3 using the conventional assay (r=0.90, p<0.001). On 
the other hand, the sensitivity of CA15-3MGL was not significantly higher than the 
sensitivity for the conventional CA15-3 assay (p=0.655), and the correlation between 
these assays was weaker (r=0.68, p<0.001). 
CA15-3 monitoring for treatment response is recommended particularly for 
patients with nonmeasurable disease as an aid to other clinical parameters16,522. If 
CA15-3 is used for disease monitoring, at least a 20-30% increase is required before 
considering treatment discontinuation, also taking into account the clinical 
evidence522. Clinical problems related to CA15-3 monitoring include the possibility 
of individual discrepancies in CA15-3 levels in contrast to the clinical situation501. In 
addition, only 80% of mBC patients have elevated levels of CA15-3500. In our study, 
the sensitivity of CA15-3WGA was significantly higher than the sensitivity of the 
conventional CA15-3 assay. Taking into account the above-mentioned clinical 
challenges in CA15-3 monitoring, the new CA15-3WGA assay should be further 
evaluated in prospective clinical trials. 
6.8 Future studies 
We have analyzed plasma levels of many other growth factors and receptors 
belonging to the VEGF family, and the results of these analyses will be published in 
the future. In addition, we have plasma available for additional exploratory analyses 
 96 
of mBC patients. Tissue samples from the primary tumors and metastases of our 
study patients were gathered and will be analyzed in the future. We will continue to 
collaborate with our research partners to further improve and evaluate the lectin-
based tumor marker method. Furthermore, we will hopefully find collaborators to 
evaluate the prognostic significance of the Tie1 receptor in mBC patients with a 
prospective study design. 
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7 SUMMARY AND CONCLUSIONS 
The present study aimed to evaluate the feasibility of bevacizumab in combination 
with standard docetaxel or paclitaxel treatment as the first-line treatment of mBC. 
In publications II-III, IL-8, Tie1, Ang2, IL-6, IL-18, MMP-2, MMP-9, YKL-40, 
resistin and HMGB1 were evaluated for their prognostic value in mBC. In paper IV, 
new lectin-based CA15-3 methods were compared to the conventional CA15-3 assay 
with the aim of improving the sensitivity and specificity of the CA15-3 assay. 
The main findings were the following: 
1. Bevacizumab therapy in combination with standard taxane treatment is feasible, 
and the additional toxicity related to bevacizumab is mostly manageable. Our 
study scheme also included bevacizumab as maintenance therapy and optional 
bevacizumab with the second-line chemotherapy, and this approach resulted in a 
long overall survival for our patients. However, bevacizumab is currently 
indicated only for the first-line treatment of mBC based on the phase III trial 
results; therefore, similar treatment designs as in our trial cannot be used in 
standard clinical care. 
2. Low plasma IL-8 levels before and during first-line chemotherapy in patients with 
mBC are prognostic for excellent long-term survival. These patients might be 
suitable for less frequent follow-up visits once our result is validated in a larger 
prospective mBC cohort. 
3. Patients with high IL-8 concentrations have a poor prognosis. These patients may 
have more chemoresistant disease and therefore could be referred to clinical trials 
with other treatment approaches than traditional chemotherapy, e.g., 
immunotherapy. 
4. The mBC patients with high circulating Tie1 levels at the baseline of their first-
line chemotherapy treatment have a poor prognosis. However, the prognosis for 
their survival is even worse if the plasma Ang2 concentration is also high. 
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5. The new lectin-nanoparticle immunoassay CA15-3WGA is more sensitive than the 
conventional CA15-3 assay and should be further prospectively evaluated. 
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Supplementary Table 1. Breast cancer staging by AJCC 7th edition 
 
Primary tumor (T)  
Tx Primary tumor cannot be assessed 
T0 No evidence of primary tumor  
Tis Carcinoma in situ 
Tis (DCIS) Ductal carcinoma in situ 
Tis (LCIS) Lobular carcinoma in situ 
Tis (Paget) Paget disease of the nipple NOT associated with invasive carcinoma and/or carcinoma in situ (DCIS 
and/or LCIS) in the underlying breast parenchyma. Carcinomas in the breast parenchyma associated 
with Paget disease are categorized based on the size and characteristics of the parenchymal disease, 
although the presence of Paget disease should still be noted 
T1 Tumor ≤ 20 mm in greatest dimension  
T1mi Tumor ≤ 1 mm in greatest dimension 
T1a Tumor > 1 mm but ≤ 5 mm in greatest dimension 
T1b Tumor > 5 mm but ≤ 10 mm in greatest dimension 
T1c Tumor > 10 mm but ≤ 20 mm in greatest dimension 
T2 Tumor > 20 mm but ≤ 50 mm in greatest dimension 
T3 Tumor > 50 mm in greatest dimension 
T4 Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or skin nodules) 
T4a Extension to chest wall, not including only pectoralis muscle adherence/invasion 
T4b Ulceration and/or ipsilateral satellite nodules and/or edema (including peau d’orange) of the skin, which 
do not meet the criteria for inflammatory carcinoma  
T4c Both T4a and T4b 
T4d Inflammatory carcinoma 
Regional lymph nodes (N) 
Clinical   
Nx Regional lymph nodes cannot be assessed (eg, previously removed) 
N0 No regional lymph node metastasis 
N1 Metastasis to movable ipsilateral level I, II axillary lymph node(s) 
N2 Metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted or in clinically 
detected* ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node 
metastasis 
N2a Metastases in ipsilateral level I, II axillary lymph nodes fixed to one another (matted) or to other 
structures 
N2b Metastases only in clinically detected* ipsilateral internal mammary nodes and in the absence of clinically 
evident level I, II axillary lymph node metastases 
N3 Metastases in ipsilateral infraclavicular (level III axillary) lymph node(s), with or without level I, II axillary 
node involvement, or in clinically detected * ipsilateral internal mammary lymph node(s) and in the 
presence of clinically evident level I, II axillary lymph node metastasis; or metastasis in ipsilateral 
supraclavicular lymph node(s), with or without axillary or internal mammary lymph node involvement  
N3a Metastasis in ipsilateral infraclavicular lymph node(s) 
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N3b Metastasis in ipsilateral internal mammary lymph node(s) and axillary lymph node(s)  
N3c Metastasis in ipsilateral supraclavicular lymph node(s) 
*"Clinically detected" is defined as detected by imaging studies (excluding lymphoscintigraphy) or by clinical examination 
and having characteristics highly suspicious for malignancy or a presumed pathologic macrometastasis on the basis of 
fine-needle aspiration (FNA) biopsy with cytologic examination.  
Pathologic (pN)*   
pNx Regional lymph nodes cannot be assessed (for example, previously removed, or not removed for 
pathologic study) 
pN0 No regional lymph node metastasis identified histologically. Note: Isolated tumor cell clusters (ITCs) 
are defined as small clusters of cells ≤ 0.2 mm, or single tumor cells, or a cluster of < 200 cells in a single 
histologic cross-section; ITCs may be detected by routine histology or by immunohistochemical (IHC) 
methods; nodes containing only ITCs are excluded from the total positive node count for purposes of 
N classification but should be included in the total number of nodes evaluated 
pN0(i-) No regional lymph node metastases histologically, negative IHC 
pN0(i+)  Malignant cells in regional lymph node(s) ≤ 0.2 mm (detected by hematoxylin-eosin [H&E] stain or 
IHC, including ITC)  
pN0(mol-) No regional lymph node metastases histologically, negative molecular findings (reverse transcriptase 
polymerase chain reaction [RT-PCR]) 
pN0(mol+)
  
Positive molecular findings (RT-PCR) but no regional lymph node metastases detected by histology or 
IHC  
pN1 Micrometastases; or metastases in 1-3 axillary lymph nodes and/or in internal mammary nodes, with 
metastases detected by sentinel lymph node biopsy but not clinically detected**  
pN1mi Micrometastases (> 0.2 mm and/or > 200 cells, but none > 2.0 mm)  
pN1a Metastases in 1-3 axillary lymph nodes (at least 1 metastasis > 2.0 mm)  
pN1b Metastases in internal mammary nodes, with micrometastases or macrometastases detected by sentinel 
lymph node biopsy but not clinically detected† 
pN1c Metastases in 1-3 axillary lymph nodes and in internal mammary lymph nodes, with micrometastases or 
macrometastases detected by sentinel lymph node biopsy but not clinically detected** 
pN2 Metastases in 4-9 axillary lymph nodes or in clinically detected‡ internal mammary lymph nodes in the 
absence of axillary lymph node metastases 
pN2a Metastases in 4-9 axillary lymph nodes (at least 1 tumor deposit > 2.0 mm) 
pN2b Metastases in clinically detected‡ internal mammary lymph nodes in the absence of axillary lymph node 
metastases 
pN3 Metastases in ≥ 10 axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or in 
clinically detected*** ipsilateral internal mammary lymph nodes in the presence of ≥ 1 positive level I, 
II axillary lymph nodes; or in > 3 axillary lymph nodes and in internal mammary lymph nodes, with 
micrometastases or macrometastases detected by sentinel lymph node biopsy but not clinically detected†; 
or in ipsilateral supraclavicular lymph nodes 
pN3a Metastases in ≥ 10 axillary lymph nodes (at least 1 tumor deposit > 2.0 mm); or metastases to the 
infraclavicular (level III axillary lymph) nodes 
pN3b Metastases in clinically detected‡ ipsilateral internal mammary lymph nodes in the presence of ≥ 1 
positive axillary lymph nodes; or in > 3 axillary lymph nodes and in internal mammary lymph nodes, 
with micrometastases or macrometastases detected by sentinel lymph node biopsy but not clinically 
detected** 
pN3c Metastases in ipsilateral supraclavicular lymph nodes 
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*Classification is based on axillary lymph node dissection, with or without sentinel lymph node biopsy. Classification 
based solely on sentinel lymph node biopsy without subsequent axillary lymph node dissection is designated (sn) for 
"sentinel node"—for example, pN0 (sn).  
** "Not clinically detected" is defined as not detected by imaging studies (excluding lymphoscintigraphy) or not detected 
by clinical examination.  
*** "Clinically detected" is defined as detected by imaging studies (excluding lymphoscintigraphy) or by clinical 
examination and having characteristics highly suspicious for malignancy or a presumed pathologic macrometastasis on 
the basis of FNA biopsy with cytologic examination.  
Distant metastasis (M)  
M0 No clinical or radiographic evidence of distant metastasis  
cM0(i+)  No clinical or radiographic evidence of distant metastases, but deposits of molecularly or microscopically 
detected tumor cells in circulating blood, bone marrow, or other nonregional nodal tissue that are no 
larger than 0.2 mm in a patient without symptoms or signs of metastases  
M1 Distant detectable metastases as determined by classic clinical and radiographic means and/or 
histologically proven > 0.2 mm 
  
 
 
Stage T N M 
0 Tis N0 M0 
IA T1 N0 M0 
IB T0-1 N1mi M0 
IIA T0-1 
T2 
N1 
N0 
M0 
M0 
IIB T2 
T3 
N1 
N0 
M0 
M0 
IIIA T0-2 
T3 
N2 
N1-2 
M0 
M0 
IIIB T4 N0-2 M0 
IIIC Any T N3 M0 
IV Any T Any N M1 
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Abstract. Aim: The study evaluated the efficacy of
bevacizumab combined with a taxane-based treatment for
advanced breast cancer. Patients and Methods: In this non-
randomized phase II study 65 patients received 10 mg/kg
bevacizumab i.v. (days 1 and 15, q4w) plus either 50 mg/m2
docetaxel (days 1 and 15, q4w) or 90 mg/m2 paclitaxel (days
1,8 and 15, q4w) i.v. until disease progression, maximal
response, unacceptable toxicity or the withdrawal of consent.
Patients without progression continued bevacizumab at 
15 mg/kg i.v. (q3w) alone, or with endocrine therapy.
(NCT00979641). Results: Progression-free survival was 11.3
months (95% confidence interval=9.7-16.0 months) and overall
survival was 35.1 months (95% confidence interval=22.2-50.3
months). More than half of the patients (62%) responded at
least partially. Bevacizumab-related serious adverse events
occurred in 10.8% patients and one patient died because of
gastrointestinal perforation. Conclusion: Treating advanced
breast cancer with a bevacizumab-containing regimen as the
first-line cytotoxic treatment resulted in excellent response rates
and long survival.
Metastatic breast cancer remains an incurable disease (1, 2).
In Finland, nearly 5,000 patients are diagnosed with invasive
breast cancer every year, and the incidence has increased
steadily over the past decades. The Finnish cancer registry
data from 2014 shows that 815 women died of metastatic
breast cancer, which was the most common cause of cancer
death in women (3). In the CONCORD-2 study, a central
analysis of population-based registry data worldwide for
cancer survival was conducted, and the results were
published in The Lancet in November 2014. The study
reported that the treatment results of breast cancer in Finland
are among the best in the world. The 5-year-survival rate of
patients with breast cancer in Finland was 86.8% [95%
confidence interval (CI)=85.9-87.7%) from 2005-2009, and
was the highest in Northern Europe (4). However, new
treatment options for advanced human epidermal growth
factor receptor 2 (HER2)-negative disease are rare, and the
overall survival benefit observed in these patients is modest
(5, 6). For this reason, advanced HER2-negative breast
cancer is a treatment challenge worldwide.
Bevacizumab is a recombinant humanized monoclonal
antibody that inhibits vascular endothelial cell proliferation by
blocking the binding of vascular endothelial growth factor A
(VEGFA) to its receptor, therefore inhibiting tumor angiogenesis
(7). Bevacizumab improves the outcomes of cytotoxic treatment
in many metastatic malignancies, including colorectal, kidney,
lung and ovarian cancer (8-11). There has been much debate
about the status of bevacizumab treatment in metastatic breast
cancer. Currently, the European Medicines Agency has only
approved bevacizumab when combined with paclitaxel or
capecitabine in a first or second-line setting (http://www.e
ma.europa.eu/ema/). In 2011, the US Food and Drug
Administration revoked its accelerated approval of a breast
cancer indication for bevacizumab due to the lack of a benefit
in breast cancer overall survival and, in addition, due to the
potentially life-threatening side-effects (http://www.fda.gov/).
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In locally advanced and metastatic breast cancer, taxane-
based treatment (docetaxel or paclitaxel), either in
combination with another agent or as single-agent, therapy
is considered one of the most effective choices for first-line
treatment (5, 12), when cytotoxic treatment is needed.
Combining bevacizumab with chemotherapy has been
studied in certain phase III studies (13-18). Most of these
studies investigated the benefit of bevacizumab combined
with a taxane. Furthermore, other chemotherapy regimens
have been explored, including capecitabine, anthracycline,
vinorelbine and gemcitabine. Adding bevacizumab has led to
higher response rates and longer progression-free survival
(PFS) throughout the trials, but no significant differences in
overall survival (OS) have yet been observed.
In addition to chemotherapy options, bevacizumab can
also be combined with endocrine therapy, and the effect may
be synergistic. Intracellular VEGF and estrogen signaling
pathways cross at several points, and it can be hypothesized
that adding bevacizumab to hormonal treatment might delay
the development of endocrine therapy resistance (19, 20). In
hormone receptor-positive advanced breast cancer, endocrine
treatment with either an anti-estrogen or an aromatase
inhibitor is a keystone of the treatment (5). It is used in
metastatic breast cancer in biologically non-aggressive forms
of the disease and in more aggressive forms after a maximal
chemotherapy response has been achieved (5). For the first-
line therapy of advanced breast cancer, an aromatase
inhibitor combined with bevacizumab was investigated in a
phase III LEA trial (21). Similarly, as reported in
chemotherapy trials, the endocrine therapy–bevacizumab
combination resulted in higher response rates but failed to
demonstrate statistically significant improvements in both
PFS and OS compared to endocrine-therapy alone.
This study aimed to investigate whether bevacizumab
combined with either docetaxel or paclitaxel is a feasible
choice for first-line therapy in metastatic breast cancer. The
study also evaluated if using bevacizumab maintenance
therapy with an endocrine therapy would have synergistic
effects.
Patients and Methods
Patients. We screened and treated 65 patients at three study centers in
Finland: Tampere, Oulu and Turku University hospitals. The study was
initiated in May 2009 and data closure took place in April 2015. The
median follow-up time was 24.1 months (range=1.6-66.3 months).
Pre- and postmenopausal women were eligible if they had
histologically or cytologically confirmed HER2-negative metastatic
adenocarcinoma of the breast and were considered as candidates for
taxane treatment. Patients were not allowed any prior chemotherapy
for advanced disease but could have been treated with (neo)adjuvant
chemotherapy if the disease-free interval was at least 6 months.
Previous endocrine therapy for advanced disease was allowed. Both
measurable and non-measurable (bone-only) diseases were eligible.
Good performance status was required [Eastern Cooperative Oncology
Group (ECOG) performance status 0-2]. Additional inclusion criteria
included adequate hematological, renal and hepatic functions.
Patients were excluded if they had history of central nervous
system metastases or pre-existing peripheral neuropathy at least
grade 2 by National Cancer Institute Common Toxicity Criteria
(NCI-CTC), version 3.0 (22). Additionally, circumstances that could
increase the serious adverse events associated with bevacizumab
were excluded, such as major surgery within the previous month,
minor surgery within the last 24 hours prior to bevacizumab
initiation, the use of anticoagulants or thrombolytic agents, a history
of bleeding diathesis or coagulopathy, uncontrolled hypertension,
clinically significant cardiovascular disease, a non-healing wound,
an active peptic ulcer or bone fracture, a history of abdominal
fistula, and a gastrointestinal perforation or intra-abdominal abscess
within 6 months of enrollment. Furthermore, patients with a history
of other malignancies were excluded.
The study protocol was approved by the Ethics Committee of
Tampere University Hospital (R08142M) and the trial identifier is
NCT00979641. Written informed consent was obtained from all
patients included in the study.
Treatment. In part I of the treatment, the patients received taxane
therapy intravenously (i.v.; 50 mg/m2 docetaxel on days 1 and 15 or
90 mg/m2 paclitaxel on days 1, 8 and 15) and 10 mg/kg bevacizumab
i.v. on days 1 and 15 on a treatment cycle of 28 days. Treatment was
continued until the maximal response, progressive disease,
unacceptable toxicities necessitating the termination of taxane
treatment or the patient’s refusal. The maximal response was defined
as an achieved response (a complete response (CR) or a partial
response PR) that was the same between two response evaluations,
or stable disease (SD) for more than 6 months. The study was
initiated with the docetaxel-bevacizumab combination. After the
negative results from the AVADO trial (14) were published, an
amendment to the study protocol was made and the following
enrolled patients were treated with a combination of paclitaxel and
bevacizumab. In part II of treatment, after taxane treatment was
discontinued, the responding patients continued to receive 15 mg/kg
bevacizumab intravenously on day 1 q 21 days. In hormone receptor-
positive patients, an endocrine therapy according to the investigator’s
choice was added to bevacizumab. This second part of the treatment
was given until disease progression, unacceptable treatment-related
toxicities or the withdrawal of the patient’s consent. The study
scheme is presented in Figure 1.
After disease progression, the continuation of bevacizumab with
a second-line therapy was optional. The preferred chemotherapy
option was capecitabine or the investigator’s choice. Capecitabine
was administered at a dose 1000 mg/m2 twice-daily per os given on
days 1-14 of a 3-week cycle. 
Dose modifications, toxicity and response evaluations. The dosing of
bevacizumab was not modified during the study. In case of grade 3-
4 bevacizumab-related toxicity, bevacizumab was either temporarily
or permanently suspended. If bevacizumab was permanently
discontinued but chemotherapy not interrupted, the patient entered the
follow-up phase of the study. The bevacizumab-related toxicities were
monitored closely and specific treatment algorithms were made for
hypertension, proteinuria, thromboembolic events, hemorrhage,
gastrointestinal perforations and impaired wound-healing. The dose
of the taxane was allowed to be reduced according to each clinic’s
standards of care in the case of taxane-related toxicity. Toxic effects
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were graded according to the NCI-CTC, version 3.0 (22). For second-
line capecitabine, dose modifications were made according to the
investigator’s assessment. In patients with moderate renal impairment,
the dose of capecitabine was reduced by 25%.
Tumor assessment was performed every 12 weeks until
progression, according to the Response Evaluation Criteria in Solid
Tumors (RECIST), version 1.1 (23). All patients were followed-up
every 6 months for an evaluation of their status and for survival by
following the patient records.
Statistical analysis. The primary endpoint of the study was PFS in
the first-line treatment setting and it was calculated from the date
of treatment initiation to the date of investigator-assessed disease
progression according to the RECIST criteria (23) or to the date of
patient death. Secondary end-points were safety, the response rate
and OS. Adverse events are displayed in standard frequency tables.
The proportions of patients with CR, PR, SD and progressive
disease (PD) as the best response were tabulated for each part of the
treatment. OS was calculated from the date of treatment initiation
to the date of death due to any cause. The median PFS and OS were
calculated according to the Kaplan–Meier method. The analysis of
PFS and OS included the stratification variable taxane choice
(docetaxel–bevacizumab or paclitaxel–bevacizumab) and hormone
receptor status. The Kaplan–Meier estimates obtained from the
model were compared with the historical control group (14).
A total of 65 patients were expected to enter the study. This number
would provide a probability of 80% for detecting a difference
corresponding to a ratio of 1.34 between this study group and historical
control group (equal to PFS of 10.7 months versus 8 months). The basis
of the assumptions was that the accrual period was 18 months, the
follow-up period was 36 months and the median PFS of the historical
control group was 8.2 months in a series of 241 patients (14).
Results
Patient baseline characteristics. Between May 2009 and
October 2013, 65 patients were enrolled. The baseline
characteristics are shown in Table I. The majority of patients
were post-menopausal with hormone receptor-positive
disease. Additionally, most patients had received different
combinations of adjuvant therapy and the vast majority of
patients had received adjuvant chemotherapy. Furthermore,
34% of the patients with either estrogen or progesterone
receptor-positive disease had received endocrine therapy for
advanced disease.
Most patients had a heavy disease burden: visceral disease
was common (82%) and liver metastases occurred in 51% of
patients. Two-fifths of the patients  had more than three
metastatic sites. In addition, bone-only disease was observed
only in five patients (Table I).
Efficacy. All 65 patients were evaluated for treatment efficacy
and the PFS and OS results are shown in Figures 2 and 3. In
part I of treatment, 32 patients were treated with docetaxel and
33 patients with paclitaxel. A total of 38 patients (58%) entered
part II of treatment. Of these patients, the majority had
hormone receptor-positive disease (87%) and only five patients
had hormone receptor-negative disease. All hormone receptor-
positive patients received endocrine therapy in part II in
addition to bevacizumab according to the physician’s choice,
with letrozole being the most common drug (n=19). Other
hormonal drugs that were used included anastrozole (n=4),
exemestane (n=4), tamoxifen (n=3) and fulvestrant (n=3).
The median PFS for the first-line treatment was 11.3 months
(95% CI=9.7-16.0, Figure 2) and the median OS was 35.1
months (95% CI=22.2-50.3; Figure 3). The overall response
rate was high. One patient (1.5%) had a CR and 39 had PR
(60.0%) in part I. SD was observed in 15 patients (23.1%).
Thus, the clinical benefit rate (CR+PR+SD) for part I was
84.6%. Only three patients (4.6%) had PD as the best response
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Figure 1. Study scheme. CR: Complete response, PR: partial response, SD: stable disease, HR: hormone receptor, q3W: every 3 weeks, PD:
progressive disease.
in part I. Docetaxel- and paclitaxel-based regimens led to
similar median survival values: median PFS 11.3 months (95%
CI=9.1-16.8) for docetaxel vs. 11.3 months (95% CI 7.4-30.7,
p=0.47) for paclitaxel, median OS 38 months (95% CI=19.8-
50.4) vs. 34.2 months (95% CI=18.1-not reached, p=0.77)
respectively. The median OS for patients with hormone
receptor-positive disease was 45.0 months (95% CI=30.2-51.3)
and for patients with triple-negative disease, it was 17.9 months
(95% CI=8.5-26.9, p=0.011).
Subsequent therapy. Patients were allowed to receive
bevacizumab together with a second-line chemotherapy
according to investigators’ choice. A total of 17 patients began
second-line bevacizumab–chemotherapy combination. The
preferred chemotherapy in the protocol was capecitabine
(n=15) but patients also received paclitaxel and vinorelbine.
The median PFS for second-line therapy was 5.1 months (95%
CI=4.4-16.1 months) and the OS was 33.8 months (95%
CI=24.7 months-NR). With the second-line bevacizumab–
chemotherapy, seven patients responded partially (41%) and
six patients had SD as the best response to the treatment
(35%). No CRs were observed. Disease progression occurred
in three patients (18%). For one patient, the response could
not be defined because at data closure, the first response
evaluation had not yet been performed.
Safety. During part I of the treatment, the bevacizumab–
chemotherapy combination was generally well tolerated and
most toxicity was mild (grade 1-2). The worst grade of a
side-effect per patient is presented. The adverse events of all
grades (1-4) that were most frequently reported were
neutropenia (n=45, 69%), musculoskeletal pain (n=45, 69%),
alopecia (n=44, 68%), leukocytopenia (n=41, 63%), fatigue
(n=35, 54%), mucositis (n=35, 54%), anemia (n=35, 54%),
epistaxis (n=34, 52%), constipation (n=27, 42%), nail
disorders (n=23, 35%), proteinuria (n=22, 34%), diarrhea
(n=22, 34%), elevated liver enzymes (n=20, 31%), nausea
(n=20, 31%) and peripheral neuropathy (n=18, 28%). Serious
adverse events during part I chemotherapy treatment are
presented in Table II. The most common serious adverse
event was neutropenia but febrile neutropenia was rare. One
patient had a grade 5 toxicity due to the treatment and died
during part I of the study. This patient had pre-existing
diverticulosis and then developed diverticulitis, which
resulted in gastrointestinal perforation and peritonitis. During
bevacizumab maintenance, grade 3-4 adverse events were
rare. The serious adverse events from part II treatment are
presented in Table III.
Bevacizumab treatment-related adverse events according
to the investigators’ judgment are summarized in Table IV.
The gastrointestinal perforation, mentioned above, was
suspected to be related to bevacizumab. Hypertension and
proteinuria were frequently reported but were usually of low
grade. However, one patient suffered from grade 4
proteinuria and renal failure. In addition, over half of the
patients had low-grade epistaxis.
In the second-line setting, the expected side-effects for
capecitabine occurred in 17 patients treated in this part of the
trial. The serious adverse events reported were grade 3 hand
and foot syndrome (n=3) and a single case of grade 4 diarrhea.
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Table I. Demographic and baseline characteristics of patients (n=65).
Characteristic                                                                              Value
Median age (range), years                                                     57 (32-75)
Menopausal status, n (%)
     Pre-menopausal                                                                 10 (15.4)
     Post-menopausal                                                                55 (84.6)
History of early-stage disease, n (%)
     Total                                                                                   57 (87.7)
Disease-free interval, n (%)
     ≤24 Months                                                                        11 (16.9)
     >24 Months                                                                        46 (70.8)
Hormone receptor status, n (%)
     ER+PR+/ER+PR−                                                             53 (81.5)
     ER−PR−                                                                             12 (18.5)
Estrogen receptor status, n (%)
     Positive                                                                               51 (78.5)
     Negative                                                                             14 (21.5)
Progesterone receptor status, n (%)
     Positive                                                                               46 (70.8)
     Negative                                                                             19 (29.2)
Prior adjuvant chemotherapy, n (%)
     Total                                                                                   46 (70.8)
     Taxane                                                                                26 (40.0)
     Anthracycline                                                                     38 (58.5)
Prior hormonal therapy, n (%)
     Total                                                                                   44 (67.7)
     (Neo)adjuvant                                                                    38 (58.5)
     Metastatic/advanced disease                                             18 (27.7)
Current stage of disease, n (%)
     IV                                                                                      65 (100.0)
Hormonal therapies used in metastatic setting, n (%)
     Anastrozole                                                                         4 (10.5)
     Exemestane                                                                         7 (18.4)
     Fulvestrant                                                                          5 (13.2)
     Letrozole                                                                            12 (31.6)
     GnRH analogs                                                                      3 (7.9)
     Tamoxifen                                                                           4 (10.5)
Number of metastatic lesions, n (%)
     ≤3                                                                                       14 (21.5)
     >3                                                                                       51 (78.5)
Extent of disease
     <3 Sites                                                                             39 (60.0)
     ≥ 3 Sites                                                                             26 (40.0)
Site of metastatic disease, n (%)
     Visceral                                                                              53 (81.5)
     Non-visceral                                                                      12 (18.5)
ER: Estrogen receptor; PR: progesterone receptor; GnRH:
gonadotrophin-releasing hormone.
Discussion
This study resulted in excellent OS of almost 3 years (35.1
months) in patients with advanced breast cancer with poor
prognostic features at the beginning of the trial. Visceral
metastases were common (80%), and most patients had
multiple metastases. Prior taxane treatment as adjuvant
chemotherapy was given to 40% of these patients. The most
favorable results towards a benefit from adding bevacizumab
to chemotherapy are reported in the E2100 trial (13). In that
study, the number of patients with visceral disease was
similar to that observed in our study (79.5-87.1% depending
on the treatment arm). Additionally, the extent of disease
(42.0-46.3% of patients had more than three metastatic sites)
was quite similar in both studies. Only approximately 15% of
E2100 patients were pre-treated with taxanes in an adjuvant
setting compared to 40% of our patients. PFS was reported
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Figure 2. Progression-free survival for the whole patient cohort. 
Figure 3. Overall survival for the whole patient cohort. 
Table II. Grade 3-4 adverse events experienced by patients in part I of
the treatment.
                                                                                   Patients (n=65)
Adverse event                                                        Grade 3       Grade 4 
Fatigue                                                                         2                    
Neutropenia                                                                 9                  16
Leukocytopenia                                                          11                  2
Elevated liver enzymes                                               1                   1
Infection                                                                       9                    
Febrile neutropenia or neutropenic sepsis                 3                   1
Peripheral neuropathy                                                 1                    
Pain                                                                              3                   1
Diarrhea                                                                       1                    
Nausea                                                                         1                    
Cardiac disorders                                                       1*                   
Osteonecrosis of the jaw                                            1                    
Drug hypersensitivity                                                  1                    
Gastrointestinal perforation                                                          1**
*Supraventricular tachycardia; **patient died, grade 5 adverse event.
Table III. Grade 3-4 adverse events experienced by patients in part II
of the treatment.
                                                                   Grade 3-4/patients
Adverse event                                 HR+ (n=33)              HR− (n=5)
Infection                                                   2                                
Leukocytopenia                                        1                                
Elevated liver enzymes                           2                                
Peripheral neuropathy                              1                                
Anorexia                                                   1                                
Cardiac disorders                                    2*                               
Hyponatremia                                           1                               1
HR+: Hormone receptor-positive (estrogen receptor+ or progesterone
receptor+); HR−: hormone receptor-negative. *Congestive heart failure,
coronary artery thrombosis.
Table IV. Bevacizumab-related events experienced by patients in this
study.
                                                                           Patients (n=65)
Adverse event                                Grade 1-2  Grade 3  Grade 4  Grade 5
Hypertension                                        16              2                             
Proteinuria                                            18              3             1              
Bleeding/hemorrhage                           9                                              
Epistaxis                                               34                                             
Gastrointestinal fistula/abscess            2                                              
Gastrointestinal perforation                                                                1
to be very similar between the E2100 study and our study
(11.8 months in E2100 and 11.3 months in our trial).
Nevertheless, the OS was remarkably longer in our trial: 35.1
months compared to 26.7 months observed in the E2100 trial.
There are some possible explanations for the long OS
observed in this study. The main difference in our study when
compared to other studies of first-line chemotherapy
combining bevacizumab with taxanes (13, 14, 16, 18) is that
after a maximal response was reached in our study,
bevacizumab was continued as a maintenance treatment with
endocrine therapy in patients with hormone receptor-positive
disease. Bevacizumab maintenance was given to 38 patients
(58%) and the majority of these patients (87%) had hormone
receptor-positive disease and received endocrine therapy with
bevacizumab. Intracellular estrogen signaling pathways and
VEGF pathways have several interactions (19, 20, 24, 25);
therefore, endocrine treatment may add a substantial benefit
to bevacizumab monotherapy, as also recently shown with
androgen signaling pathways and VEGF in prostate cancer
(26). In addition, using biweekly instead of triweekly
docetaxel infusions might have led to lower treatment toxicity
and, therefore, to prolonged survival. This was previously
demonstrated in our randomized phase III Prosty trial where
triweekly and biweekly docetaxel dosing were compared in
advanced castration-resistant prostate cancer (27). Weekly
paclitaxel compared to triweekly infusions has also
demonstrated survival benefit in advanced breast cancer (28).
This trial has many differences compared to the LEA trial
(21). In the LEA trial, patients with advanced disease were
endocrine treatment-naïve. In our study, one-third of the
patients with hormone receptor-positive disease had received
hormonal therapies for advanced disease, meaning that the
patients seemed to have less hormone treatment-sensitive
disease. Half of the patients in our trial also had liver
metastasis compared to only 20% in the LEA trial. Thus, our
patients had less favorable prognoses. The OS for this patient
population is, as expected, shorter with less favorable
prognostic features. In the LEA trial, the OS was 52.1
months in patients treated with the first-line bevacizumab-
endocrine therapy combination. This exceeds that of the
patients with hormone receptor-positive disease of our study
by only 7.1 months, which is less than expected considering
the poor prognostic features of the disease at the beginning
of our patients’ treatments. Both these studies favor the
hypothesis of an interaction between hormonal and
angiogenetic cellular pathways in breast cancer.
In preclinical studies, it has been reported that tumor
progression may be accelerated after short-term angiogenesis
inhibition (29). On the other hand, treating colorectal cancer
with second-line bevacizumab-chemotherapy combination
after disease progression with first-line therapy including
bevacizumab was shown to have survival benefits (30).
Therefore, some patients with metastatic adenocarcinoma
may benefit from prolonged VEGF inhibition in terms of
survival. This is one possible explanation for the long OS
seen in our study.
High response rates have been reported in all of the trials
with bevacizumab combined with a first-line chemotherapeutic.
The response rates previously reported with the bevacizumab–
taxane combination range from 36.9% to 64.1% compared to
21.2-46.4% with single taxane therapy (13, 14, 31). Similarly,
good responses were achieved in this study. The clinical benefit
rate was 84.6% and 62% of patients responded at least with PR
according to the RECIST criteria, which is in line with
previously published data.
In this small series of patients, no difference in PFS or OS
was observed between the two taxane-treated groups. Half
of the patients in the study were treated with paclitaxel and
the other half with docetaxel. Thus, there is an indication that
docetaxel and paclitaxel are similarly effective with
bevacizumab.
Bevacizumab adds treatment toxicity compared to single
taxane chemotherapy. In this study, bevacizumab-related
serious events were rare (10.8%). However, one patient died
because of bevacizumab-related toxicity, which in this case
was a fatal peritonitis. The contributing factor was underlying
diverticulosis in our patient. Additionally, high-grade
proteinuria and hypertension were observed, which are
known side-effects of bevacizumab (13-17, 31). Caution
should be exercised when treating patients with known risk
factors for the use of bevacizumab, namely a history of
thromboembolic events, cardiovascular disease or risk factors
for abdominal infection and fistula, among others. The other
grade 3-4 toxicities observed were related to chemotherapy
or to the metastatic disease itself and were reported at the
anticipated rates. In the AVADO trial, 75-78% of the patients,
depending on the treatment arm, treated with a bevacizumab–
docetaxel combination had at least one grade 3 toxicity due
to the treatment (14), whereas a minimum of grade 3 toxicity
was observed in 71% of our patients. Only 24% of the
patients had grade 3-4 toxicity during bevacizumab–
capecitabine treatment in our study. No unexpected new side-
effects were reported in our study. In conclusion, combining
bevacizumab with paclitaxel or docetaxel or to second-line
capecitabine has an acceptable side-effect profile.
The small sample size does not allow us to draw any
conclusions about the efficacy of second-line chemotherapy.
Although our patients presented many poor prognostic
features at baseline, the OS achieved of nearly 3 years is
remarkable. This study intended to determine whether
bevacizumab adds an advantage to taxane treatment followed
by a bevacizumab maintenance therapy with an endocrine
therapy. With an OS of 17.9 months in patients with triple-
negative disease and 45.0 months in a hormone receptor-
positive study population, it can be concluded that
combining bevacizumab with a conventional taxane
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treatment is a treatment option. This is especially true in
patients with a heavy disease burden and needing rapid
tumor shrinkage. We have gathered a comprehensive serum,
plasma and tumor biopsy collection from the study
population and we aim to explore markers predictive for the
long response to bevacizumab combination therapies.
Acknowledgements
The Authors would like to thank the research nurses and the patients
that participated in this study. Roche Inc., Basel, Swiss supported
the study financially (study monitoring, electronic CRF-system and
partially expenses of bevacizumab).
References
1 Andre F, Slimane K, Bachelot T, Dunant A, Namer M, Barrelier
A, Kabbaj O, Spano JP, Marsiglia H, Rouzier R, Delaloge S and
Spielmann M: Breast cancer with synchronous metastases:
trends in survival during a 14-year period. J Clin Oncol 22:
3302-3308, 2004.
2 Foukakis T, Fornander T, Lekberg T, Hellborg H, Adolfsson J
and Bergh J: Age-specific trends of survival in metastatic breast
cancer: 26 years longitudinal data from a population-based
cancer registry in Stockholm, Sweden. Breast Cancer Res Treat
130: 553-560, 2011.
3 Finnish cancer registry. (http://www.cancerregistry.fi) Updated
March 3, 2016. Assessed September 21, 2016.
4 Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang
XS, Bannon F, Ahn JV, Johnson CJ, Bonaventure A, Marcos-
Gragera R, Stiller C, Azevedo e Silva G, Chen WQ, Ogunbiyi
OJ, Rachet B, Soeberg MJ, You H, Matsuda T, Bielska-Lasota
M, Storm H, Tucker TC, Coleman MP and CONCORD Working
Group: Global surveillance of cancer survival 1995-2009:
analysis of individual data for 25,676,887 patients from 279
population-based registries in 67 countries (CONCORD-2).
Lancet 385: 977-1010, 2015.
5 Cardoso F, Costa A, Norton L, Senkus E, Aapro M, Andre F,
Barrios CH, Bergh J, Biganzoli L, Blackwell KL, Cardoso MJ,
Cufer T, El Saghir N, Fallowfield L, Fenech D, Francis P, Gelmon
K, Giordano SH, Gligorov J, Goldhirsch A, Harbeck N, Houssami
N, Hudis C, Kaufman B, Krop I, Kyriakides S, Lin UN, Mayer
M, Merjaver SD, Nordstrom EB, Pagani O, Partridge A, Penault-
Llorca F, Piccart MJ, Rugo H, Sledge G, Thomssen C, Van’t Veer
L, Vorobiof D, Vrieling C, West N, Xu B and Winer E: ESO-
ESMO 2nd international consensus guidelines for advanced breast
cancer (ABC2)dagger. Ann Oncol 25: 1871-1888, 2014.
6 Cortes J, O’Shaughnessy J, Loesch D, Blum JL, Vahdat LT,
Petrakova K, Chollet P, Manikas A, Dieras V, Delozier T,
Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE,
Seegobin S, Mir D, Meneses N, Wanders J, Twelves C and
EMBRACE (Eisai Metastatic Breast Cancer Study Assessing
Physician’s Choice Versus E7389) investigators: Eribulin
monotherapy versus treatment of physician’s choice in patients
with metastatic breast cancer (EMBRACE): a phase 3 open-label
randomised study. Lancet 377: 914-923, 2011.
7 Marty M and Pivot X: The potential of anti-vascular endothelial
growth factor therapy in metastatic breast cancer: clinical
experience with anti-angiogenic agents, focusing on bevacizumab.
Eur J Cancer 44: 912-920, 2008.
8 Chen YX, Yang Q, Kuang JJ, Chen SY, Wei Y, Jiang ZM and
Xie DR: Efficacy of adding bevacizumab in the first-line
chemotherapy of metastatic colorectal cancer: evidence from
seven randomized clinical trials. Gastroenterol Res Pract 2014:
594930, 2014.
9 Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati
A, Lilenbaum R and Johnson DH: Paclitaxel-carboplatin alone
or with bevacizumab for non-small-cell lung cancer. N Engl J
Med 355: 2542-2550, 2006.
10 Bracarda S, Bellmunt J, Melichar B, Negrier S, Bajetta E,
Ravaud A, Sneller V and Escudier B: Overall survival in patients
with metastatic renal cell carcinoma initially treated with
bevacizumab plus interferon-alpha2a and subsequent therapy
with tyrosine kinase inhibitors: a retrospective analysis of the
phase III AVOREN trial. BJU Int 107: 214-219, 2011.
11 Gaitskell K, Martinek I, Bryant A, Kehoe S, Nicum S and Morrison
J: Angiogenesis inhibitors for the treatment of ovarian cancer.
Cochrane Database Syst Rev (9):CD007930. doi: CD007930, 2011.
12 NCCN Clinical Practice guidelines in oncology. Breast Cancer.
(http://www.nccn.org) Version 2.2016. Assessed September 21, 2016.
13 Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA,
Shenkier T, Cella D and Davidson NE: Paclitaxel plus
bevacizumab versus paclitaxel alone for metastatic breast cancer.
N Engl J Med 357: 2666-2676, 2007.
14 Miles DW, Chan A, Dirix LY, Cortes J, Pivot X, Tomczak P,
Delozier T, Sohn JH, Provencher L, Puglisi F, Harbeck N, Steger
GG, Schneeweiss A, Wardley AM, Chlistalla A and Romieu G:
Phase III study of bevacizumab plus docetaxel compared with
placebo plus docetaxel for the first-line treatment of human
epidermal growth factor receptor 2-negative metastatic breast
cancer. J Clin Oncol 28: 3239-3247, 2010.
15 Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK,
Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing
AP, Langmuir V and Rugo HS: Randomized phase III trial of
capecitabine compared with bevacizumab plus capecitabine in
patients with previously treated metastatic breast cancer. J Clin
Oncol 23: 792-799, 2005.
16 Robert NJ, Dieras V, Glaspy J, Brufsky AM, Bondarenko I,
Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, Phan
SC and O’Shaughnessy J: RIBBON-1: randomized, double-
blind, placebo-controlled, phase III trial of chemotherapy with
or without bevacizumab for first-line treatment of human
epidermal growth factor receptor 2-negative, locally recurrent
or metastatic breast cancer. J Clin Oncol 29: 1252-1260, 2011.
17 Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O’Neill V
and Rugo HS: RIBBON-2: a randomized, double-blind, placebo-
controlled, phase III trial evaluating the efficacy and safety of
bevacizumab in combination with chemotherapy for second-line
treatment of human epidermal growth factor receptor 2-negative
metastatic breast cancer. J Clin Oncol 29: 4286-4293, 2011.
18 Zielinski C, Lang I, Inbar M, Kahan Z, Greil R, Beslija S, Stemmer
SM, Zvirbule Z, Steger GG, Melichar B, Pienkowski T, Sirbu D,
Petruzelka L, Eniu A, Nisenbaum B, Dank M, Anghel R,
Messinger D, Brodowicz T and TURANDOT investigators:
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine
as first-line treatment for HER2-negative metastatic breast cancer
(TURANDOT): primary endpoint results of a randomised, open-
label, non-inferiority, phase 3 trial. Lancet Oncol, 2016.
Tiainen et al: Bevacizumab–Taxane Combination in Advanced Breast Cancer
6437
19 Roy V and Perez EA: Biologic therapy of breast cancer: focus
on co-inhibition of endocrine and angiogenesis pathways. Breast
Cancer Res Treat 116: 31-38, 2009.
20 Manders P, Beex LV, Tjan-Heijnen VC, Span PN and Sweep
CG: Vascular endothelial growth factor is associated with the
efficacy of endocrine therapy in patients with advanced breast
carcinoma. Cancer 98: 2125-2132, 2003.
21 Martin M, Loibl S, von Minckwitz G, Morales S, Martinez N,
Guerrero A, Anton A, Aktas B, Schoenegg W, Munoz M, Garcia-
Saenz JA, Gil M, Ramos M, Margeli M, Carrasco E, Liedtke C,
Wachsmann G, Mehta K and De la Haba-Rodriguez JR: Phase
III trial evaluating the addition of bevacizumab to endocrine
therapy as first-line treatment for advanced breast cancer: the
letrozole/fulvestrant and avastin (LEA) study. J Clin Oncol 33:
1045-1052, 2015.
22 Cancer Therapy Evaluation Program, Common Terminology
Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH,
DHHS. (http://ctep.cancer.gov). Publish Date: August 9, 2006.
23 Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D,
Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein
L, Shankar L, Dodd L, Kaplan R, Lacombe D and Verweij J:
New response evaluation criteria in solid tumours: revised
RECIST guideline (version 1.1). Eur J Cancer 45: 228-247, 2009.
24 Gagliardi AR, Hennig B and Collins DC: Antiestrogens inhibit
endothelial cell growth stimulated by angiogenic growth factors.
Anticancer Res 16: 1101-1106, 1996.
25 Takei H, Lee ES and Jordan VC: In vitro regulation of vascular
endothelial growth factor by estrogens and antiestrogens in
estrogen-receptor positive breast cancer. Breast Cancer 9: 39-42,
2002.
26 McKay RR, Zurita AJ, Werner L, Bruce JY, Carducci MA, Stein
MN, Heath EI, Hussain A, Tran HT, Sweeney CJ, Ross RW,
Kantoff PW, Slovin SF and Taplin ME: A Randomized Phase II
Trial of Short-Course Androgen Deprivation Therapy With or
Without Bevacizumab for Patients With Recurrent Prostate
Cancer After Definitive Local Therapy. J Clin Oncol 34: 1913-
1920, 2016.
27 Kellokumpu-Lehtinen PL, Harmenberg U, Joensuu T,
McDermott R, Hervonen P, Ginman C, Luukkaa M, Nyandoto
P, Hemminki A, Nilsson S, McCaffrey J, Asola R, Turpeenniemi-
Hujanen T, Laestadius F, Tasmuth T, Sandberg K, Keane M,
Lehtinen I, Luukkaala T, Joensuu H and PROSTY study group:
2-Weekly versus 3-weekly docetaxel to treat castration-resistant
advanced prostate cancer: a randomised, phase 3 trial. Lancet
Oncol 14: 117-124, 2013.
28 Mauri D, Kamposioras K, Tsali L, Bristianou M, Valachis A,
Karathanasi I, Georgiou C and Polyzos NP: Overall survival
benefit for weekly vs. three-weekly taxanes regimens in advanced
breast cancer: A meta-analysis. Cancer Treat Rev 36: 69-74, 2010.
29 Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen
JG and Kerbel RS: Accelerated metastasis after short-term
treatment with a potent inhibitor of tumor angiogenesis. Cancer
Cell 15: 232-239, 2009.
30 Bennouna J, Sastre J, Arnold D, Osterlund P, Greil R, Van
Cutsem E, von Moos R, Vieitez JM, Bouche O, Borg C, Steffens
CC, Alonso-Orduna V, Schlichting C, Reyes-Rivera I,
Bendahmane B, Andre T, Kubicka S and ML18147 Study
Investigators: Continuation of bevacizumab after first progression
in metastatic colorectal cancer (ML18147): a randomised phase
3 trial. Lancet Oncol 14: 29-37, 2013.
31 Lang I, Brodowicz T, Ryvo L, Kahan Z, Greil R, Beslija S,
Stemmer SM, Kaufman B, Zvirbule Z, Steger GG, Melichar B,
Pienkowski T, Sirbu D, Messinger D, Zielinski C and Central
European Cooperative Oncology Group: Bevacizumab plus
paclitaxel versus bevacizumab plus capecitabine as first-line
treatment for HER2-negative metastatic breast cancer: interim
efficacy results of the randomised, open-label, non-inferiority,
phase 3 TURANDOT trial. Lancet Oncol 14: 125-133, 2013. 
Received September 28, 2016
Revised October 21, 2016
Accepted October 26, 2016
ANTICANCER RESEARCH 36: 6431-6438 (2016)
6438
 PUBLICATION 
II 
Low Plasma IL-8 Levels During Chemotherapy Are Predictive of Excellent 
Long-Term Survival in Metastatic Breast Cancer 
Tiainen Leena, Hämäläinen Mari, Luukkaala Tiina, Tanner Minna, Lahdenperä 
Outi, Vihinen Pia, Jukkola Arja, Karihtala Peeter, Moilanen Eeva, Kellokumpu-
Lehtinen Pirkko-Liisa 
Clinical Breast Cancer 2019 19(4):e522-e533 
https://doi.org/10.1016/j.clbc.2019.03.006 
Publication reprinted with the permission of the copyright holders. 
 
  
  
 
 
 
 
 
 
Original Study
Low Plasma IL-8 Levels During Chemotherapy
Are Predictive of Excellent Long-Term Survival in
Metastatic Breast Cancer
Leena Tiainen,1,3 Mari Hämäläinen,4 Tiina Luukkaala,2 Minna Tanner,1,3
Outi Lahdenperä,5 Pia Vihinen,5 Arja Jukkola,1,3 Peeter Karihtala,6 Eeva Moilanen,4
Pirkko-Liisa Kellokumpu-Lehtinen1,3
Abstract
Plasma interleukin (IL)-8 levels were monitored in 58 patients with metastatic breast cancer before and during
ﬁrst-line chemotherapy, and changes in the IL-8 levels were correlated with patient survival data. Monitoring
plasma IL-8 levels before and during chemotherapy identiﬁes patients with excellent prognosis whose IL-8
levels stay constantly below 16.6 pg/mL.
Background: Interleukin (IL)-8 is a proinﬂammatory cytokine, and high levels of IL-8 are associated with poor prog-
nosis in many malignancies. The objective of this study was to explore the clinical beneﬁt of monitoring plasma IL-8
levels during breast cancer chemotherapy. Patients and Methods: We conducted an exploratory analysis of several
circulating proteins, including IL-8, in the plasma. Plasma samples were obtained from 58 metastatic breast cancer
patients who took part in a prospective phase 2 ﬁrst-line bevacizumab chemotherapy trial. Samples were analyzed
before therapy, after 6 weeks and 6 months of treatment, and at the ﬁnal study visit. On the basis of a trajectory
analysis of the plasma IL-8 levels, the patients were divided into 3 trajectory groups. Results: Plasma IL-8, IL-6, IL-18,
matrix metalloproteinase (MMP)-2, MMP-9, YKL-40, resistin, and high-mobility group box 1 (HMGB1) concentrations
were measured, and the most pronounced predictor of patient survival was IL-8. On the basis of the trajectory analysis
of the IL-8 levels, the majority of patients (n ¼ 35, 60%) belonged to trajectory group 1, and these patients had
signiﬁcantly lower IL-8 levels before and during the entire chemotherapy treatment period than did the patients in the
other groups. Trajectory group 1 patients had signiﬁcantly better overall survival compared to patients in trajectory
group 2 (n ¼ 17; age-adjusted HR ¼ 2.45; 95% conﬁdence interval, 1.21-5.97; P ¼ .012) and 3 (n ¼ 6; age-adjusted
HR ¼ 8.65; 95% conﬁdence interval, 3.16-23.7; P < .001). Conclusion: Low IL-8 levels during chemotherapy treat-
ment might help identify patients with prolonged survival.
Clinical Breast Cancer, Vol. 19, No. 4, e522-33 ª 2019 The Authors. Published by Elsevier Inc. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Introduction
Breast cancer is the most common cause of cancer-related death
in women.1 Currently, patients with human epidermal growth
factor 2 (HER2)-negative advanced breast cancer will survive for
approximately 2 to 3 years after diagnosis of advanced cancer.2-5
The disease of most patients will respond to chemotherapy and
endocrine therapy, but the cancer will eventually progress. More
investigational effort should be expended to ﬁnd patients with
disease that will not respond to current therapies and who are in
need of novel investigational treatment options. Furthermore, early
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palliative care improves patient quality of life, symptom manage-
ment, and even treatment outcomes.6-8 In particular, patients with
chemoresistant cancer might beneﬁt from earlier palliative symptom
management if these patients could be better identiﬁed.
Interleukin (IL)-8 (alternatively known as CXCL8) is a proin-
ﬂammatory cytokine.9 Its complex effects on the tumor microen-
vironment may result in tumor proliferation, survival, and
chemoresistance in malignant disease.10-14 High IL-8 serum levels
and tumor expression are known to be associated with poor patient
prognosis in many malignant diseases, including breast can-
cer.13,15,16 Even in localized breast cancer, patients with high
circulating IL-8 levels have a poorer prognosis than patients with
low IL-8 levels.17,18
In addition to IL-8, many other cytokines and circulating regu-
latory factors are associated with breast cancer and are considered to
be potential biomarkers for cancer prognosis.19-34 Serum concen-
trations of IL-6 and IL-18 are elevated in breast cancer patients,19,20
and high circulating IL-6 levels are linked to shorter survival in
metastatic breast cancer patients than are low circulating IL-6
levels.21,22 Additionally, IL-6 and IL-18 are associated with
chemotherapy resistance.23,24 Matrix metalloproteinase (MMP)-2
and MMP-9 serum levels are associated with poor overall survival
(OS), even in patients with localized breast cancer.25 YKL-40 (also
known as chitinase-3elike protein 1) has been suggested to play a
role in cell proliferation, differentiation, inﬂammation, and tissue
remodeling, and has been associated with malignancies with poor
survival.35-37 In patients with either local or advanced breast cancer,
high serum YKL-40 levels predict a poor prognosis.26-28
Obesity is a known risk factor for breast cancer.38 Therefore,
adipocytokines, including resistin, may be related to breast cancer
development and prognosis. Serum resistin levels are known to be
elevated in breast cancer patients compared to healthy controls.29,30
Additionally, compared to low resistin expression, high resistin
expression in the primary breast cancer tumor tissue is associated
with poorer patient survival and more unfavorable clinicopathologic
features of the primary cancer.31 High-mobility group box 1
(HMGB1) is a ubiquitous nuclear protein that contributes to DNA
repair and the stabilization of nuclear homeostasis.32 HMGB1 is
expressed at higher levels in many tumor types compared to healthy
tissue,33 and its expression is associated with many diseases,
including cancer.34
We conducted an exploratory analysis of multiple plasma cyto-
kines and other circulating proteins. The aim of the study was to
identify prognostic markers for metastatic breast cancer. IL-8 levels,
a promising biomarker, were explored before and during chemo-
therapy treatment for their value in predicting patient prognosis.
We also measured plasma levels of IL-6, IL-18, MMP-9, MMP-2,
YKL-40, resistin, and HMGB1, and investigated their prognostic
signiﬁcance.
Patients and Methods
We conducted a prospective phase 2 trial for metastatic breast
cancer patients. The study patients had histologically veriﬁed
HER2-negative advanced breast cancer and had not received pre-
vious chemotherapy in a metastatic setting. A total of 65 patients
were enrolled onto the trial at 3 Finnish university oncology clinics
between 2009 and 2013 (NCT00979641). The study inclusion
criteria, trial design, and clinical results have been published pre-
viously.2 In brief, study patients were treated with a bevacizumab
and taxane (paclitaxel or docetaxel) combination as the ﬁrst-line
treatment for metastatic breast cancer. Patients without disease
progression continued bevacizumab treatment after the taxane
chemotherapy was discontinued. Patients with estrogen
receptorepositive breast cancer also received endocrine therapy with
bevacizumab maintenance therapy. For second-line therapy after
disease progression, the continuation of bevacizumab was optional
with chemotherapy. All patients provided written informed consent,
and the regional ethics committee of Tampere University Hospital
approved the study protocol (R08142M).
Plasma samples were gathered before the initiation of chemo-
therapy (baseline), after 6 weeks of treatment, after 6 months of
treatment, and at the ﬁnal study visit.
Measurement of Plasma Cytokines
Plasma IL-8, IL-6, IL-18, MMP-2, MMP-9, YKL-40, resistin,
and HMGB1 concentrations were measured by enzyme-linked
immunosorbent assays (ELISAs) using reagents from BD Bio-
sciences (Erembodegem, Belgium; IL-8), eBioscience (San Diego,
CA; IL-6 and IL-18), R&D Systems Europe (Abingdon, UK;
MMP-2, MMP-9, YKL-40, resistin), and IBL International
(Hamburg, Germany; HMGB1). ELISAs were carried out accord-
ing to a standard protocol. In brief, for MMP-2, MMP-9, YKL-40,
and resistin, a 96-well plate was coated with capture antibody and
incubated overnight at 4C. The wells were washed with phosphate-
buffered salinee0.05% Tween 20 and blocked with 1% bovine
serum albumin in phosphate-buffered saline, 250 mL per well, for 1
hour at room temperature (RT). The wells were washed, and the
standards, and samples diluted in reagent diluent (1% bovine serum
albumin in phosphate-buffered saline) were added to the wells and
incubated for 2 hours at RT. The wells were washed. Detection
antibodies diluted in reagent diluent (with normal goat serum for
MMP-9) were added and incubated for 1.5 h at RT. Streptavidin-
conjugated to horseradish peroxidase was added after the wash step
and incubated for 15 minutes at RT. The wells were washed, and
BioFX TMB substrate solution (SurModics, Eden Prairie, MN) was
added and incubated for 15 minutes in the dark at RT. After adding
50 mL of stop solution (1 N H2SO4), the absorbance of each well
was measured at 450 nm with a correction wavelength at 540 nm
within 20 minutes with a Victor3 Multilabel Counter (Perkin
Elmer, Turku, Finland), and the results were calculated from a
standard curve using the smoothed spline method with MultiCalc
software (Perkin Elmer). For IL-8, IL-6, IL-18, and HMGB1,
ELISAs were performed according to the manufacturer’s protocols
and then measured and calculated as stated above.
Patient Characteristics
Plasma samples were available from 58 patients (89%). Patient
characteristics are listed in Table 1. After taxane discontinuation,
patients without disease progression and with hormone
receptorepositive disease received endocrine therapy in combina-
tion with bevacizumab. Letrozole was the most common endocrine
therapy choice (n ¼ 19). The other endocrine therapies included
anastrozole (n ¼ 4), exemestane (n ¼ 4), tamoxifen (n ¼ 3), and
fulvestrant (n ¼ 3).
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Baseline samples were available from 53 patients. Breast cancer
progression was the reason for study discontinuation for most pa-
tients (n ¼ 36, 55%). Final plasma samples were available from 50
patients, of whom 24 had disease progression as the reason for
treatment discontinuation (48%). The remaining 26 patients dis-
continued the study treatment as a result of treatment side effects.
Plasma samples at week 6 and month 6 were available only from
patients who were following the study treatment plan at that time
point.
Statistical Analysis
The statistical plan for the analysis was exploratory. IL-8, IL-6,
IL-18, MMP-9, MMP-2, YKL-40, resistin, and HMGB1 levels
were dichotomized as low or high for each patient using the median
value for each molecule as the cutoff value. Additionally, IL-8, IL-6,
IL-18, MMP-9, MMP-2, YKL-40, resistin, and HMGB1 levels
were divided into 4 groups using the baseline quartile ranges as the
cutoff values.
IL-8 values were clustered by the trajectory analysis originally
presented by Nagin.39 Trajectory groups are clusters of individuals
following similar trajectories to an outcome over time.40 The tra-
jectories were created according to all measurements of IL-8 levels in
each patient as a continuous outcome measure. These trajectories
are presented in Figure 1. The analyses undertaken were latent class
mixture models of quadratic trajectories including a random inter-
cept and concomitant variables. Models were ﬁtted by the FlexMix
package41 of the statistical program R 3.3.0.42 Relative goodness of
ﬁt was assessed using the Bayesian information criteria.
Because of the nonparametric distribution of the IL-8 levels,
medians with the conﬁdence interval (CI) of the median are re-
ported. The Mann-Whitney U test was used to compare the median
IL-8 levels of different baseline characteristics and trajectory groups.
Hazard ratios (HR) with 95% CIs were calculated by Cox pro-
portional hazard regression analysis. Multivariable analyses were
adjusted for age (continuous), menopause status (premenopausal/
postmenopausal), hormone receptor status (negative/positive),
presence of visceral metastasis (yes/no), number of metastatic lesions
(cutoff of 3 metastatic lesions), and extent of disease (cutoff of 3
metastatic sites). Median OS, median progression-free survival
(PFS), and their CIs were calculated by the Kaplan-Meier method.
The Wilcoxon signed-rank test was used to compare the baseline,
week 6, month 6, and ﬁnal plasma IL-8 levels between the different
trajectory groups. P < .05 was considered statistically signiﬁcant.
Statistical analyses were performed by SPSS 23 software (IBM,
Armonk, NY).
Results
IL-8 Levels and Patient Baseline Characteristics
There were no statistically signiﬁcant differences in the baseline
IL-8 levels between groups with different baseline characteristics,
including menopause status (P ¼ .104), hormone receptor status
(P ¼ .152), number of metastatic lesions (P ¼ .539), and presence
of visceral disease (P ¼ .941). Borderline signiﬁcantly lower baseline
IL-8 levels were observed in patients with <3 metastatic sites
compared to the patients with 3 metastatic sites (<3 metastatic
sites median baseline IL-8: 8.9 pg/mL; 95% CI, 7.8-9.9 pg/mL
vs. 3 metastatic sites median IL-8: 12.5 pg/mL; 95% CI, 8.0-25.4
pg/mL; P ¼ .057).
Prognostic Signiﬁcance of Baseline IL-8 Levels
The patients were divided into two groups (low and high baseline
plasma IL-8 level) using a median value of 9.4 pg/mL as the cutoff
point. The PFS and OS of these IL-8 groups are listed in Table 2.
The high baseline IL-8 group had a signiﬁcantly shorter OS
(P ¼ .023).
Trajectory Analysis of IL-8 Levels
The distributions of the 3 trajectory groups are presented in
Figure 1 and Table 3. Trajectory group 1 patients had constantly
low IL-8 concentrations; the range of IL-8 levels in trajectory group
Table 1 Baseline Characteristics and Efﬁcacy Results in
Plasma Biomarker Population and of Patients With
Baseline Samples Available Compared to Overall
Study Population
Characteristic
Plasma Biomarker
Population
(N [ 58)
Overall Study
Population
(N [ 65)
Age (y), median (range) 58 (32-75) 57 (32-75)
Menopausal Status
Premenopausal 9 (15.5) 10 (15.4)
Postmenopausal 49 (84.5) 55 (84.6)
History of early stage
disease
52 (89.7) 57 (87.7)
Disease-Free Interval, mo
24 10 (19.2) 11 (16.9)
>24 42 (80.8) 46 (70.8)
Hormone Receptor Status
ERþ and/or PRþ 47 (81.0) 53 (81.5)
ER and PR 11 (19.0) 12 (18.5)
No. of Metastatic Lesions
3 11 (19.0) 14 (21.5)
>3 47 (81.0) 51 (78.5)
Extent of Disease
<3 sites 36 (62.1) 39 (60.0)
3 sites 22 (37.9) 26 (40.0)
Site of Metastatic Disease
Visceral disease 46 (79.3) 53 (81.5)
Nonvisceral disease 12 (20.7) 12 (18.5)
Overall survival, median
(95% CI)
37.5 (25.4-49.6) 35.1 (22.2-50.3)
Progression-free survival,
median (95% CI)
11.3 (8.3-14.4) 11.3 (9.7-16.0)
Best Response to
Treatment
Complete response/partial
response
38 (71.7) 40 (61.5)
Stable disease 13 (24.5) 15 (23.1)
Progressive disease 2 (3.8) 3 (4.6)
Data are presented as n (%) unless otherwise indicated.
Abbreviations: CI ¼ conﬁdence interval; ER ¼ estrogen receptor; PR ¼ progesterone receptor.
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1 was 2.6 to 16.6 pg/mL during the entire treatment period. Tra-
jectory groups 2 and 3 had signiﬁcantly higher IL-8 levels at base-
line, at week 6, at month 6, and at the ﬁnal study visit compared to
trajectory group 1 (Table 3). The ﬁnal IL-8 levels of trajectory
group 3 patients were signiﬁcantly higher than their month 6 IL-8
plasma levels (P ¼ .043). In trajectory group 3, there were no
signiﬁcant changes in the IL-8 levels between the baseline and week
6 and between week 6 and month 6. The changes in the IL-8 levels
in trajectory groups 1 and 2 over time were not statistically
signiﬁcant.
The patients belonging to trajectory group 3 with very high IL-8
levels had signiﬁcantly shorter PFS than the patients belonging to
the other groups (Table 4, Figure 2A). No signiﬁcant differences in
PFS were detected between the patients in trajectory groups 1 and
2. In addition, the patients in trajectory groups 2 and 3 had
signiﬁcantly shorter OS than the patients in trajectory group 1 using
both an age-adjusted HR and a multivariable Cox model adjusted
for age, menopause status, hormone receptor status, presence of
visceral metastases, number of metastatic lesions, and extent of the
disease (Table 4, Figure 2B).
To further examine the clinical utility of IL-8 levels, a cutoff
value of 16.6 pg/mL was found to be useful for ﬁnding patients with
a signiﬁcantly more favorable long-term prognosis. All the IL-8
levels in trajectory group 1 remained below 16.6 pg/mL before
and during the entire chemotherapy treatment period. A cutoff
value of 16.6 pg/mL could identify all of the 35 patients who were
categorized into trajectory group 1. In contrast, only one trajectory
group 2 patient (1/17, 5.9%) had IL-8 levels constantly below 16.6
pg/mL, and all of the patients in trajectory group 3 had IL-8 levels
higher than 16.6 pg/mL before or during chemotherapy treatment.
For PFS, the age-adjusted HR was borderline signiﬁcant for the
patients with IL-8 levels higher than 16.6 pg/mL before or during
chemotherapy treatment (age-adjusted HR 2.00; 95% CI, 0.97-
4.14; P ¼ .060), while the multivariable HR was not statistically
signiﬁcant (multivariable HR ¼ 1.91; 95% CI, 0.89-4.09; P ¼
.094; Figure 3A). However, the HR for OS was strongly signiﬁcant
for both the age-adjusted and multivariable Cox models for the
patients with IL-8 levels higher than 16.6 pg/mL before or during
chemotherapy treatment (age-adjusted HR 3.02; 95% CI, 1.60-
5.71; P ¼ .001, multivariable HR ¼ 3.90; 95% CI, 1.88-8.12; P <
.001; Figure 3B).
Highest Baseline IL-8 Quartile Level and Prognosis
A very high baseline plasma IL-8 level was also a strong sign of
poor prognosis without knowledge of IL-8 levels during treatment.
The highest (>18.8 pg/mL) baseline IL-8 level quartile patients had
the poorest prognosis in terms of median PFS and OS, at 9.6
months (95% CI, 5.47-13.7 months) and 19.7 months (95% CI,
8.60-30.9 months), respectively (Supplemental Table 1 in the on-
line version). The multivariable HR for PFS was 6.52 (95% CI,
1.58-26.9; P ¼ .010) for the highest plasma IL-8 quartile, and the
multivariable HR for OS was 8.38 (95% CI, 2.60-27.0; P < .001).
All of the patients in the highest quartile belonged to trajectory
groups 2 (n ¼ 9) and 3 (n ¼ 4). Altogether, a high baseline IL-8
level > 18.8 pg/mL (the highest quartile) could identify 62%
Figure 1 Interleukin 8 Trajectory Groups. Shown Are
Trajectory Groups 1 (n [ 35), 2 (n [ 17), and 3
(n [ 6)
Trajectory groups
nikuelretnI
-
)l
m/gp( 8
Baseline
Week 6
Month 6
Final
Table 2 Cox Regression Analysis for PFS and OS Grouped by Low or High Baseline IL-8 Levels Using Median as Cutoff Value
Baseline IL-8 pg/mL No. Patients No. Events
Adjusted HR 1a Adjusted HR 2b
HR 95% CI P HR 95% CI P
PFS
Low 9.4 27 15 1 1
High >9.4 26 16 1.44 0.70-2.93 .316 1.32 0.58-3.00 .493
OS
Low 9.4 27 16 1 1
High >9.4 26 23 2.14 1.10-4.12 .023c 1.65 0.82-3.34 .159
Abbreviations: CI ¼ conﬁdence interval; HR ¼ hazard ratio; IL ¼ interleukin; OS ¼ overall survival; PFS ¼ progression-free survival.
aHR adjusted for age.
bHR adjusted for age, menopause status, hormone receptor status, presence of visceral metastasis, number of metastatic lesions, and extent of disease.
cStatistically signiﬁcant.
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(13/21) of the patients in the poorer prognosis trajectory groups 2
and 3 with the baseline plasma samples available.
IL-6, IL-18, MMP-9, MMP-2, YKL-40, Resistin, and
HMGB1 Baseline Levels as Prognostic Markers for
Survival
A Cox regression analysis was also performed for all other
measured markers: IL-6, IL-18, MMP-9, MMP-2, YKL-40, resis-
tin, and HMGB1. Using the median and quartile levels as cutoff
values, there were no statistically signiﬁcant differences in PFS using
all individual markers (Supplemental Tables 2 and 3 in the online
version). Using the median as a cutoff value, a high baseline MMP-
9 level was borderline signiﬁcant for longer OS (multivariable HR¼
0.52; 95% CI, 0.26-1.03; P ¼ .063). Using the baseline quartile
levels as cutoff values, the baseline quartile level of 50% to 75% for
MMP-9 was prognostic for OS (multivariable HR ¼ 0.37; 95% CI,
0.13-1.01; P ¼ .054), as was the highest baseline quartile MMP-9
level (multivariable HR for OS 0.22; 95% CI, 0.07-0.68; P ¼
.009). The highest baseline quartile level of YKL-40 was a sign of
poor prognosis in an age-adjusted Cox regression (HR 3.08; 95%
CI, 1.10-8.61; P ¼ .031). However, in multivariable analysis, the
highest baseline level of YKL-40 lost its prognostic signiﬁcance
(multivariable HR ¼ 2.13; 95% CI, 0.65-6.97; P ¼ .211). For
IL-6, IL-18, MMP-2, resistin, and HMGB1, the median and
quartile cutoff level groups revealed no signiﬁcant OS differences
(Supplemental Tables 4 and 5 in the online version).
Discussion
IL-8 level monitoring during chemotherapy for metastatic breast
cancer is a promising approach for identifying patients with good
prognosis. High baseline plasma IL-8 levels are known to be a poor
prognosticmarker in breast cancer.15However, to our knowledge, our
study is novel in its monitoring of plasma IL-8 levels in metastatic
breast cancer patients during chemotherapy. We identiﬁed a large
group of patients belonging to trajectory group 1 (35/58, 60.3%)who
had a substantially better prognosis than the rest of the patients. The
median OS (50 months) for trajectory group 1 patients was excep-
tionally good (95%CI, 43.5-56.3months) in patients withmetastatic
HER2-negative breast cancer. In contrast, the median OS for tra-
jectory group 2 patients (median OS 24 months; 95% CI, 15.5-32.0
months) was less than half of the OS in the group 1 patients. Inter-
estingly, the remaining 6 patients belonging to trajectory group 3 had
exceptionally high IL-8 levels during the entire chemotherapy period,
and these patients had a short median OS of 8 months. High IL-8
levels are known to be a sign of chemoresistance.12,43 The poor sur-
vival of our trajectory group 3 patients is a conﬁrmatory ﬁnding for the
previously reported chemoresistant nature of metastatic cancer with
high IL-8 levels.
Table 3 Median IL-8 Levels in 3 Trajectory Groups
Trajectory
Group No. Patients
Baseline IL-8 (pg/mL) Week 6 IL-8 (pg/mL) Month 6 IL-8 (pg/mL) Final IL-8 (pg/mL)
Median 95% CI Median 95% CI Median 95% CI Median 95% CI
1 35 8.05 7.40-9.40 7.30 5.90-9.00 7.60 6.50-8.90 7.90 6.30-9.90
2 17 21.7 12.4-27.5 13.4 11.3-18.0 11.6 8.40-16.1 15.1 7.30-20.2
3 6 38.9 9.30-175 16.2 11.9-50.2 39.4 9.50-93.4 78.9 56.4-113
1 vs. 2 P <.001a <.001a .006a .001a
1 vs. 3 P .002a .002a <.001a <.001a
2 vs. 3 P .199 .332 .009a .001a
Abbreviations: CI ¼ conﬁdence interval of median; IL ¼ interleukin.
aStatistically signiﬁcant.
Table 4 PFS and OS of Patients of 3 Trajectory Groups
Trajectory
Group No. Patients No. Events
HR 1a HR 2b
HR 95% CI P HR 95% CI P
PFS
1 35 19 1 1
2 17 9 1.27 0.52-3.08 .589 0.94 0.35-2.54 .917
3 6 6 4.56 1.65-12.6 .003c 4.01 1.24-12.9 .020c
OS
1 35 22 1 1
2 17 15 2.45 1.21-5.97 .012c 3.29 1.45-7.45 .004c
3 6 6 8.65 3.16-23.7 <.001c 7.82 2.27-26.9 .001c
Abbreviations: CI ¼ conﬁdence interval; HR ¼ hazard ratio; IL ¼ interleukin; OS ¼ overall survival; PFS ¼ progression-free survival.
aHR adjusted for age.
bHR adjusted for age, menopause status, hormone receptor status, presence of visceral metastasis, number of metastatic lesions, and extent of disease.
cStatistically signiﬁcant.
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In addition to the high IL-8 levels during chemotherapy treat-
ment, exceptionally high baseline IL-8 levels were a strong sign of
poor prognosis, even without knowledge of IL-8 levels during
treatment. In our study, the IL-8 levels in the highest baseline
quartile were above 18.8 pg/mL, and the PFS (multivariable
HR ¼ 6.52; 95% CI, 1.58-26.9; P ¼ .010) and OS (multivariable
HR ¼ 8.38; 95% CI, 2.60-27.0; P < .001) of these patients were
signiﬁcantly shorter than those of the patients in the lowest IL-8
quartile group. This result was similar to a previous report that
showed that patients with baseline plasma IL-8 levels higher than
Figure 2 PFS and OS by Multivariable Cox Regression. (A) PFS and (B) OS of 3 Trajectory Groups Using Multivariable Cox Regression
Adjusted for Age, Menopause Status, Hormone Receptor Status, Presence of Visceral Metastasis, Number of Metastatic
Lesions, and Extent of Disease. Median Survivals and Their Conﬁdence Intervals Were Calculated by Kaplan-Meier Method.
*Log-rank P Value Between Trajectory Groups 1 and 2. **Log-rank P Value Between Trajectory Groups 1 and 3
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Time (months)
Median months 
(95% CI)
Group 1 13.9 (8.56-19.3)
Group 2 11.3 (6.90-15.8)
Group 3 6.44 (4.74-8.14)
p value* 0.917
p value** 0.020
Median months 
(95% CI)
Group 1 49.9 (43.5-56.3)
Group 2 23.8 (15.5-32.0)
Group 3 8.41 (6.60-10.2)
p value* 0.004
p value** 0.001
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Abbreviations: OS ¼ overall survival; PFS ¼ progression-free survival.
Figure 3 PFS and OS Based on Trajectory Analysis. (A) PFS and (B) OS in Patient Population Dichotomized Based on Trajectory
Analysis Using All Plasma IL-8 Levels Before and During Chemotherapy Treatment. Red Line Indicates That Plasma IL-8
Levels at Baseline, Week 6, Month 6, and at Study Discontinuation Are Below 16.6 pg/mL. Blue Line Indicates That One or
Several Measurements of Plasma IL-8 Levels Are Above 16.6 pg/mL Before or During Chemotherapy Treatment. Multivariable
Cox Regression Adjusted for Age, Menopause Status, Hormone Receptor Status, Presence of Visceral Metastasis, Number of
Metastatic Lesions, and Extent of Disease. Median Survivals and Their Conﬁdence Intervals Were Calculated by Kaplan-
Meier Method
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Log rank p value <0.001
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Abbreviations: IL ¼ interleukin; OS ¼ overall survival; PFS ¼ progression-free survival.
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the median value of 17.2 pg/mL had shorter survival than patients
with lower IL-8 levels (P ¼ .0045).15
Several studies have been conducted to ﬁnd a clinically useful
biomarker to select patients who might beneﬁt from the addition of
the vascular endothelial growth factor A (VEGF-A) antibody bev-
acizumab to standard chemotherapy for the treatment of metastatic
breast cancer.44-48 In our study, the patients were treated with
bevacizumab combined with either paclitaxel or docetaxel chemo-
therapy as ﬁrst-line treatment for metastatic breast cancer. It has
been shown that IL-8 can promote angiogenesis and may activate
vascular endothelial growth factor receptor 2 (VEGFR2).49 VEGF-
A is a ligand for VEGFR2. In our study, very high baseline IL-8
levels were a sign of poor prognosis. Accordingly, in our study,
the patients with the highest plasma IL-8 levels at baseline had the
shortest treatment beneﬁt. The high baseline plasma levels of
proangiogenic IL-8 might be one reason for the lack of beneﬁt from
bevacizumab-based therapy. However, because our study did not
have a placebo control arm as a comparator, this hypothesis should
be tested prospectively in future studies.
The other markers analyzed in our study failed to demonstrate
any clear prognostic signiﬁcance. Zhang and Adachi21 reported that
patients with circulating IL-6 levels higher than the median con-
centration of 4 pg/mL in their study exhibited poor survival.
However, the highest quartile plasma IL-6 cutoff value for our study
patients was 3.8 pg/mL, suggesting that most of our study patients
had low plasma IL-6 concentrations. This is in accordance with the
ﬁnding that plasma IL-6 levels were not prognostic in our hands. In
addition, the limited patient population in our study might partly
explain why the other tested circulating markers had no prognostic
value.
The plasma analyses in our study were exploratory and were
performed retrospectively. In the future, it would be useful to
monitor plasma IL-8 levels prospectively in clinical trials involving
metastatic breast cancer patients. IL-8 levels are known to correlate
with the tumor burden in many malignant diseases.50 Rising IL-8
levels during treatment could be a sign of chemoresistance, and it
therefore might be beneﬁcial to refer patients with rising IL-8 levels
to new treatment modalities. It might be worthwhile to study
whether patients with high plasma concentrations of the proin-
ﬂammatory cytokine IL-8 would beneﬁt from novel immunother-
apies. In an unselected metastatic breast cancer population, the
response rates to immunotherapies have been low.51 However, in a
report of novel immunotherapies, a clear association was seen be-
tween the treatment response and IL-8 levels in melanoma and
nonesmall-cell lung cancer patients.52 Nevertheless, the correlation
between high IL-8 levels and the response rates to immunotherapies
in metastatic breast cancer remains unexplored.
Conclusion
Low plasma IL-8 levels during chemotherapy in metastatic breast
cancer patients are a clear sign for excellent long-term prognosis. We
found that patients with constantly low plasma IL-8 levels had a better
prognosis than the patients with plasma IL-8 levels higher than 16.6
pg/mL. Plasma IL-8 levels might therefore be useful for the selection
of patients with excellent prognosis and those who might be suitable
for less intensive radiologic imaging and follow-up visits.
Clinical Practice Points
 High circulating IL-8 levels are associated with poor prognosis in
patients with advanced breast cancer and are related to
chemoresistance.
 Metastatic breast cancer patients with constantly low plasma IL-8
levels during ﬁrst-line chemotherapy have an excellent long-term
prognosis.
 Very high baseline plasma IL-8 levels are associated with
signiﬁcantly shorter PFS and OS.
 Monitoring circulating IL-8 levels during ﬁrst-line chemotherapy
might be beneﬁcial to distinguish good-prognosis patients who
might be suited to less intensive treatment and follow-up
schedules.
 Patients with very high plasma IL-8 levels either at the beginning
of chemotherapy treatment or during therapy for metastatic
breast cancer should be followed more intensively because of the
chemoresistant nature of their disease.
 In the future, whether patients with high plasma IL-8 levels and
therefore poor prognosis might beneﬁt from novel treatment
modalities, ie, immunologic therapy, should be prospectively
explored.
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Supplemental Table 1 PFS and OS for Study Patients Grouped by Baseline IL-8 Quartile
Baseline IL-8 pg/mL No. Patients No. Events
HR 1a HR 2b
HR 95% CI P HR 95% CI P
PFS
<Q25 <7.7 13 5 1 1
Q25-Q50 7.7-9.4 14 10 2.12 0.70-6.39 .180 2.15 0.53-8.65 .279
Q50-Q75 9.4-18.8 13 7 1.34 0.42-4.27 .618 0.99 0.20-4.76 .995
>Q75 >18.8 13 9 5.22 1.62-16.8 .006c 6.52 1.58-26.9 .010c
OS
<Q25 <7.7 13 6 1 1
Q25-Q50 7.7-9.4 14 10 2.70 0.95-7.69 .062 3.46 1.08-11.0 .035c
Q50-Q75 9.4-18.8 13 10 2.29 0.81-6.46 .115 1.64 0.51-5.28 .406
>Q75 >18.8 13 13 7.44 2.62-21.1 <.001c 8.38 2.60-27.0 <.001c
Abbreviations: CI ¼ conﬁdence interval; HR ¼ hazard ratio; IL ¼ interleukin; OS ¼ overall survival; PFS ¼ progression-free survival; Q ¼ quartile.
aHR adjusted for age.
bHR adjusted for age, menopause status, hormone receptor status, presence of visceral metastasis, number of metastatic lesions, and extent of disease.
cStatistically signiﬁcant.
Supplemental Table 2 Cox Regression Analysis for PFS Grouped by Low or High Baseline IL-6, IL-18, MMP-9, MMP-2, YKL-40,
Resistin, and HMGB1 Levels Using Median as Cutoff Value
Baseline Value No. Patients No. Events
HR 1a HR 2b
HR 95% CI P HR 95% CI P
IL-6 pg/mL
Low 1.8 27 15 1 1
High >1.8 26 16 0.84 0.40-1.73 .637 0.44 0.18-1.07 .071
IL-18 pg/mL
Low 99.2 27 17 1 1
High >99.2 26 14 0.60 0.29-1.25 .176 0.71 0.31-1.60 .411
MMP-9 ng/mL
Low 76.4 27 18 1 1
High >76.4 26 13 0.72 0.35-1.47 .370 0.56 0.25-1.29 .177
MMP-2 ng/mL
Low 244.5 27 15 1 1
High >244.5 26 16 0.91 0.42-1.95 .810 0.80 0.37-1.74 .585
YKL-40 ng/mL
Low 60.3 27 16 1 1
High >60.3 26 15 1.26 0.60-2.65 .536 0.951 0.40-2.22 .909
Resistin ng/mL
Low 13.4 27 15 1 1
High >13.4 26 16 1.44 0.69-2.99 .325 1.13 0.53-2.39 .749
HMGB1 ng/mL
Low 7.1 27 15 1 1
High >7.1 26 16 1.28 0.60-2.71 .512 1.27 0.59-2.71 .535
Abbreviations: CI ¼ conﬁdence interval; HMGB1 ¼ high-mobility group box 1; HR ¼ hazard ratio; IL ¼ interleukin; MMP ¼ matrix metalloproteinase; PFS ¼ progression-free survival.
aHR adjusted for age.
bHR adjusted for age, menopause status, hormone receptor status, presence of visceral metastasis, number of metastatic lesions, and extent of disease.
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Supplemental Table 3 PFS Analysis by Cox Regression for Study Patients Using Baseline IL-6, IL-18, MMP-9, MMP-2, YKL-40,
Resistin, and HMGB1 Quartile Levels as Cutoff Values
Baseline Value No. Patients
HR 1a HR 2b
HR 95% CI P HR 95% CI P
IL-6 pg/mL
<Q25 <0.7 15 1 1
Q25-Q50 0.7-1.8 12 0.85 0.30-2.40 .767 1.38 0.33-5.65 .652
Q50-Q75 1.8-3.8 14 0.57 0.21-1.57 .286 0.31 0.09-1.05 .060
>Q75 >3.8 12 1.23 0.43-3.55 .692 1.02 0.27-3.80 .973
IL-18 pg/mL
<Q25 <53.5 13 1 1
Q25-Q50 53.5-99.2 14 1.23 0.45-3.36 .676 1.11 0.40-3.13 .831
Q50-Q75 99.2-264.3 14 0.65 0.24-1.75 .401 0.70 0.24-2.01 .516
>Q75 >264.3 12 0.65 0.23-1.87 .432 0.81 0.24-2.69 .733
MMP-9 ng/mL
<Q25 <49.6 13 1 1
Q25-Q50 49.6-76.4 14 1.02 0.40-2.60 .963 0.84 0.28-2.47 .756
Q50-Q75 76.4-129.6 13 0.82 0.31-2.18 .700 0.68 0.24-1.92 .474
>Q75 >129.6 13 0.61 0.20-1.89 .396 0.34 0.09-1.30 .118
MMP-2 ng/mL
<Q25 <218.8 13 1 1
Q25-Q50 218.8-244.5 14 1.35 0.46-3.90 .579 1.43 0.44-4.70 .548
Q50-Q75 244.5-284.0 13 1.05 0.34-3.18 .927 0.96 0.27-3.36 .959
>Q75 >284.0 13 1.15 0.35-3.75 .807 1.05 0.31-3.46 .935
YKL-40 ng/mL
<Q25 <38.3 13 1 1
Q25-Q50 38.3-60.3 14 0.99 0.35-2.78 .995 1.68 0.54-5.28 .368
Q50-Q75 60.3-113.3 13 1.30 0.42-3.98 .640 1.24 0.42-3.70 .688
>Q75 >113.3 13 1.23 0.43-3.49 .698 1.03 0.27-3.89 .962
Resistin ng/mL
<Q25 <11.4 13 1 1
Q25-Q50 11.4-13.4 14 1.04 0.36-3.00 .931 1.43 0.40-5.06 .572
Q50-Q75 13.4-15.6 13 1.69 0.60-4.73 .315 2.06 0.61-6.99 .242
>Q75 >15.6 13 1.30 0.46-3.67 .609 1.01 0.33-3.06 .982
HMGB1 ng/mL
<Q25 <5.1 13 1 1
Q25-Q50 5.1-7.1 14 1.27 0.45-3.61 .643 0.74 0.24-2.30 .610
Q50-Q75 7.1-9.7 13 1.87 0.60-5.83 .281 2.29 0.62-8.45 .213
>Q75 >9.7 13 1.24 0.42-3.68 .688 0.76 0.24-2.35 .640
Abbreviations: CI ¼ conﬁdence interval; HMGB1 ¼ high-mobility group box 1; HR ¼ hazard ratio; IL ¼ interleukin; MMP ¼ matrix metalloproteinase; PFS ¼ progression-free survival; Q ¼ quartile.
aHR adjusted for age.
bHR adjusted for age, menopause status, hormone receptor status, presence of visceral metastasis, number of metastatic lesions, and extent of disease.
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Supplemental Table 4 Cox Regression Analysis for OS Grouped by Low or High Baseline IL-6, IL-18, MMP-9, MMP-2, YKL-40,
Resistin, and HMGB1 Levels Using Median as Cutoff Value
Baseline Value No. Patients No. Events
HR 1a HR 2b
HR 95% CI P HR 95% CI P
IL-6 pg/mL
Low 1.8 27 19 1 1
High >1.8 26 20 1.10 0.57-2.12 .771 1.12 0.52-2.39 .771
IL-18 pg/mL
Low 99.2 27 18 1 1
High >99.2 26 21 1.38 0.72-2.63 .319 1.21 0.60-2.43 .588
MMP-9 ng/mL
Low 76.4 27 21 1 1
High >76.4 26 18 0.73 0.38-1.37 .330 0.52 0.26-1.03 .063
MMP-2 ng/mL
Low 244.5 27 20 1 1
High >244.5 26 19 0.96 0.47-1.93 .910 1.42 0.66-3.05 .362
YKL-40 ng/mL
Low 60.3 27 18 1 1
High >60.3 26 21 1.87 0.94-3.73 .071 1.41 0.66-2.99 .370
Resistin ng/mL
Low 13.4 27 19 1 1
High >13.4 26 20 1.13 0.60-2.12 .701 1.09 0.56-2.13 .784
HMGB1 ng/mL
Low 7.1 27 20 1 1
High >7.1 26 19 0.93 0.47-1.86 .850 1.19 0.57-2.48 .626
Abbreviations: CI ¼ conﬁdence interval; HMGB1 ¼ high-mobility group box 1; HR ¼ hazard ratio; IL ¼ interleukin; MMP ¼ matrix metalloproteinase; PFS ¼ progression-free survival.
aHR adjusted for age.
bHR adjusted for age, menopause status, hormone receptor status, presence of visceral metastasis, number of metastatic lesions, and extent of disease.
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Supplemental Table 5 OS Analysis by Cox Regression for Study Patients Using Baseline IL-6, IL-18, MMP-9, MMP-2, YKL-40,
Resistin, and HMGB1 Quartile Levels as Cutoff Values
Baseline Value No. Patients
HR 1a HR 2b
HR 95% CI P HR 95% CI P
IL-6 pg/mL
<Q25 <0.7 15 1 1
Q25-Q50 0.7-1.8 12 2.66 1.04-6.77 .039c 1.64 0.48-5.60 .426
Q50-Q75 1.8-3.8 14 1.51 0.59-3.88 .386 0.92 0.31-2.65 .878
>Q75 >3.8 12 2.29 0.82-6.39 .111 2.23 0.76-6.54 .142
IL-18 pg/mL
<Q25 <53.5 13 1 1
Q25-Q50 53.5-99.2 14 0.67 0.26-1.73 .415 0.52 0.19-1.43 .205
Q50-Q75 99.2-264.3 14 0.80 0.31-2.00 .635 0.65 0.25-1.66 .369
>Q75 >264.3 12 1.62 0.66-3.96 .290 1.20 0.42-3.39 .729
MMP-9 ng/mL
<Q25 <49.6 13 1 1
Q25-Q50 49.6-76.4 14 0.50 0.20-1.21 .128 0.39 0.14-1.06 .067
Q50-Q75 76.4-129.6 13 0.50 0.20-1.23 .133 0.37 0.13-1.01 .054c
>Q75 >129.6 13 0.48 0.19-1.22 .128 0.22 0.07-0.68 .009c
MMP-2 ng/mL
<Q25 <218.8 13 1 1
Q25-Q50 218.8-244.5 14 1.93 0.75-4.99 .170 1.81 0.59-5.52 .295
Q50-Q75 244.5-284.0 13 1.21 0.41-3.56 .728 1.77 0.52-5.97 .356
>Q75 >284.0 13 1.73 0.61-4.91 .300 2.16 0.74-6.29 .158
YKL-40 ng/mL
<Q25 <38.3 13 1 1
Q25-Q50 38.3-60.3 14 1.56 0.56-4.32 .386 2.00 0.70-5.74 .195
Q50-Q75 60.3-113.3 13 1.97 0.63-6.06 .238 2.10 0.68-6.41 .191
>Q75 >113.3 13 3.08 1.10-8.61 .031c 2.13 0.65-6.97 .211
Resistin ng/mL
<Q25 <11.4 13 1 1
Q25-Q50 11.4-13.4 14 1.10 4.31-2.83 .835 0.97 0.30-3.08 .966
Q50-Q75 13.4-15.6 13 1.22 0.47-3.13 .673 1.26 0.46-3.45 .645
>Q75 >15.6 13 1.17 0.45-3.03 .744 0.95 0.35-2.55 .919
HMGB1 ng/mL
<Q25 <5.1 13 1 1
Q25-Q50 5.1-7.1 14 1.81 0.73-4.44 .195 1.65 0.65-4.21 .288
Q50-Q75 7.1-9.7 13 1.22 0.46-3.24 .679 1.95 0.67-5.63 .217
>Q75 >9.7 13 1.35 0.49-3.68 .550 1.34 0.48-3.72 .568
Abbreviations: CI ¼ conﬁdence interval; HMGB1 ¼ high-mobility group box 1; HR ¼ hazard ratio; IL ¼ interleukin; MMP ¼ matrix metalloproteinase; PFS ¼ progression-free survival; Q ¼ quartile.
aHR adjusted for age.
bHR adjusted for age, menopause status, hormone receptor status, presence of visceral metastasis, number of metastatic lesions, and extent of disease.
cStatistically signiﬁcant.
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Abstract
Background: Angiopoietin growth factors (Angs) regulate angiogenesis and lymphangiogenesis by binding to the
endothelial Tie2 receptor. Ang2 expression is elevated in tissue hypoxia and inflammation, which also induce cleavage
of the extracellular domain of the orphan Tie1 receptor. Here we have examined if the concentrations of Ang2 and the
soluble extracellular domain of Tie1 in patient plasma are associated with the prognosis of patients with metastatic
breast cancer.
Methods: Plasma Tie1 and Ang2 levels were measured in metastatic breast cancer patients treated in a phase II trial
with a taxane-bevacizumab combination chemotherapy in the first-line treatment setting. They were analyzed before
treatment, after 6 weeks and 6months of treatment, and at the final study visit. Using the median concentrations as
cutoffs, Tie1 and Ang2 data were dichotomized into low and high concentration groups. Additionally, we analyzed
Tie1 concentrations in plasma from 10 healthy women participating in a breast cancer primary prevention study.
Results: Plasma samples were available from 58 (89%) of the 65 patients treated in the trial. The baseline Tie1 levels of
the healthy controls were significantly lower than those of the metastatic patients (p < 0.001). The overall survival of
the patients with a high baseline Tie1 level was significantly shorter (multivariate HR 3.07, 95% CI 1.39–6.79, p = 0.005).
Additionally, the progression-free survival was shorter for patients with a high baseline Tie1 level (multivariate HR 3.78,
95% CI 1.57–9.09, p = 0.003). In contrast, the baseline Ang2 levels had no prognostic impact in a multivariate Cox
proportional hazard regression analysis. The combined analysis of baseline Tie1 and Ang2 levels revealed that patients
with both high Tie1 and high Ang2 baseline levels had a significantly shorter overall survival than the patients with low
baseline levels of both markers (multivariate HR for overall survival 4.32, 95% CI 1.44–12.94, p = 0.009).
Conclusions: This is the first study to demonstrate the prognostic value of baseline Tie1 plasma concentration in
patients with metastatic breast cancer. Combined with the results of the Ang2 analyses, the patients with both high
Tie1 and Ang2 levels before treatment had the poorest survival.
Trial registration: Clinicaltrials.gov: NCT00979641, registration date 19-DEC-2008. The regional Ethics Committee:
R08142M, registration date 18-NOV-2008.
Keywords: Tie1, Angiopoietin-2, Angiogenesis, Metastatic breast cancer, Prognostic marker
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Background
Several drugs targeting the vascular endothelial growth
factor (VEGF) and VEGF receptors (VEGFR) are currently
used as treatment of various cancer types in clinics [1].
VEGF targeting antibodies alleviate age-related macular
degeneration, but in cancer therapy, they provide only
limited benefits. For this reason, a significant interest has
emerged in the targeting of the more recently character-
ized Ang/Tie endothelial growth factor system, which has
essential functions in embryonic development, the regen-
eration of the mature vasculature, tissue inflammation
and tumor angiogenesis [2–6]. Angiopoietin growth fac-
tors (Ang1–4) bind to the Tie2 receptor. The homologous
Tie1 protein does not bind angiopoietins directly, al-
though it participates in the Ang-Tie2 signal transduction
complex [2, 6–8].
Ang1 stabilizes the vasculature after angiogenesis and
is a more potent Tie2 agonist than Ang2, which can act
as an agonist or antagonist of the Tie2 receptor, depend-
ing on a number of other factors [9–11]. In normal
homeostasis, Ang2 levels are low, but the Ang2/Ang1
ratio is increased in inflamed tissues, e.g. in sepsis and in
malignancies, including breast cancer [12, 13]. High Ang2
levels are associated with poor patient survival in multiple
malignancies, breast cancer among others [14–19]. Some
of the Ang/Tie system targeted antibodies have already
been evaluated in clinical trials, but so far, the effects of
anti-Ang2 monotherapy have been modest [20–22]. A
better understanding of Ang function is clearly needed for
the rational development of effective Ang-pathway tar-
geted therapies. Although Tie1 expression in endothelial
cells is increased in tumor vessels and deletion of the Tie1
gene in tumor-bearing mice decreased tumor growth and
angiogenesis in preclinical experiments [4, 23], the signifi-
cance of Tie1 in tumor progression is also unclear. Tie1
ectodomain cleavage occurs in vivo in association with
acute [11] and chronic inflammation [24], leading to in-
creased concentration of the soluble extracellular domain
in the serum of patients with severe viral infections [11].
Furthermore, Tie1 deletion in a murine metastasis model
tightened endothelial barrier and therefore, reduced meta-
static foci [25].
In the present study, we investigated the prognostic
value of the circulating levels of Tie1 and Ang2 in pa-
tients who received first-line taxane-bevacizumab com-
bination -chemotherapy combination for the treatment
of metastatic breast cancer. Additionally, we explored if
a combined analysis of Tie1 and Ang2 levels would help
to identify the patients with poor prognosis in need of
novel treatment approaches.
Methods
All together 65 patients with histologically verified
HER2-negative advanced breast cancer were enrolled
into the single-arm, prospective, phase 2 study in three
Finnish university cancer clinics between May 2009 and
October 2013 (NCT00979641). The method of patient
recruitment, the study design and the clinical trial results
were previously published [26]. Briefly, patients included
in the study received a taxane (paclitaxel 90mg/m2 on
days 1, 8 and 15 or docetaxel 50mg/m2 on days 1 and 15)
with bevacizumab (10mg/kg on days 1 and 15) on a treat-
ment cycle of 4 weeks as the first-line chemotherapy for
metastatic breast cancer. Docetaxel was given to 32 pa-
tients and 33 patients received paclitaxel.
Bevacizumab 15mg/kg every three weeks was continued
as maintenance therapy for those patients with non-pro-
gressive disease after taxane discontinuation. In addition
to bevacizumab, patients with hormone receptor-positive
disease received endocrine therapy. Furthermore, bevaci-
zumab could be continued with second-line chemother-
apy. All patients provided written informed consent and
the regional Ethics Committee approved the study proto-
col (R08142M).
Blood samples were obtained from the patients during
treatment. EDTA samples for plasma analysis were
obtained at the baseline, every 6 weeks during the bev-
acizumab-taxane combination, at the discontinuation of
taxane treatment, during the bevacizumab maintenance
therapy, first every three weeks for the first two months
and thereafter every 12 weeks, and at the final study visit.
Healthy control samples were obtained from 10 women
participating in a mammography screening program at
the Hatanpää Breast Clinic in Tampere. These women vol-
untarily participated in a breast cancer primary prevention
study currently in progress at the University of Tampere
and, as a part of the accepted protocol, blood samples
were drawn for scientific purposes. All participants gave
their written informed consent and the regional Ethics
Committee approved the study (R15023).
Measurement of plasma Tie1 and Ang2 levels by ELISA
assay
Tie1 and Ang2 levels were measured in patient plasma
samples using a modified hTie1 and hAng2 ELISA
protocol (R&D Systems Europe Ltd., Abingdon, UK,
Duoset, DY5907 and DY623, respectively). Briefly, a 96-
well plate was coated with 100 μl of diluted capture anti-
body (1:180 in PBS) per well and incubated o/n at room
temperature (RT). The wells were washed three times
with PBS-0.05% Tween 20, followed by blocking with
300 μl/well of the Reagent Diluent 2 (R&D, Y995) for
1.5 h at RT on an orbital shaker for Tie1 or with 250 μl/
well of 1% BSA in PBS for 1 h at RT for Ang2. The wells
were washed 3 x with PBS-0.05% Tween 20. For Tie1,
50 μl/well of the reagent RD1–89 (R&D, DILUENT08)
was added. Standards and samples diluted in the RD5–
17 reagent (R&D, RD508) were pipetted into the wells at
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100 μl/well and incubated for 2 h at RT on an orbital
shaker. For Ang2, 100 μl of a sample or standards in di-
luent reagent (1% BSA in PBS) was added to the wells,
and incubated for 2 h at RT. The wells were washed 3 x
with PBS-0.05% Tween 20 and 100 μl of detection anti-
body diluted 1:180 in diluent reagent (Reagent Diluent 2,
R&D, for Tie1, 1% BSA in PBS for Ang2) was added and
incubated for 2 h at RT on an orbital shaker for Tie1
and for 1.5 h at RT for Ang2. After washing 3 x with
PBS-0.05% Tween 20, 100 ul of SA-HRP solution per
well (in Reagent Diluent 2 for Tie1, and in 1% BSA in
PBS for Ang2) was added before incubating for 20 min
at RT. The wells were washed 3 x with PBS-0.05% Tween
20. Then a mixture of Color Reagent A and Color Reagent
B for Tie1 (R&D, DY999) and BioFX®TMB substrate solu-
tion for Ang2 (SurModics, Eden Prairie, MN, USA) was
added at 100 μl/well and incubated for 20min in the dark
at RT. Stop solution (50 μl of 1M HCl) was added, and
the absorbance of each well was measured within 20–30
min using a microplate reader with the filter set to 450
nm and the correction wavelength set to 540 nm. The
interassay coefficients of variation for Tie1 and Ang2 were
11.4 and 7.1%, respectively.
Patient characteristics
The patient population and the analyzed plasma samples
were identical to our previous paper focusing on plasma
interleukin-8 levels as a prognostic marker [27]. At the
baseline, plasma samples were available from 53 patients
(82%). Overall, plasma samples were available from 58
(89%) of the 65 patients treated in the study. Key charac-
teristics of the study population and the main efficacy
outcomes are presented in Table 1. Plasma samples for
Tie1 and Ang2 were analyzed at four time points: at the
baseline, six weeks after the treatment initiation, six
months after the treatment initiation and at the final
visit. The number of patients that had plasma samples
analyzed and the reasons for exclusions are presented in
a flow chart (Fig. 1). Six weeks’ and six months’ samples
were available only for those patients that were still on
study treatment at that time point.
The median progression-free survival (PFS) and overall
survival (OS) were similar for patients treated with doce-
taxel or paclitaxel (PFS: p = 0.47, OS: p = 0.77). The median
OS for patients with triple-negative breast cancer was 17.9
months (95% CI 8.5–26.9). Furthermore, the median OS
for patients with hormone receptor positive metastatic
breast cancer was 45.0months (95% CI 30.2–51.3).
The mean age of the ten healthy controls was 57.8
years (range 54–67).
Statistical analysis
The statistical plan for the biomarker analysis was ex-
ploratory. Tie1 and Ang2 were dichotomized as low or
high for each patient using the median value as the cut-
off. Sensitivity, specificity and area under curve (AUC)
for plasma Tie1 concentration were determined using
receiver operator characteristic (ROC) analysis. Baseline
Tie1 or Ang2 levels as independent prognostic factors
(below/above median) were evaluated using Cox propor-
tional hazard regression analysis. Multivariate analysis
was performed using the Cox model, and it was adjusted
by age (continuous), menopausal status (yes/no), hormone
receptor status (negative/positive), presence of visceral
metastasis (yes/no), number of metastatic lesions (cut-off
of three metastatic lesions) and extent of the disease (cut-
off of three metastatic sites). The Mann-Whitney U test
Table 1 Baseline characteristics and the efficacy outcomes of
the plasma biomarker population compared to the overall study
population
Plasma biomarker
population (n = 58)
Overall study
population (n = 65)
Age, years
Median (range) 58 (32–75) 57 (32–75)
Menopausal status, n (%)
Pre-menopausal 9 (15.5) 10 (15.4)
Post-menopausal 49 (84.5) 55 (84.6)
History of early stage disease,
n (%)
52 (89.7) 57 (87.7)
Disease free interval, n (%)
≤ 24months 10 (19.2) 11 (19.3)
> 24 months 42 (80.8) 46 (80.7)
Hormone receptor status, n (%)
ER+ and/or PR+ 47 (81.0) 53 (81.5)
ER- and PR- 11 (19.0) 12 (18.5)
Number of metastatic lesions, n (%)
≤ 3 11 (19.0) 14 (21.5)
> 3 47 (81.0) 51 (78.5)
Extent of disease
< 3 sites 36 (62.1) 39 (60.0)
≥ 3 sites 22 (37.9) 26 (40.0)
Site of metastatic disease, n (%)
Visceral disease 46 (79.3) 53 (81.5)
Non-visceral disease 12 (20.7) 12 (18.5)
Median overall survival,
months (95% CI)
37.5 (25.4–49.6) 35.1 (22.2–50.3)
Median progression-free
survival, months (95% CI)
11.3 (8.3–14.4) 11.3 (9.7–16.0)
Response to treatment
Complete response/partial
response
38 (71.7) 40 (61.5)
Stable disease 13 (24.5) 15 (23.1)
Progressive disease 2 (3.8) 3 (4.6)
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was used to compare differences in the baseline Tie1 and
Ang2 levels between groups with different baseline char-
acteristics. The Wilcoxon signed rank test was used to
compare between baseline and week 6 plasma Tie1 and
Ang2 levels. P-values under 0.05 were considered statisti-
cally significant. Statistical analyses were performed using
SPSS version 23 statistical software package (SPSS Inc.,
Chicago, IL, USA).
Results
Tie1 and Ang2 plasma levels
For the study population, the median Tie1 level at base-
line was 21.0 ng/ml (95% CI 17.8–23.3, Fig. 2a), and the
median Ang2 level at baseline was 1.29 ng/ml (95% CI
1.03–1.52, Fig. 2b). The baseline Tie1 levels were signifi-
cantly lower in the healthy controls than in the meta-
static breast cancer patients (Fig. 2a). The median Tie1
level for healthy controls was 12.8 ng/ml (95% CI 10.4–
16.5, Fig. 2a). The most optimal cut-off value (16.0 ng/ml)
for plasma Tie1 concentration had a sensitivity of 77.4%,
but a specificity of only 30.0%, for distinguishing metastatic
breast cancer patients from healthy controls with an AUC
0.917 (95% CI 0.839–0.995, p < 0.001).
There were no statistically significant differences in
baseline Tie1 or Ang2 levels between groups with differ-
ent baseline characteristics, including menopausal status
(p = 0.09 for Tie1, p = 0.13 for Ang2), hormone receptor
status (p = 0.80 for Tie1, p = 0.14 for Ang2), number of
metastatic lesions (p = 0.69 for Tie1, p = 0.37 for Ang2)
or visceral disease (p = 0.92 for Tie1, p = 0.15 for Ang2).
Only the patients with more than three metastatic sites
had significantly higher baseline Tie1 levels than the pa-
tients with fewer metastatic sites (median Tie1 23.7 ng/ml,
95% CI 21.0–29.0 vs. 17.8 ng/ml, 95% CI 16.0–21.1, p =
0.002). Similarly, the patients with more than three
metastatic sites had significantly higher baseline Ang2
levels (median Ang2 1.08 ng/ml, 95% CI 0.66–1.36 vs.
1.54 ng/ml, 95% CI 1.23–2.29, p = 0.008).
Differences in Tie1 and Ang2 concentrations between
baseline and week six samples were analyzed to evaluate
the treatment effect. The median baseline Tie1 level was
21.0 ng/ml (95% CI 17.8–23.3), which was significantly
higher than the median Tie1 level at six weeks (15.4 ng/ml
[95% CI 14.1–17.1], p < 0.001, Fig. 2a). The median de-
crease in the Tie1 level between these two time points was
22.9% (95% CI 20.9–27.4). The median baseline Ang2
level was 1.29 ng/ml (95% CI 1.03–1.52) and the median
Ang2 level at six weeks was 0.62 ng/ml (95% CI 0.57–
0.84). The median decrease in the levels of Ang2 from the
baseline to six weeks, 47.0% (95% CI 34.5–52.9), was also
statistically significant (p < 0.001, Fig. 2b).
Effect of Tie1 or Ang2 levels on survival
Median progression-free survival was longer for patients
in the low baseline Tie1 level group than for the patients
in the high baseline Tie1 group (Fig. 3a, Table 2). No dif-
ference was observed in progression-free survival in rela-
tion to baseline Ang2 levels (Fig. 3b, Table 2).
The overall survival was significantly shorter for pa-
tients with a high baseline Tie1 concentration (Fig. 3c,
Table 3). Additionally, patients with high baseline Ang2
levels had shorter overall survival when analyzed by the
age-adjusted Cox hazard regression model (Table 3).
However, in a multivariate Cox model adjusted by age,
menopausal status, hormone receptor status, presence of
visceral metastases, number of metastatic lesions and ex-
tent of disease, a high baseline levels of Ang2 alone was not
a significant factor for poor prognosis (Fig. 3d, Table 3).
Effect of combined analysis of Tie1 and Ang2 levels on
survival
For progression-free survival, the combined analysis of
baseline Tie1 and Ang2 levels did not add any value
compared to the Tie1 analysis on its own (Fig. 4a, Table 2).
However, the combined analysis for high or low baseline
Fig. 1 Flow diagram of study patient plasma samples analyzed at
baseline, after six weeks’ treatment, after six months’ treatment and
at final visit. Final plasma samples were taken at the final study visit
and the reasons for discontinuation are presented in the chart
Tiainen et al. BMC Cancer          (2019) 19:732 Page 4 of 10
Tie1 and Ang2 levels was more effective in the selection of
patients with better overall survival (Fig. 4b, Table 3). The
median overall survival for patients with low baseline levels
of both Tie1 and Ang2 was 46.8months (95% CI 23.8–
79.8). In contrast, the median overall survival for patients
with high baseline levels of both Tie1 and Ang2 was only
21.5months (95% CI 8.8–34.7).
Changes in plasma tie 1 or Ang2 levels and prognosis
The median decline in Ang2 levels between baseline and
week six was 47.0%. The patients with Ang2 level de-
cline higher than the median value had significantly
worse prognoses. Multivariate Hazard Ratio (HR) for
overall survival was 4.53 (95% CI 1.82–11.27, p = 0.001).
In contrast, a high Tie1 decline during the first six weeks
of treatment was not prognostic. The median Tie1 decline
during this time period was 22.9%. The patients had simi-
lar survival whether they had Tie1 decline higher or lower
than median value between baseline and week six (multi-
variate HR for overall survival 1.04, 95% CI 0.46–2.33, p =
0.921).
Only seven patients, i.e. 14% of the patients whose
final samples were available, had at least 30% increased
Tie1 plasma concentrations at their final visits, when
compared to the previous measurements in each patient.
For all these patients, the reason for study discontinu-
ation was disease progression. Nevertheless, these pa-
tients had a similar overall survival as the patients with
stable or declining Tie1 levels (multivariate HR 2.30,
95% CI 0.90–5.85, p = 0.078). At least 30% increased
Ang2 concentration was observed in 24 patients at their
final visits (48% of the patients whose final samples were
available). The overall survival of these patients was
significantly worse than in the patients with stable or
declining Ang2 values (multivariate HR 2.17, 95% CI
1.09–4.31, p = 0.027).
Discussion
The baseline concentration of the extracellular fragment
of the orphan Tie1 receptor in bevacizumab plus tax-
ane-treated breast carcinoma patients was found to be
associated with both their overall survival and their pro-
gression-free survival (multivariate HR for overall sur-
vival 3.07, 95% CI 1.39–6.79, p = 0.005, multivariate HR
for progression-free survival 3.78, 95% CI 1.57–9.09, p =
0.003). Previous studies have reported strong Tie1 ex-
pression in malignant tissues, including breast cancer
[23, 28–30]. In gastric cancer, patients with Tie1 expres-
sion in their formalin-embedded tissue specimens had
worse survival than the patients without Tie1 expression
[30]. However, the prognostic value of circulating Tie1
levels has not been previously studied in malignant
diseases.
Metastatic breast cancer patients had significantly higher
baseline plasma Tie1 levels than the healthy controls (p <
0.001). However, circulating Ang2 levels are known to be
higher on cancer patients [31] and therefore, we did not
analyze plasma Ang2 levels on healthy controls.
Previous studies have indicated that the high concen-
tration of the circulating Tie2 ligand Ang2 is associated
with poor patient prognosis [16–19], and Ang2/Tie sys-
tem-targeting antibodies and tyrosine kinase inhibitors
are currently in clinical trials, including in those focused
on breast cancer [20, 22]. In our study however, the
a b
Fig. 2 Plasma Tie1 and Ang2 levels. a Tie1 levels of healthy controls compared to the Tie1 levels of patients with metastatic breast cancer at
baseline and at week six after treatment. b Ang2 levels of patients with metastatic breast cancer at baseline and at week six after treatment.
mBCa =metastatic breast cancer
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baseline Ang2 level was not a significant prognostic
marker for either progression-free survival or overall
survival. However, it has been reported that an increase
in serum Ang2 concentration during anti-VEGF treat-
ment contributes to acquired drug resistance [32]. In
our study, for the final plasma samples, a cut-off point
of 30% was chosen because it was considered as a clinic-
ally meaningful change. In half of the patients of our
study, the Ang2 plasma concentration was the highest at
their final visit, and these patients had poor overall sur-
vival (multivariate HR 2.17, 95% CI 1.09–4.31, p =
0.027), perhaps because of increased acquired tumor
chemoresistance [32].
Targeting of both Tie1 and Ang2 would be an interest-
ing trial approach in the future for the treatment of
breast cancer. In our study, high baseline Tie1 and Ang2
concentrations were associated with median overall sur-
vival of only 21.5 months (95% CI 8.8–34.7). This was
significantly less than in the patients who had low
plasma concentrations of both Tie1 and Ang2 (46.8
months, 95% CI 23.8–79.8, p = 0.009). Interestingly,
additive inhibition of tumor growth was observed when
angiopoietin activity was blocked in Tie1-deficient mice
[4]. The possible synergistic effect of dual inhibition of
Tie1 and Ang2 might be due to Ang2 influencing earlier
phase in tumor growth than Tie1 [25].
a b
c d
Fig. 3 Progression-free survivals and overall survivals grouped by baseline plasma Tie1 or Ang2 levels a Progression-free survival for patients with
high or low plasma Tie1 at baseline. b Progression-free survival for patients with high or low plasma Ang2 at baseline. c Overall survival for patients
with high or low plasma Tie1 at baseline. d Overall survival for patients with high or low plasma Ang2 at baseline. Cox regression analysis adjusted by
age, menopausal status, hormone receptor status, presence of visceral metastasis, number of metastatic lesions and extent of the disease
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According to our study, high baseline Tie1 level ap-
pears to be the best way to find the patients with short
progression-free survival. In fact, the baseline Ang2 level
and the combined analysis of Tie1 and Ang2 baseline
levels do not provide additional information in terms of
progression-free survival compared to Tie1 levels alone.
The Tie1 levels in healthy individuals were lower than
in patients with metastatic disease before chemotherapy.
During the bevacizumab and taxane therapy, the Tie1
levels declined substantially. However, the decline in
Tie1 concentration was not related to the patient sur-
vival. Only the decrease in Ang2 concentration was
prognostic, with a multivariate hazard ratio of 4.53 (95%
CI 1.82–11.27, p = 0.001).
Bevacizumab has been investigated in several phase III
trials as treatment of metastatic breast cancer. However,
none of the trials has proven overall survival advantage for
patients treated with bevacizumab [33]. Therefore, bevaci-
zumab in only recommended for the treatment of highly
selected patients with a need of a tumor response more
commonly achieved with bevacizumab [33, 34]. All of our
study patients were treated with bevacizumab. However,
the effect of bevacizumab to Tie1 levels remains unex-
plored in this study. However, the main finding of our study
was the prognostic value of pretreatment circulating Tie1
levels and bevacizumab did not confound this analysis.
Although, to our knowledge, this is the first study to
evaluate the prognostic role of plasma Tie1 levels in
Table 3 Cox regression analysis for overall survival
N n Overall survival
Age-adjusted HR [95% CI] p value multivariate HRa [95% CI] p value
Baseline Tie1
Low 27 15 1 1
High 26 24 2.82 [1.41–5.66] 0.003 3.07 [1.39–6.79] 0.005
Baseline Ang2
Low 27 15 1 1
High 26 24 2.33 [1.20–4.54] 0.012 1.58 [0.72–3.46] 0.246
Combined analysis
Tie1 and Ang2 low 18 8 1 1
Tie1 low, Ang2 high 9 7 2.21 [0.78–6.25] 0.135 1.34 [0.42–4.22] 0.612
Tie1 high, Ang2 low 9 7 2.77 [0.95–8.09] 0.062 2.73 [0.88–8.46] 0.080
Tie1 and Ang2 high 17 17 4.79 [1.93–11.90] 0.001 4.32 [1.44–12.94] 0.009
Abbreviations: N number of patients, n number of events, HR hazard ratio, CI confidence interval. Statistically significant results are highlighted in bold
aHazard ratio adjusted by age, menopausal status, hormone receptor status, presence of visceral metastasis, number of metastatic lesions and extent of
the disease
Table 2 Cox regression analysis for progression-free survival
N n Progression-free survival
Age-adjusted HR [95% CI] p value multivariate HRa [95% CI] p value
Baseline Tie1
Low 27 16 1 1
High 26 15 2.13 [1.02–4.46] 0.043 3.78 [1.57–9.09] 0.003
Baseline Ang2
Low 27 14 1 1
High 26 17 1.21 [0.59–2.47] 0.597 1.22 [0.54–2.77] 0.620
Combined analysis
Tie1 and Ang2 low 18 9 1 1
Tie1 low, Ang2 high 9 7 1.27 [0.47–3.43] 0.632 1.16 [0.39–3.39] 0.783
Tie1 high, Ang2 low 9 5 3.86 [1.18–12.57] 0.025 4.45 [1.25–15.79] 0.021
Tie1 and Ang2 high 17 10 2.02 [0.80–5.07] 0.133 3.88 [1.25–12.06] 0.019
Abbreviations: N number of patients, n number of events, HR hazard ratio, CI confidence interval. Statistically significant results are highlighted in bold
aHazard ratio adjusted by age, menopausal status, hormone receptor status, presence of visceral metastasis, number of metastatic lesions and extent of
the disease
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breast cancer patients, the study has some limitations.
Our study is a single-arm study with no control arm,
and thus, the impact of bevacizumab on patient survival
and the Tie1 and Ang2 concentrations during therapy
cannot be evaluated. Furthermore, the study population
size is limited, and therefore, our findings must be vali-
dated in a larger patient cohort.
Although immunohistochemical staining of Tie1 in
tumor samples is associated with poor patient survival
in breast cancer [35], the availability of tissue samples
from metastatic tumors varies depending on tumor loca-
tion, tumor load and the clinical need to accept the
complication risks and discomfort related to needle aspi-
rations. Circulating prognostic markers are more useful,
and thus, high baseline circulating Tie1 and Ang2 levels
before and during the treatment can be an additional
way to identify patients with poor prognoses in this patient
population, regardless of standard clinical characteristics.
Most such patients do not derive a long-term benefit from
the current chemotherapy treatment options. Novel treat-
ment approaches, for example immunotherapies, are enter-
ing the clinics for many malignant diseases, and patients
with poor prognoses should increasingly be referred to clin-
ical trials. In preclinical studies, anti-angiogenic drugs and
immune checkpoint inhibitors have demonstrated synergis-
tic benefits [36], and they should be further studied in pro-
spective clinical trials.
Conclusions
High baseline plasma Tie1 level is a promising prognos-
tic marker for both poor progression-free survival and
for poor overall survival in metastatic breast patients
treated with bevacizumab-taxane combination. The pre-
dictive value of circulating Tie1 levels should be evalu-
ated in prospective clinical trials.
Abbreviations
Ang: Angiopoietin; Ang2: Angiopoietin-2; CI: Confidence interval; HR: Hazard
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Fig. 4 Progression-free survival and overall survival grouped by
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levels. a Progression-free survival and b Overall survival for patients with
high or low baseline Tie1 and Ang2. Cox regression analysis adjusted by
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value between Tie1 low, Ang2 low and Tie1 low, Ang2 high, bp-value
between Tie1 low, Ang2 low and Tie1 high, Ang2 low, cp-value between
Tie1 low, Ang2 low and Tie1 high, Ang2 high
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Abstract
Cancer antigen 15–3 (CA15-3) is widely utilized for monitoring metastatic breast cancer
(BC). However, its utility for early detection of breast cancer is severely limited due to poor
clinical sensitivity and specificity. The glycosylation of CA15-3 is known to be affected by BC,
and therefore it might offer a way to construct CA15-3 glycovariant assays with improved
cancer specificity. To this end, we performed lectin-based glycoprofiling of BC-associated
CA15-3. CA15-3 expressed by a BC cell line was immobilized on microtitration wells using an
anti-CA15-3 antibody. The glycosylation of the immobilized CA15-3 was then detected by
using lectins coated onto europium (III)-doped nanoparticles (Eu+3-NPs) and measuring the
time-resolved fluorescence of Eu. Out of multiple lectin-Eu+3-NP preparations, wheat germ
agglutinin (WGA) and macrophage galactose-type lectin (MGL) -Eu3+-NPs bound to the BC
cell line-dericed CA15-3 glycovariants (CA15-3Lectin). To evaluate the clinical performance of
these two lectin-based assays, plasma samples frommetastatic BC patients (n = 53) and
healthy age-matched women (n = 20).Plasma CA15-3Lectin measurements better distin-
guished metastatic BC patients from healthy controls than the conventional CA15-3 immuno-
assay. At 90% specificity, the clinical sensitivity of the assays was 66.0, 67.9 and 81.1% for
the conventional CA15-3, CA15-3MGL and CA15-3WGA assays, respectively. Baseline CA15-
3MGL and CA15-3WGA were correlated to conventional baseline CA15-3 levels (r = 0.68,
p0.001, r = 0.90, p!0.001, respectively). However, very low baseline CA15-3MGL levels 5
U/mL were common in this metastatic breast cancer patient population.In conclusion, the
new CA15-3Lectin concept could considerably improve the clinical sensitivity of BC detection
compared to the conventional CA15-3 immunoassays and should be validated further on a
larger series of subjects with different cancer subtypes and stages.
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Introduction
Breast cancer (BC) is the most common cancer type and the second leading cause of cancer death
in women worldwide [1]. Cancer antigen 15–3 (CA15-3 also known as MUC1) is shed from
tumor cells and is a well-known serological marker for monitoring the clinical course of BC
patients. A persistent increase in circulating concentration of this marker may suggest an inade-
quate response to cancer therapy in patients with metastatic BC. However, it has poor sensitivity,
especially at early stages of the disease.[2] CA15-3 can also be elevated in healthy individuals and
in patients with benign conditions, and it lacks the specificity needed for cancer screening, diag-
nosis, staging, and/or sole use in monitoring of post-therapy recurrence [3]. A study on retrospec-
tive samples found the sensitivity of the commercial Elecsys CA 15–3 immunoassay to be 7, 11,
39 and 78% on stage I, II, III and IV BC patients, respectively [4]. Recently an ultrasensitive, sim-
ple and reliable electrochemical immunosensor was developed to detect the lowest alteration of
CA 15–3 and CA125, biomarker of breast and ovarian cancer patients respectively [5,6].
For monitoring metastatic breast cancer, international recommendations for the treatment
of metastatic BC only recommend the monitoring of CA15-3 levels for patients with non-
evaluable metastases, mainly bone-dominant disease [7,8]. Transient increases in plasma
CA15-3 levels are possible without tumor progression [9]. This phenomenon is observed espe-
cially in the beginning of chemotherapy due to necrosis and apoptosis of tumor cells. Addi-
tionally, consensus about clinically meaningful increase in plasma CA15-3 levels to predict
disease progression or clinically meaningful decrease to reflect a treatment response do not
exist today. Nevertheless, in general plasma CA15-3 levels correlate with the response to che-
motherapy in patients with metastatic breast cancer [10,11].
Protein glycosylation plays an important role in a wide variety of normal and disease-
related biological processes. The phenomenon of aberrant glycosylation associated with malig-
nant transformation, tumor progression and metastasis is well documented [12] and occurs in
essentially all types of human cancers. A large number of altered glycosyl epitopes are classified
as tumor-associated carbohydrate antigens. [13,14] Among these, the aberrant expression of
Tn and sialyl-Tn antigens, L-fucose and terminal N-acetylglucosamine (GlcNAc) have been
widely detected in breast cancers [15,16]. Especially, abnormal O-glycans, such as Tn antigen,
are found in over 90% of breast cancers[17]. Overall, changes in glycosylation result in the pro-
duction of various cancer-associated glycoproteins with cancer-associated glycoforms, which
are antigenically distinct from the corresponding molecules of the normal tissue. Taking into
account these modifications, the specificity of diagnostic cancer markers can be expected to be
improved by using the aberrant glycoforms as targets.
CA15-3 is upregulated and aberrantly glycosylated in breast and other carcinomas [18].The
CA15-3, derived from a large transmembrane protein Mucin 1 with molecular weight ranging
from 500 to 1000 kDa, contains multiple O- and N-linked glycosylation sites. The O-glycans of
CA15-3 produced by the normal breast tissue are core 2-based and can be complex, while the
O-glycans added to the BC mucin are mainly core 1-based [19]. The resulting truncated gly-
cans carried on BC-associated CA15-3 include Tn and T antigens and their sialylated forms
[14]. CA15-3 purified from the culture medium of human BC YMB-S cells contains 3-O-sul-
fated or 3-sialylated core 1 and extended core 1 glycans. [20]
Glycans participate in early stages of tumorigenesis [12] and it has been reported that the
expression level of an enzyme responsible for mucin-type glycosylation, N-acetylgalactosami-
nyltransferase-14, declines with breast cancer progression [21]. Thus, it is reasonable to
assume that the cancerous glycovariants of glycoprotein tumor markers appear early and differ
throughout the course of the disease. Therefore, glycovariant markers may be useful for early
detection as well as for monitoring cancer progression.
Breast cancer specific CA15-3 lectin assay
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Various lectins, members of a carbohydrate binding protein family, have previously been
used to investigate the differences in glycosylation between soluble glycoproteins expressed by
cancerous and benign tissues. A recent study described the use of a 3-sulfated core 1 -specific
galectin-4 (Gal-4) to establish an assay exhibiting superior clinical performance compared to
the conventional CA15-3 immunoassay for BC detection [22]. Also, C-type lectin receptors
(CLR) such as macrophage galactose-type lectin (MGL) have been demonstrated to show
increased binding to CA15-3 from lysates of colon cancer tissue compared to the healthy lysed
colon tissues of the same patients [23]. The Lens culinaris agglutinin, a lectin found in lentil, in
turn binds specifically to hepatocellular carcinoma -associated glycovariant of ċ-fetoprotein
(AFP) and is the only lectin used in a commercial application to detect a biomarker glycovar-
iant [24]. While showing these promising binding specificities, lectins unfortunately tend to
have weak binding affinity, which apparently limits their exploitation in practical assay
applications.
We previously reported a novel lectin-based approach for the detection of cancer-associated
glycosylation of CA125, a well-known mucin 16 -derived cancer marker used e.g. for monitor-
ing of epithelial ovarian cancer. The approach, relying on the use of highly fluorescent euro-
pium(III)-doped nanoparticles (Eu+3-NPs) coated with the lectin MGL, enabled highly
sensitive detection of CA125 produced by ovarian cancer cell line OVCAR-3. In the clinical
evaluation, the resulting optimized assay (CA125MGL) showed good discrimination between
the samples of epithelial ovarian cancer patients and those with endometriosis, a condition
that has decisively hampered the use of CA125 for early detection/screening of ovarian cancer.
[25] In addition, we found that the new assay could alarm clinicians much earlier (4–6
months) than the conventional CA125 assay about disease relapse. These results motivated us
to explore possibilities of the lectin nanoparticle assay concept for detecting the altered glyco-
sylation of CA15-3 in the blood streams of BC patients.
In the present work, we utilized the lectin-Eu+3-NP approach for the glycoprofiling of
CA15-3 with a panel of 28 lectins in order to identify lectins recognizing BC related changes in
carbohydrate structures of CA15-3. The discovered promising lectins were then validated with
plasma from patients with metastatic BC and healthy female controls. Additionally, we
explored new CA15-3lectin assays in monitoring response of metastatic breast cancer.
Materials andmethods
Clinical samples
Plasma samples from 53 metastatic breast cancer patients were analyzed. These patients partic-
ipated in a first-line chemotherapy trial for metastatic breast cancer (NCT00979641). The sam-
ples were analyzed at baseline, after six weeks of chemotherapy treatment, after six months of
study treatment and at the final study visit. The trial design and the patient demographics have
been published previously [26]. In brief, the patients with metastatic HER2-negative BC were
enrolled into the trial, if they had not received previous chemotherapy for the advanced dis-
ease. The mean age of the study patients was 58 years (range 32–75). Most of the patients had
hormone receptor positive disease (81%) and visceral metastases (79%). The median time
between six-month sample and the final plasma sample was 11.8 months (inter quartile range
3.5.-18.9 months). The Ethics Committee of Tampere University Hospital approved the study
protocol (R08142M). Clinically meaningful change in CA15-3 levels was defined as 30% simi-
larly as the partial response criterion in the response evaluation criteria in solid tumors [27].
The definition of clinically meaningful change in circulating tumor markers varies around 20–
40% in previous studies [10,28]. Disease progression was defined as investigator-assessed
radiological progression according to the RECIST criteria [27].
Breast cancer specific CA15-3 lectin assay
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Control plasma samples were obtained from 20 healthy women participating in a mam-
mography-screening program in Tampere City Breast Clinic. These women voluntarily took
part in a breast cancer primary prevention study currently in progress at University of Tam-
pere and as a part of the study, plasma samples were drawn for scientific purposes. The mean
age of these healthy controls was 56 years (range 54–67). All participants gave written
informed consent (Ethics approval R15023).
Reagents
CA15-3 isolated from the breast cancer cell line ZR-75-1 (ATCC CRL-1500) (BC-CA15-3),
two monoclonal anti-CA15-3 antibodies; Ma552 and Ma695, that specifically recognize a
PDTRPAPG region of the protein core and sialylated carbohydrate epitope expressed on the
CA15-3 antigen respectively, were provided by Fujirebio Diagnostics (Go¨teborg, Sweden).
Streptavidin-coated yellow 96-well plates, wash buffer and red assay buffer were purchased
from Kaivogen (Turku, Finland). Europium(III)-doped Fluoro-Max polystyrene nanoparticles
(97 nm in diameter) (Eu+3-NP) were acquired from Seradyn (Indianapolis, IN, USA). A panel
of plant lectins with different glycan binding specificities (Table A in S1 Dataset) was obtained
from Vector laboratories (Burlingame, CA, USA). The recombinant human lectins were pur-
chased from R&D Systems (Abingdon, United Kingdom).
Preparation of lectin-Eu3+-NPs
The use of Eu+3-NPs has been described before [29]. The coating of lectins on Eu+3-NPs was
performed essentially as described before [30]. The buffer used for storage of the lectin coated
Eu+3-NPs was 10 mM Tris-HCl, pH 7.8, supplemented with 0.1% BSA and 0.01% sodium
azide at +4˚C, covered from light. The particles were thoroughly vortexed and sonicated before
every use to disperse aggregates.
Labelling of antibodies with biotin
Both solid-phase monoclonal antibodies (Ma552 and Ma695 mAb) were biotinylated with
40-fold molar excess of biotin isothiocyanate, for 4 h at room temperature (RT). The labelled
antibodies were separated from the unconjugated biotin by using NAP-5 and NAP-10 gel-fil-
tration columns (GE Healthcare, Schenectady, NY, USA) by using 50 mM Tris–HCl (pH
7.75), containing 150 mMNaCl and 0.5 g/L NaN3. The labelled antibodies were stabilized
with 1 g/L BSA (Bioreba, Nyon, Switzerland) and stored at +4˚C. [31]
In-house CA15-3 Lectin-NP assay
The assay principle is represented in Fig 1. Biotinylated Ma552 or Ma695 mAb (100 ng/30 μl/
well) in buffer solution was incubated for 1 h at RT to immobilize them on streptavidin-coated
yellow low-fluorescence microtiter wells. The wells were washed two times with wash buffer
and 25 μl of CA15-3 standard/sample (diluted 1:40 in buffer) was added and incubated for 1 h
at RT with slow shaking. The immobilized BC-CA15-3 was detected by lectin-Eu3+-NPs as a
tracer by using time-resolved fluorescence (TRF). Ten million lectin Eu+3 -NPs per well in
25 μl of assay buffer containing additional 6 mM CaCl2 was added. The wells were incubated
for two hours at RT in shaking and washed six times. To detect the lectin-Eu3+-NPs bound to
BC-CA15-3, the TRF of Eu (ĕex: 340 nm; ĕem: 615 nm) was measured for 400 μs after a 400 μs
delay using Victor3V 1420 Multilabel counter (Wallac, Turku, Finland).
Breast cancer specific CA15-3 lectin assay
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Conventional CA15-3 immunoassay
CA15-3 concentrations were analysed in plasma samples with a CA15-3 enzyme immunoassay
(Fujirebio Diagnostics Inc., Malvern, PA, USA) according to manufacturer’s instructions.
Statistical analysis
Receiver operating characteristics (ROC) were determined and compared, and the areas under
the curve (AUC) values calculated using R version 3.3. [32] with the pROC package [33]. The
measured concentrations of each assay (Table B in S1 Dataset) were used as the classifier. The
comparison of ROCs was done using the bootstrap method provided in the pROC package. Due
to the nonparametric distribution of the CA15-3 levels, medians with the interquartile range
(IQR) of the median were reported. CA15-3 levels of healthy controls were compared to CA15-3
levels of metastatic BC patients using the MannWhitney U-test. Wilcoxon Rank test was used
when comparing baseline and week six CA15-3 levels in relation to the treatment response.
Spearman’s correlation was used to study the correlation between conventional CA15-3 levels
and CA15-3MGL or CA15-3WGA levels. TheWilcoxon signed-rank test and Spearman’s correla-
tion analyses were performed using SPSS version 23 statistical software package (SPSS Inc., Chi-
cago, IL, USA). P value of less than 0.05 was considered significant in all statistical tests.
Results
Screening of lectins for binding to BC-CA15-3
Altogether 28 lectins with various carbohydrate-binding specificities (Table A in S1 Dataset)
were tested to investigate the glycosylation patterns of the cancer cell line -derived BC-CA15-3
Fig 1. The principle of the conventional and in-house Eu+3-NP-based CA15-3 lectin assays. In the conventional CA15-3 immunoassay, the capture and tracer mAbs
bind to the protein and glycan epitopes of CA15-3. Alternatively, in the lectin assay, the CA15-3 is captured with mAbs and detected with lectins, which have been coated
on the surface of Eu3+-NPs. This method allows multivalent binding of the tracer to the glycan moieties of BC-CA15-3.
https://doi.org/10.1371/journal.pone.0219480.g001
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preparation. Fig 2 shows the signal-to-background ratios obtained with the corresponding lec-
tin-NP tracers using two different monoclonal antibodies (Ma552 and Ma695) for capturing
CA15-3. Four of the tested nanoparticle tracers; MGL- WGA-, Gal-4-, and DSL-NPs, recog-
nized BC-CA15-3 and the trend was similar for both capture antibodies. WGA exhibited high-
est signal-to-background ratio followed by MGL, Gal-4 and DSL (Fig 2). WGA- and
MGL-NPs displayed excellent recovery (93% to 98%) when BC-CA15-3 was spiked into pooled
healthy plasma samples whereas Gal-4- and DSL-NPs scarcely bound to BC-CA15-3 spiked
Fig 2. Lectin NPs binding to BC-associated CA15-3 from cell line ZR-75-1 (ATCC CRL-1500) using the lectin assay principle depicted in Fig 1.
The different lectin Eu+3-NPs used are shown on the x-axis and the y-axis displays the signal to background ratios using either biotinylated Ma695
(bioMa695) or biotinylated Ma552 (bioMa552) as the capture mAb.
https://doi.org/10.1371/journal.pone.0219480.g002
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similarly in plasma. We selected MGL (here after, CA15-3MGL) andWGA (CA15-3WGA) for
further evaluation using clinical samples.
Characteristics of CA15-3MGL CA15-3WGA assays
The analytical performance of the CA15-3MGL and CA15-3WGA assays were preliminarily
tested using a BC-CA15-3 in a range of concentrations from 1 to 1000 U/mL. Saturation
was not observed at the maximum used BC-CA15-3 of 1000 U/mL. The limit of detection,
which was set to be the concentration of BC-CA15-3 required for a signal equivalent to the
mean of blank calibrator (n = 20) plus three times the standard deviation, was less than 1 U/
mL. Linear in response was observed at a maximum of 125 U/mL (S1 Fig). No cross-reactiv-
ity was observed towards two other glycoprotein cancer markers, CA125 and prostate spe-
cific antigen (S2 Fig).
Plasma CA15-3, CA15-3MGL, and CA15-3WGA concentrations in the study
cohort
We next studied whether CA15-3 in the plasma of BC patients binds with MGL andWGA
similar to CA15-3 of a breast cancer cell line. The baseline EDTA plasma samples from 53
patients with metastatic BC and 20 healthy individuals were measured for CA15-3MGL and
CA15-3WGA and compared with the conventional CA15-3 immunoassay. To assess the diag-
nostic value of the tumor markers in metastatic BC, ROC curves were plotted and AUC was
calculated. The highest AUC value was achieved with CA15-3WGA (0.943) followed by CA15-
3MGL (0.852) while the conventional CA15-3 immunoassay yielded the lowest AUC of 0.827
(Fig 3). At 90% specificity the sensitivities of the assays were 81.1, 67.9 and 66.0% for the
CA15-3 WGA, CA15-3MGL and conventional CA15-3, respectively. The difference in the AUC
compared to the conventional assay was significant for CA15-3WGA (p = 0.007) but not for
CA15-3MGL (p = 0.655).
Metastatic BC patients had higher median baseline plasma levels of conventional CA15-3 as
well as CA15-3MGL and CA15-3WGA levels than the healthy controls (Table 1). Plasma samples
were available from 53 metastatic breast cancer patients. However, both baseline and week six
samples were available only from 41 patients. Median CA15-3 levels were lower at week six
than at baseline for all three CA15-3 assays in the entire study population (p-values 0.007,
<0.001,<0.001 for CA15-3, CA15-3MGL and CA15-3WGA, respectively). The decline in CA15-
3 levels was more pronounced in responding patients for all CA15-3 assays, especially CA15-
3MGL (Table 2). For all the three different CA15-3 assays, the responding patients had a signifi-
cant decrease in all assays of CA15-3 between baseline and week six (p-values 0.003,<0.001
and<0.001 for CA 15–3, CA15-3MGL and CA15-3WGA, respectively, Table 2).
Baseline conventional CA15-3 and CA15-3MGL levels correlated to each other (r = 0.68,
p<0.001, Fig 4A and 4B). However, almost half of the metastatic BC patients had very low
baseline CA15-3MGL levels ( 5 U/Ml, dashed vertical line in Fig 4B). A stronger correlation
was observed between conventional CA15-3 and CA15-3WGA (r = 0.90, p<0.001, Fig 4C
and 4D).
Additionally, we studied CA15-3 levels at disease progression (Fig 5).We had plasma sam-
ples available from 19 patients who had a disease progression at final study visit. A clinically
meaningful 30% increase in the final CA15-3 levels was observed in eight patients (42%) with
the conventional CA15-3, nine patients (47%) with the CA15-3MGL and six patients (32%)
with the CA15-3WGA. The patients with rising CA15-3 levels at disease progression were not
entirely the same individuals for the different CA15-3 assays. Specifically, five patients had
similar increase in final CA15-3MGL levels and CA15-3 levels. However, four patients with
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rising CA15-3MGL levels did not have an increase in conventional CA15-3 levels. Furthermore,
a similar increase was observed in four patients in final CA15-3WGA and conventional CA15-3
levels. However, two patients with rising CA15-3WGA levels did not have an increase in con-
ventional CA15-3 levels. Additionally, at least 30% decrease in the final CA15-3 levels at dis-
ease progression was observed in three patients (16%) with the conventional CA15-3, 3
patients (16%) with CA15-3MGL and five patients (26%) with CA15-3WGA.
Fig 3. ROC plot displaying the AUC of conventional CA15-3 (green), CA15-3MGL (purple) and CA15-3WGA (red) frommetastatic
breast cancer patients (n = 53) and healthy control (n = 20). The 95% confidence intervals of the ROCs are depicted as shaded areas and
displayed numerically in brackets. The color of shadings corresponds to the plotted lines and the overlap of conventional CA15-3 and CA15-
3MGL is dark green, the overlap of all assays is brown and the overlap of CA15-3MGL and CA15-3WGA is dark red.
https://doi.org/10.1371/journal.pone.0219480.g003
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Discussion
The results suggest that the glycovariant specific assays provide advantages over the conven-
tional CA15-3 immunoassay in monitoring of BC patients, and especially for the detection of
metastatic disease and its recurrence.
CA15-3 is a tumor marker commonly used for monitoring patients with advanced BC.
However, the currently employed sandwich immunoassays that target two protein epitopes
have moderate clinical sensitivity and specificity. [34] While it has been established that abnor-
mal glycosylation occurs in cancers and there has been investigations into multiple different
approaches for their detection [35] the efforts to further develop the CA15-3 based diagnostic
assay have been limited. The changes in glycosylation can lead to altered interactions of glyco-
proteins expressed by the tumor cell with different lectins. The development of glycoprofiling
assays for blood-derived products has been made difficult by the fact that cancer specific gly-
covariants may only exist in small amounts in blood and are therefore problematic to detect.
We have previously utilized the lectin-NP -based platform successfully to explore the
Table 1. CA15-3 levels by conventional CA15-3, CA15-3MGL, and CA15-3WGA assay for healthy controls and for metastatic BC patients at study baseline.
n Conventional CA15-3 CA15-3MGL CA15-3WGA
Healthy controls
Median CA15-3 U/mL (IQR) 20 13.3 (7.9–23.1) 2.0 (0.2–3.6) 1.6 (0.5–2.7)
Metastastic BC patients, Baseline
Median CA15-3 U/mL (IQR) 53 47.4 (18.9–99.9) 4.4 (1.3–16.5) 7.0 (3.1–41.0)
p-valuea <0.001 0.013 <0.001
Abbreviations: n = number of patients, IQR = interquartile range, BC = breast cancer
a Mann-Whitney U-test
https://doi.org/10.1371/journal.pone.0219480.t001
Table 2. CA15-3 levels with different assays depending on the best response to the chemotherapy treatment.
n Baseline
Median CA15-3, U/mL
(IQR)
Week 6
Median CA15-3 U/mL
(IQR)
Change, median %
(IQR)a
pb Declining CA15-3 levels, n
(%)c
Increase in CA15-3 levels, n
(%)d
Conventional CA15-3
PR 25 71.1 (29.4–228) 55.4 (28.8–103) -23.8 [-52.7-(-14.0)] 0.003 10 (40.0) 2 (8.0)
SD 14 19.2 (12.6–81.4) 25.8 (14.9–71.0) -0.4 (-37.1–60.5) 0.875 4 (28.6) 5 (35.7)
PD 2 24.1 (15.0–33.1) 29.2 (17.5–40.9) +20.1 (16.7–23.6) 0.180 0 0
CA15-3MGL
PR 25 6.3 (2.1–45.1) 2.4 (0.9–4.8) -75.0 [-86.4-(-41.0)] <0.001 18 (78.2) 3 (13.0)
SD 14 3.2 (1.0–5.4) 2.2 (0.8–3.6) -33.3 (-67.0–33.3) 0.036 7 (53.8) 4 (30.7)
PD 2 4.1 (3.2–5.0) 3.0 (2.2–3.9) -17.0 (-56.0–21.9) 0.655 1 (50.0) 0
CA15-3WGA
PR 25 13.2 (5.3–76.5) 8.0 (3.5–33.2) -27.2 [-55.9-(-19.4)] <0.001 12 (48.0) 2 (8.0)
SD 14 3.2 (2.4–8.7) 5.0 (2.7–8.2) +22.2 (-25.4–60.0) 0.851 3 (21.4) 7 (50.0)
PD 2 4.7 (2.3–7.0) 5.8 (2.3–9.3) +16.4 (0–32.9) 0.317 0 1 (50.0)
Abbreviations: n = number of patients, CI = confidence interval, PR = partial response, SD = stable disease, PD = progressive disease
a Change in CA15-3 levels from baseline to week six in percentiles, median
b Wilcoxon Rank Test
c Patients with 30% decline in CA15-3 levels from baseline to week six
d Patients with 30% increase in CA15-3 levels from baseline to week six
https://doi.org/10.1371/journal.pone.0219480.t002
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glycosylation of serum glycoprotein CA125 in ovarian cancer patients [25]. Two features in a
combination enhance the analytical sensitivity of lectin-NPs; 1) signal amplification provided
by the thousands of Eu chelates doped in a single particle and 2) the strengthening of the func-
tional affinity (avidity) of the lectins to their target glycostructure epitopes enabled by the
high-density immobilization of lectin on the particles.
The present study shows for the first time that a qualitative glycovariant assay to detect the
changes of the CA15-3 glycoprotein can improve on the diagnostic utility of current assays.
We developed an assay for sensitive and quantitative detection of aberrant glycosylation on
BC-CA15-3 providing enhanced preference for the cancer-associated glycovariant of the
tumor marker. An antibody recognizing the protein/glycan epitopes of CA15-3 was used for
Fig 4. Correlation of the conventional CA15-3 and CA15-3Lectin assays. A: Scatterplot of baseline conventional CA15-3 levels and baseline CA15-3MGL levels in
metastatic breast cancer patients. r = 0.68, p<0.001 B: Enlargement of the scatterplot for the patients with the lowest CA15-3 levels for both conventional CA15-3
and CA15-3MGL. Very low baseline CA15-3MGL levels< 5 U/mL were observed in 29 patients (44.6%), dashed vertical line at x-axis C: Scatterplot of baseline
conventional CA15-3 levels and baseline CA15-3WGA levels in metastatic breast cancer patients. r = 0.90, p<0.001.D: Enlargement of the scatterplot for the patients
with conventional CA15-3< 250 U/mL and CA15-3WGA< 130 U/mL, 85% of the study patients.
https://doi.org/10.1371/journal.pone.0219480.g004
Breast cancer specific CA15-3 lectin assay
PLOSONE | https://doi.org/10.1371/journal.pone.0219480 July 25, 2019 10 / 16
the immobilization and a panel of lectins was tested for the ability to bind the immobilized
CA15-3. The tested panel of 28 lectins covers a variety of common human glycans. Only two
of the tested lectin-Eu+3-NP preparations exhibited satisfactory binding to the BC-associated
CA15-3. Those lectins were WGA and recombinant human MGL. WGA and MGL recognize
the GlcNAc and GalNAc -containing epitopes respectively, frequently expressed on the surface
of cancer cells [36–38]. Using CA15-3WGA and CA15-3MGL assays, in the plasma of metastatic
BC patients are likely to serve as more cancer-specific than the conventional assay. In patients
with metastatic BC, the newly developed CA15-3WGA assay was able to detect 81% compared
to 66% with conventional CA15-3 assay when only 10% of controls were misdiagnosed with
both assays.
Consistent with these findings, Nollau P et al. describe the use of recombinant MGL (also
known as CLEC10A), for the detection of ligands in sections from formalin-fixed, paraffin-
embedded normal and cancerous mammary tissues. In comparison to normal mammary
glands, a pronounced staining of tumour tissues was observed. [37] Beatson R et al. also
observed that MUC1 carrying both Tn and STn epitopes can bind to the human lectin MGL,
and using atomic force microscopy they showed that Tn and sTn bind to MGL with a similar
de-adhesion force. [39] Our study reports the binding of that same human lectin MGL with
plasma of BC patients and particularly with CA15-3. Blixt et al. reported that high levels of a
subset of autoantibodies to the core 3-MUC1 (GlcNAcČ1-3GalNAc-MUC1) and STn-MUC1
glycoforms were significantly associated with reduced incidence and increased time to metas-
tasis, which also supports our findings of MGL binding [18].
As far as we know, this study is the first to report WGA’s specificity for BC-CA15-3. WGA
is a plant lectin, which specifically recognizes the sugars NeuNAc and GlcNAc [39]. It has been
reported that terminal GlcNAc is characteristic of a group of protein- and lipid-linked glycans
overexpressed in many malignant tumor tissues including breast carcinoma [16].
Fig 5. CA15-3 levels of 19 patients who had a disease progression at the time of final plasma sampling and a previous reference plasma available
while on study treatment (Reference). A. Conventional CA15-3. Two patients with very high CA15-3 levels were excluded (Reference CA15-3 110.6 U/
mL, Final 986.4 U/mL and Reference 1825.5 U/mL, Final 3909.7 U/mL) B. CA15-3MGL. C. CA15-3WGA. One patient with very high CA15-3WGA level
was excluded (Reference CA15-3WGA 393.1 U/mL, Final CA15-3WGA 430.9 U/mL).
https://doi.org/10.1371/journal.pone.0219480.g005
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Chandrasekaran EV et al studied the complex carbohydrate-lectin interactions by determining
the effects of substituents in mucin core 2 tetrasaccharide GalČ1-4GlcNAcČ1-6(GalČ1–3) Gal-
NAcċ-OR and fetuin glycopeptides on their binding to agarose immobilized lectin WGA.
Compounds with ċ2-3-sialyl T-hapten, ċ2-6-Sialyl LacdiNAc, ċ2-3-sialyl D-FucČ1–3 GalNAc
and Fucċ-1-2 D-FucČ-1-3GalNAc displayed regular binding and GalNAc, LewisX and Lacdi-
NAc plus D-Fuc Č-1-3 GalNAcċ exhibited particularly tight binding.[40] A previous study by
Bird-Liebermann EL et al identified GlcNAc as a biomarker for endoscopic visualization of
Barrett’s esophagus to detect dysplastic esophageal tissue [41]. Using a serum CA15-3 lectin
assay based on antibody-capture, Ideo et al. showed that 3-sulfated core 1 specific Gal-4 can be
used to measure CA15-3 that is present in BC[22]. We observed in our study that Gal-4 bound
more poorly to BC-CA15-3 than MGL andWGA.
The specificity provided by the immobilizing antibody together with the glycan-recognition
of the lectins, which is enhanced through the avidity made possible by the Eu+3-NPs, consti-
tute the technical concept behind the novel CA15-3MGL and CA15-3WGA assays. These assay
strongly prefer the cancer-associated glycovariants compared to conventional CA15-3 sand-
wich immunoassay. Based on previously published research on the nature of CA15-3 glycosyl-
ation in malignant and benign states, the WGA preference for cancer CA15-3 would have
been difficult to predict. It is possible that the glycan eiptopes reactive with MGL andWGA
are be present on several CA15-3 glycans, being a sizable 500–1000 kDa glycoprotein. The
extracellular domain of CA15-3 consists mainly of 25–150 tandem repeats of 20 amino acids.
Each repeat carries five O-linked glycosylation sites, thus glycans can potentially be repeated
125–750 times on each molecule allowing engagement of relevant lectins.[20] The high
amount of glycans makes the presence of multiple binding sites for MGL andWGA Eu+3-NPs
plausible and may provide for high avidity even at low CA15-3 concentration. The low limit of
detection and great linearity of the standard in the range of 1-100 U/ml of analyte agrees with
this assessment.
The monitoring of conventional CA15-3 levels for therapy response of metastatic BC is cur-
rently recommended only as an adjunctive assessment to aid clinical decisions[42].This is
mostly due to low sensitivity and specificity of the conventional CA15-3 assay. Additionally,
the conventional CA15-3 levels may have discrepancies compared to clinical findings and
radiological assessments[10]. Although for majority of patients, the tumor markers decline in
responding patients and increase in progressing patients, misinterpretations are possible if
tumor markers are evaluated alone for an individual patient. In our study, 10 patients (40%)
with a partial response to study treatment had at least 30% decline in conventional CA15-3 lev-
els between baseline and week six. However, declining plasma levels for responding patients
were more common both with the CA15-3MGL method (18 patients, 78%) and the CA15-3WGA
method (12 patients, 48%). Therefore, new CA15-3lectin assays recognize the responding
patients better than the conventional CA15-3. False positive increases in CA15-3 levels were
observed for responding patients for all three assays between baseline and week six (two
patients for conventional CA15-3 and CA15-3WGA, three patients for CA15-3MGL). At the
time of progressive disease, only minority of patients had over 30% increase in their CA15-3
levels [conventional CA15-3 assay 8 patients (42%), CA15-3MGL 9 patients (47%), CA15-3WGA
5 patients (26%)].
Comparing the new lectin assays to one another, CA15-3WGA seems to be more suitable for
clinical use than CA15-3MGL. The clinical utility for CA15-3MGL levels is limited due to very
low< 5 IU/mL baseline levels detected for almost half of our study patients. Additionally, the
correlation between conventional CA15-3 and CA15-3WGA was more pronounced (r = 0.90,
p<0.001). Nevertheless, for this limited patient population, CA15-3MGL and CA15-3WGA seem
not yet to be ideal assays for clinical utility and the possibilities for misinterpretations for an
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individual patient remains as it does for the conventional CA15-3 assay. However, it would be
worthwhile test these CA15-3lectin assays in a prospective trial involving metastatic breast can-
cer patients.
This study suggests that using CA15-3 mAb andWGA and MGL Eu3+NPs are more sensi-
tive in distinguishing metastatic BC patients from healthy controls than conventional CA15-3
immunoassay.
Due to the limited amount of patient samples used in this proof of concept study report,
studies for further validation, to establish the clinical performance of CA15-3WGA and CA15-
3MGL assays for BC surveillance, and monitoring progression and therapeutic responses of
metastatic disease, are now under investigation. The findings also warrant further investigation
of this approach in other cancers.
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